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A b st r a c t
In recent years, molecular genetics research has identified a large number of putative 
susceptibility genes for a variety of complex psychiatric and neurodegenerative disorders. 
However, in most instances, the particular functional variants involved have not been 
identified, and it is typically unclear by what mechanism the pathogenic effect is mediated. 
Where a genetic association does not appear to be fully explicable by variants that alter the 
amino acid sequence of a protein, it is a reasonable hypothesis that the association might be 
mediated by c/5-acting variants that alter gene expression. This hypothesis was tested in 
this thesis in relation to 10 putative susceptibility genes for psychiatric and 
neurodegenerative disorders. The genes were DISCI, RELN, GABRA4, GABRA5, 
GABRB1, GABRB2, GABRG2y GABRG3, NOS1AP and MAPT. Each one of these genes 
was investigated by assays of relative allelic expression applied to a large number of post­
mortem human brain samples. Samples were also genotyped for relevant variants that had 
previously shown association with disease in order to test those variants for a putative cis- 
regulatory effect. C/5-regulatory variation manifested as unequal expression of each 
parental gene copy at the mRNA level was detected in nearly all of the genes in at least one 
tissue sample. However, for only two genes (RELN and MAPT) was evidence obtained that 
specific variants implicated in disease influenced expression.
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G e n e r a l  in t r o d u c t io n
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Chapter 1: Introduction
________________________ C h a pt e r  1: In t r o d u c t io n ________________________
1.1: Genetic Variation in the Human Genome
Genetic variation plays a primary role in phenotypic diversity and is an important 
determinant of disease susceptibility. In order to affect phenotype, a genetic variant must 
influence the function of one or more genes. This can happen either by altering the amino 
acid structure of proteins (protein-coding variation), or by changing the temporal, spatial or 
quantitative aspects of gene expression (regulatory variation).
The human genome harbours many types of variation in both its structure and sequence. 
Variants with population frequencies of >1% are referred to as polymorphisms, and by far 
the most abundant in the human genome are single nucleotide polymorphisms (SNPs), 
where one of the four nucleotides (adenine, thymine, guanine or cytosine) is substituted 
with another. The human genome is estimated to harbour ~10 million SNPs (Kruglyak & 
Nickerson, 2001; Reich, Gabriel & Altshuler, 2003), an average of approximately one 
every 320 bases. Other types of variant include repeat polymorphisms including 
microsatellites (repeats of 1-6 nucleotides) and minisatellites (repeats of up to -60  
nucleotides), deletions and insertions (of one or more nucleotides), copy number variants 
(deletions or duplications of >1 kb), other structural chromosome rearrangements (e.g. 
inversions, translocations etc.), and abnormalities of whole chromosome number. Only a 
minority of all genetic variants are expected to have important phenotype effects, most 
being likely to have no functional consequence.
12: Most Genetic Variation Poes Not Affect Protein Structure
Protein-coding sequences are, in general, remarkably conserved among higher species. For 
example, an average orthologous protein in humans and chimpanzees differs by just two
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amino acids, and ~29% of proteins are identical (Chimpanzee Sequencing and Analysis 
Consortium, 2005). Commensurate with this high level o f conservation is that protein- 
coding sequences also show relatively little variation between human individuals. 
Resequencing efforts have found that human genes contain on average approximately four 
coding SNPs, o f which only half are non-synonymous (i.e. predicted to change the amino 
acid sequence of the encoded protein) (Cambien et al., 1999; Cargill et al., 1999; Halushka 
et al., 1999; Stephens et al., 2001; Freudenberg-Hua et al., 2003; Livingston et al., 2004).
These same studies have also indicated that coding SNPs are generally less frequent (i.e. 
have lower minor allele frequencies) than non-coding SNPs, and that non-synonymous 
SNPs are less frequent than synonymous SNPs (also Tsunoda et al., 2004). Furthermore, 
only 25-30% of non-synonymous SNPs are predicted to affect protein function (Sunyaev 
et al., 2001; Ng & Henikoff, 2002; Yue & Moult, 2005), and these SNPs are less frequent 
than those that are predicted to be functionally neutral (Sunyaev et al., 2001; Freudenberg- 
Hua et al., 2003; Wong et al., 2003; Livingston et al., 2004). Therefore, it can be estimated 
that o f the ~10 million SNPs in the human genome, only 12,500-15,000 (i.e. <0.002%) are 
likely to have an important functional effect on protein structure, and most of these are 
likely to be relatively infrequent at the population level.
The above findings are consistent with the view that non-synonymous SNPs are under 
strong purifying selective pressure. For example, the finding that only half of observed 
coding SNPs are non-synonymous is at odds with the expected rate of two thirds if 
mutations in coding regions were random. Although such variants, are more likely to have 
significant effects on phenotype than random variants, their apparently low number and 
frequency suggest that their combined role in determining phenotypic differences may be 
limited.
3
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It has long been hypothesised that the clear phenotypic differences between humans and 
chimpanzees are primarily due to alterations in gene regulation rather than protein structure 
(King & Wilson, 1975). As will be mentioned in later sections, support for this view is 
growing. More pertinent to the present thesis, however, is whether this hypothesis also 
applies to differences between human individuals. It has been estimated that humans are 
more polymorphic at functional regulatory sequences than they are in protein-coding exons 
(Rockman & Wray, 2002). As will be described in section 1.9, this view has now received 
empirical support.
13: Gene Expression
Gene expression is the cellular process by which DNA sequences of genes are transcribed 
into RNA and, typically, then translated into proteins. During embryonic development, the 
particular complement o f genes expressed in each cell is integral to the determination of 
each cell’s fate. Throughout life, changes in gene expression are directed by signal 
transduction cascades to allow cells to alter their function in response to physiological and 
environmental influences. Hence, gene expression is a highly dynamic process that can be 
regulated at several levels and in many different ways.
The process o f gene expression is illustrated in Figure 1.1. The first stage of gene 
expression is transcription, during which the DNA sequence of a gene is used as a template 
for RNA synthesis. The resultant pre-mRNA then undergoes three modifications to form 
mature mRNA. These modifications include splicing (the excision of introns and joining of 
exons), 5’ capping (the linkage of a 7-methylguanosine nucleoside to the 5’ end), and 3’ 
polyadenylation (the linkage of -200 adenylate residues to the 3’ end to form a poly(A) 
tail). The mature mRNA is then transported out o f the nucleus for translation, whereby it is
4
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used to instruct the manufacture of a protein. The end-product of gene expression is not 
necessarily a protein, however, since many genes do not code for proteins. Such non­
coding genes are expressed primarily by transcription, the end product being non-coding 
RNA (ncRNA). There is growing realisation that ncRNAs may play important roles in 
coordinating the expression of protein-coding genes (Mattick, 2001; Mattick & Makunin, 
2006).
Genomic DNA
El E3 —  E4 E5
Pre-mRNA I
Transcription
mRNA
m7G-
I 5’ Capping 
I RNA Splicing 
▼ v3' Polyadenylation 
— -AAAAA
_  Translation
Protein
H.N I I M O I M M f O— OOt-COOH
Folding, post-translational 
modification, subcellular 
localisation etc.
jCOOH
I
v >
Figure 1.1: The process of gene expression. Genomic DNA is transcribed into pre- 
mRNA. The pre-mRNA is then modified such that the 5’ end is capped, intronic 
sequences are spliced out, and a poly(A) tail is added to the 3’ end. The mature mRNA 
is then translated into a protein, which adopts a three-dimensional structure and may 
be subject to further modifications to alter function.
1.4: Gene Regulation by C/s-Regulatory Elements and 7>fl/is-Regulatorv Factors
Regulation of gene expression, whether at the level of transcription, pre-mRNA 
modification, or translation, is controlled by the binding of protein or often RNA factors to
5
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regulatory sequences in the genome. A prime example is the core promoter, normally 
located at the 5’ end of a gene, which includes binding sites (i.e. recognition sequences) for 
a number of proteins necessary for initiation of transcription. Regulatory elements are also 
commonly present in introns, as well as in exons, but can also be located many kilobases 
from the gene(s) they influence, as will be described later. Such sequences on the same 
DNA or RNA molecule as the gene or transcript being regulated are described as cis- 
regulatory elements.
In contrast to c/s-regulatory elements, the protein or RNA factors that bind them are 
usually encoded by distantly located genes, often on different chromosomes. Since they are 
required to migrate to their site of action, where they influence expression of both 
chromosomal copies of a gene, they are described as /r<ms-regulatory. Examples of trans- 
regulatory factors include RNA polymerases, transcription factors, hormones, various 
species of regulatory ncRNAs, and even trans-acting DNA-DNA interactions (Gonddr & 
Ohlsson, 2009). In terms of their regulation, genes encoding trans-regulatory factors (or 
subunits thereof) are no different from any other genes; hence they too are also regulated 
by c/s-regulatory elements and rnmv-regulatory factors.
1.5: Gene Regulation at the Level of Transcription
The expression of a gene can be regulated at any of the stages indicated in Figure 1.1, and 
even following translation, a protein can be modified to alter its location, activity, and 
abundance (e.g. Fortini, 2009). However, it is at the first stage, at the level of transcription, 
that the fundamental aspects of gene expression are controlled. For example, the types of 
cell in which a gene is expressed, the times in development that it is expressed, and the
6
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degree to which it is expressed in adults, both basally and in response to physiological and 
environmental signals, are largely determined at this level (Ooi & Wood, 2008).
As already mentioned, the transcription of protein-coding genes is initiated at the core 
promoter, typically at the 5’ end of a gene, and is dependent on the binding and recruitment 
of multiple proteins including transcription factors and the RNA-synthesising enzyme, 
RNA polymerase II (Butler & Kadonaga, 2002; Levine & Tjian, 2003). Transcription 
factors may directly bind to recognition sequences in the promoter, or, like RNA 
polymerase II, associate with other transcription factors that do. The ensemble of trans- 
regulatory proteins at the core promoter forms the basal transcription complex, which is 
sufficient to direct only low levels of transcription. A generalised example of a typical core 
promoter is shown in Figure 1.2.
-37 to -32 -31 to -26 -2 to +4 +28 to +32
 . .  .  r  _ _______
| d ---------1 Inr  B U t
GGGCGCC TATAAA GG TTA
Figure 1.2: A generalised core promoter containing a TFIIB recognition element 
(BRE), TATA box, initiator (Inr), and downstream promoter element (DPE). 
Approximate nucleotide positions of each element relative to the transcription start 
site (indicated by an arrow) are shown at the top. Consensus recognition sequences for 
protein factors that bind each element are shown at the bottom. Figure is adapted from 
Butler & Kadonaga (2002).
The basal transcription complex is not adequate to initiate more than low levels of 
transcription. Most genes therefore have a variety of additional c/s-regulatory elements 
that, when bound to by specific transcription factors, can interact with the basal
7
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transcription complex to modulate transcriptional rate (Levine & Tjian, 2003; Maston, 
Evans & Green, 2006). Examples, shown in Figure 1.3, include the proximal promoter, 
located just 5’ of the core promoter, and a number of more distant elements such as 
enhancers and silencers, which can increase or decrease transcription respectively.
LCR E R PP CP IE I
Figure 13: Os-regulatory elements involved in transcriptional regulation. LCR = 
locus control region; E = enhancer; R = repressor; PP = proximal promoter; CP = core 
promoter; IE = intronic enhancer; I = insulator. El and E2 represent exons. The arrow 
indicates the transcription start site.
These additional elements typically contain recognition sequences for tissue-specific 
transcription factors, and may mediate responses to signalling molecules such as hormones 
(e.g. glucocorticoids or retinoic acid) and second messengers (e.g. cyclic AMP). Further 
examples of c/s-regulatory elements include locus control regions, which can regulate 
transcription of whole loci or gene clusters, and insulators (also known as boundary 
elements), which prevent genes from being affected by c/s-regulatory elements of 
neighbouring genes. As indicated in Figure 1.3, transcriptional c/s-regulatory elements can 
be located throughout the gene as well as in distal regions. At present, the c/s-regulatory 
elements that control expression of most genes have not been characterised, hence, their 
number, position and functional effect are largely unknown.
Thus far, transcription and its regulation have been described in terms of their reliance on 
the capacity of various transcription factors to recognise and bind to specific nucleotide 
sequences within and around a gene. However, transcription is also reliant on a number of
8
Chapter 1: Introduction
epigenetic factors. Chromosomal DNA is wrapped around specialised proteins known as 
histones to form chromatin. Chromatin structure can be altered by covalent modifications 
to the histones, and in turn altered structure can determine ease of access of transcription 
factors to their target DNA sequences. Consequently, the regulation of chromatin by 
modification can have profound effects on gene expression. For example, histone 
acetylation at lysine residues generally correlates with an ‘open’ chromatin structure and 
transcriptional activation (Shahbazian & Grunstein, 2007), whereas histone methylation at 
lysine and arginine residues can lead to either transcriptional activation or repression 
depending on the particular amino acids targeted (Zhang & Reinberg, 2001). As well as 
histones, DNA can also be methylated at cytosine bases of CpG dinucleotides. Many cis- 
regulatory elements of genes, particularly promoters, are embedded within CpG islands, 
sequences of typically 300-3,000 nucleotides with a high (e.g. >50%) CpG dinucleotide 
content. CpG methylation is generally correlated with transcriptional silencing (Ballestar & 
Wolffe, 2001; Scarano et al.y 2005).
The structure of chromatin and the modification state of histones and DNA play an 
important role in cell differentiation and the establishment of cell type- and tissue-specific 
patterns of gene expression (Reik, 2007; Vasanthi & Mishra, 2008). Furthermore, these 
epigenetic factors, particularly DNA methylation, are central to the maintenance of mono- 
allelic transcriptional phenomena. These include X inactivation in females, where one of 
the two X chromosomes is randomly selected for permanent transcriptional silencing 
(Mohandas et al., 1981), and genomic imprinting, a phenomenon that is estimated to affect 
100-200 genes (Falls et al.y 1999) whereby one copy of the gene is permanently silenced 
dependent on parent-of-origin, in some cases in a tissue-specific manner.
9
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1.6: Cis- and Trans-Regulatory Variants
Variants that occur in c/s-regulatory elements of genes (c/s-regulatory variants), or in any 
functional (i.e. protein-coding or regulatory) sequence of genes that encode trans- 
regulatory factors (/ram-regulatory variants) have the potential to alter gene expression.
For example, c/s-regulatory variants may abolish, create or modify binding sites for 
transcription factors, whereas variants in genes that encode transcription factors may alter 
their production or their capacity to bind DNA or interact with other proteins. As shown in 
Figure 1.4, a defining characteristic of c/s-regulatory variants is that they act in an allele- 
specific manner and thus only influence expression of a gene copy on the same 
chromosome. Copy number variants that encompass genes are also likely to influence gene 
expression levels by altering gene dosage in cis. In contrast, /r<ms-regulatory variants 
influence expression of both gene copies.
mRNA
f 4  mRNA
\ \  1 
(fiH i'H M  11 11- (S W  e i  l - f l B - n n -
—  --------------------
mRNA
f
mRNA
4
\  '
(fH El H H - T B T -
>1 7 
( t >  e i  |—
Figure 1.4: Cis- and frows-regulatory variants. In this hypothetical example, a cis- 
regulatory variant with alleles G (top) and T (bottom) in the core promoter of a gene 
results in twice as much mRNA being produced from one gene copy than from the 
other. In contrast, a functional variant in a gene that encodes either a low (left) or high 
(right) activity /ra/w-regulatory protein (e.g. RNA polymerase II) results in a two-fold 
difference in mRNA from both copies of the target gene.
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As regulatory elements that control expression of most genes are largely uncharacterised, 
the cis- or frans-regulatory variants that influence expression of any given gene are also 
largely unknown. Furthermore, unlike variants that affect protein structure, which typically 
occur in exons and have predictable effects on amino acid sequence, variants that influence 
expression of a gene can be very difficult to recognise. Although in silico tools are under 
continual development (Wasserman & Sandelin, 2004), variants that have functionally 
important regulatory effects in vivo cannot be reliably predicted based on inspection of 
DNA sequence alone.
1.7: Natural Variation in Gene Expression
Since the advent of microarray technology, it has become increasingly clear that species, 
populations, and individuals show substantial variation in their gene expression profiles.
For example, comparisons between humans and chimpanzees have found that 
approximately 10-20% of genes are significantly differentially expressed in a variety of 
tissues including brain (Enard et al., 2002; Caceres et al., 2003; Khaitovich et al., 2004,
2005; Gilad et al., 2006). Of note is that, in one study, gene expression differences in brain 
were as great between human individuals as they were between humans and chimpanzees 
(Enard et al., 2002).
Human inter-individual differences in gene expression have also been found in peripheral 
blood. In a study of 75 healthy blood donors, 370 o f -18,000 genes (i.e. -2% ) were found 
to differ in expression by more than 2 fold relative to the mean in at least five individuals 
(Whitney et al., 2003). In two subsequent studies (Radich et al., 2004; Eady et al., 2005), 
the proportion of genes differentially expressed in blood was higher at 5% and 39% 
respectively. The inconsistent figures between the studies are likely due to differences in
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microarray platform, the specific cell types analysed, and in particular, the statistical 
criteria used to define a significant difference in expression.
Gene expression differences between species and / or strains of several other organisms 
have also been reported. In a comparison of two strains of the budding yeast Sacharomyces 
Cerevisiae, 1,528 of 6,215 genes (i.e. -25%) were found to be significantly differentially 
expressed, whereas at the threshold used, 23 were expected by chance (Brem et al., 2002).
In mice, 7,861 of 23,574 genes (i.e. -33%) were found to be differentially expressed in 
liver tissue between two parental inbred strains or at least 10% of F2 progeny (Schadt et al., 
2003). Similar proportions of differentially expressed genes have been identified in 
Drosophila (Rifkin, Kim & White, 2003) and Fundulus fish (Oleksiak, Churchill & 
Crawford, 2002). Taken together, these findings suggest that variability in expression of a 
large number o f genes is a natural and common feature of probably all eukaryotic 
organisms.
1.8: The Heritabilitv of Gene Expression
Although environmental factors are likely to contribute to the above-described variation in 
gene expression, it is clear from studies of yeast, mice and humans that the expression of 
many genes is highly heritable (Brem et al., 2002; Schadt et al., 2003; Monks et al., 2004).
In humans, heritability of gene expression has been studied using lymphoblastoid cell lines 
derived from members of several large families that have been made available by the 
Centre d'Etudes du Polymorphisme Humain (CEPH) in Paris, France (Dausset et al.,
1990). In one such study, five genes that showed highly variable expression in 35 unrelated 
individuals were found to be expressed less variably in siblings, and most similarly in 
monozygotic twins (Cheung et al., 2003), consistent with a genetic component. In a
12
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separate study involving 15 families it was found that o f the 2,430 genes that were 
differentially expressed in children, expression levels of 762 (i.e. -31%) were significantly 
heritable (Monks et al., 2004). Median heritability was estimated to be 34%; however, it is 
of note that, for some genes, genetic factors were predicted to account for 100% of the 
observed variation in expression. In a smaller study, which measured expression of 25 
genes in 10 CEPH families, median heritability was estimated at 42% (Deutsch et al., 
2005). Evidence of heritable variation in gene expression in native human tissues (i.e. 
blood) has also been reported (Sharma et al., 2005; Tan et al., 2005).
1.9: Genetic Mapping of Gene Expression
Genetic variants that contribute to heritable variation in gene expression can be mapped by 
‘genetical genomic" studies in which gene expression profiling is combined with classical 
genetic methods such as linkage and association (Jansen & Nap, 2001). In these studies, 
expression levels o f individual genes are treated as quantitative traits, which, just like any 
other heritable phenotype, are then genetically mapped to one or more expression 
quantitative trait loci (eQTLs). Given that these studies are based on measures of each 
gene’s absolute expression, effects arising from cis or trans genetic variation cannot be 
readily distinguished. These studies have generally therefore categorized eQTLs as either 
cis- or trans-acting based on their genetic distance from the regulated gene (e.g. in one 
study [Morley et al., 2004], eQTLs were defined as c/s-acting if they were observed within 
5 Mb of the regulated gene). This approach has been successfully applied to several 
organisms, including yeast (Brem et al., 2002; Yvert et al., 2003; Brem & Kruglyak,
2005), fruit flies (Wayne & McIntyre, 2002), fish (Oleksiak, Churchill & Crawford, 2002), 
mice (Schadt et al., 2003; Chesler et al., 2005), rats (Hubner et al., 2005; Petretto et al.,
2006), as well as humans (Schadt et al., 2003; Monks et al., 2004; Morley et al., 2004).
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In humans, the genetical genomics approach has been employed in several studies of 
CEPH family cell lines (Monks et al., 2004; Morley et al., 2004; Deutsch et al., 2005), 
and, together, these studies have identified significant eQTLs for hundreds of genes. 
Although these studies differed in scale, design and the number of eQTLs found, a 
consistent finding is that most of the eQTLs they identified were trans-acting. For instance, 
in the study that mapped the largest number o f eQTLs, 110 (77.5%) of the 142 gene 
expression traits that had the strongest evidence for linkage mapped to a single trans 
eQTL, whereas 27 (19%) mapped to a single cis eQTL (Morley et al., 2004). As in other 
studies (e.g. Monks et al., 2004, Deutsch et al., 2005), this study also found that expression 
of a smaller proportion of genes was linked to more than one locus. O f the 142 most 
strongly linked traits, two (1.5%) mapped to a cis and a trans eQTL, and three (2%) 
mapped to two trans eQTLs. When the analysis was widened to the 984 expression traits 
with linkage at a less stringent level o f significance, 164 (16%) mapped to more than one 
eQTL, 152 of which mapped to trans eQTLs, and 12 to cis and trans eQTLs, suggesting 
that where more than one regulatory locus influences an expression trait, each contributes a 
smaller effect. Interestingly, consistent with findings in yeast (Brem et al., 2002; Yvert et 
al., 2003), mice (Schadt et al., 2003; Chesler et al., 2005) and rats (Hubner et al., 2005), 
this study also identified a number of loci to which expression of a large number of genes 
was linked. For instance, expression of 31 genes mapped to chromosome 14q32, and 
expression of 25 mapped to chromosome 20ql3, whereas if eQTLs mapped randomly 
across the genome, no more than four hits was expected to occur at each locus. The authors 
termed these eQTL hotspots ‘master regulators’, as they presumably contain 
polymorphism in genes encoding /rans-regulatory factors that influence expression of a 
large number of genes.
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The genetics o f gene expression has also been studied by genetic association. In one study,
374 expression traits that previously showed evidence of cis linkage were followed up by 
testing SNPs within 50 kb 5’ or 3’ of the relevant gene for association with the gene’s 
expression level in cell lines from 57 unrelated CEPH individuals (Cheung et al., 2005). It 
was found that 65 (17%) of these traits were associated with at least one cis SNP. In a 
further analysis, the 27 expression traits that showed the strongest cis linkages were tested 
for association with -770,000 SNPs genome-wide. Of these 27 traits, 14 (52%) showed 
genome-wide significant evidence for association with at least one SNP: 12 associated only 
with cis variants, one with a cis and a trans variant, and one with a trans variant only. A 
notable finding was that although cis associations were generally only found at one region 
of each gene, the associations were found to be approximately equally likely to occur at the 
5’ end, within, or at the 3’ end of the gene.
A genome-wide association analysis of global gene expression in lymphoblastoid cells, 
assessed by microarray, has more recently been carried out using the 270 individuals 
genotyped through the HapMap Consortium (Stranger et al., 2007). Analysis of over 2.2 
million common (minor allele frequency of >5%) SNPs in each population provided 
evidence for at least 1,348 genes with association signals in cis, and at least 180 in trans. 
Thirty-seven percent of cis signals and 15% of trans signals were replicated in at least one 
separate population.
Large-scale association analysis of genetic variation and gene expression has also been 
performed in native human tissues (Gdring et al., 2007; Myers et al., 2007a; Schadt et al.,
2008; Emilsson et al., 2008). For example, in a recent report, inter-individual variability in 
global gene expression in post-mortem human brain was assessed in cerebral cortex
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samples from 193 control individuals using genome-wide genotyping and gene expression 
microarrays (Myers et al., 2007). In this study, 58% of the -24,000 transcripts on the 
expression array were found to be cortically expressed in at least 5% of the samples. 
Furthermore, significant associations were found between 99 transcripts and 433 SNPs 
acting in cis (i.e. within 1 Mb 5’ or 3’ of the gene), and between 2,876 transcripts and 
16,701 SNPs acting in trans.
1.10: Functional Assays of Putative Regulatory Variation
Functional assays of genetic variation can be used for two purposes. The first is to identify 
functional regulatory variants, which can subsequently be used as rational candidates for 
disease association testing. The aforementioned ‘genetical genomics' studies represent 
good examples of the type of hypothesis-free approach that can be used for this purpose.
The second is to test whether or not specific variants, which may have already been found 
to show association with disease, have effects on gene expression.
A variety of methods are available to assess the wide range of potential regulatory effects 
that variants can have (Knight, 2003; Prokunina & Alarcon-Riquelme, 2004). A few 
examples include northern blotting and reverse transcription PCR, which can be used to 
determine effects on splicing; so called ‘DNA footprinting’ and ‘gel-shift’ assays to 
investigate DNA-protein interactions (e.g. transcription factor binding sites); and bisulphite 
sequencing to evaluate effects on methylation. In addition to these methods, which 
primarily test for qualitative effects, a number of methods to investigate quantitative 
effects on gene expression are also available and commonly used.
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The most widely used of such methods is the reporter gene assay. In this assay, a putative 
regulatory sequence containing either allele of a variant is cloned alongside a reporter gene 
into a vector, which is then transfected into cultured cells (Alam & Cook, 1990). The 
activity of the reporter gene product is then quantitatively measured as an indicator of 
transcriptional efficiency, making it possible to compare the regulatory potential of each 
allele o f the variant sequence.
Reporter gene assays can provide valuable information on the potential of genetic variants 
to influence gene expression (Hoogendom et al.y 2003). However, it must be appreciated 
that these assays represent an in vitro method where a variant DNA sequence is tested in a 
highly unnatural transcriptional environment. For instance, the DNA sequence is typically 
naked (i.e. devoid of chromatin proteins), isolated from other cu-regulatoiy elements, and 
may be subjected to fra/ts-regulatory proteins that it would not normally encounter. For 
these reasons, variants that are found to have a regulatory effect in reporter gene assays 
cannot always be assumed to have a similar effect in vivo (Cirulli & Goldstein, 2007).
An alternative, commonly used approach is to simply compare the total abundance of a 
gene’s mRNA or protein products (e.g. as quantified by real-time PCR or western blot 
analysis) between tissue samples derived from individuals of different genotypes. If the 
variant in question has a regulatory effect it is expected that homozygotes for either allele 
will have significantly different mRNA or protein levels, and that heterozygotes will have 
levels in an intermediate range.
This approach has the obvious advantage that variants are tested in their normal 
chromosomal and physiological context. However, unlike reporter gene assays, effects of
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putative regulatory variants are inferred by association, making it more difficult to attribute 
causative status to a particular variant. In addition, this type of experiment is subject to a 
number of potentially confounding factors, as tissue samples, particularly human tissues 
obtained post-mortem, may differ in respects other than genotype for the variant in 
question. For example, they may differ in terms o f pre-agonal state, post-mortem interval, 
or method of preparation, all of which may influence RNA quality. Differences in pre- 
mortem exposure to environmental factors (e.g. diet or drugs), variability in intrinsic trans­
acting molecules such as hormones, and variation in genes encoding trans-rcgulatory 
proteins or RNAs may also influence gene expression levels. The capacity of this approach 
to detect modest regulatory effects of any variant is therefore limited, especially in 
comparisons of human post-mortem tissues where most of these confounds cannot be 
avoided.
1.11: Assays of Relative Allelic Expression
By comparing the relative expression level of the two chromosomal copies of a gene within 
individual tissue samples, it is possible to control most o f the above-mentioned variables 
that can confound comparisons of total expression between samples. This, essentially, is 
the rationale behind assays of relative allelic expression.
Assays o f relative allelic expression enable the indirect screening of genes for the presence 
of functional sequence variants in c/s-regulatory elements, as well as other c/s-acting 
regulatory phenomena such as epigenetic modification. The basic principle of these assays 
is illustrated in Figure 1.5.
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Figure 1.5: Assays of relative allelic expression make use of a SNP within a 
transcribed exon of a gene (left). In heterozygotes, mRNAs transcribed from each 
copy of the gene can be distinguished (middle). The relative abundance of mRNAs 
from each gene copy can therefore be measured in cDNA by a quantitative method of 
allele discrimination (right). A: In the absence of cw-regulatory variation (top), each 
mRNA will be present in a 1:1 ratio. B: In heterozygotes for cw-regulatory variation
(bottom), each mRNA will be present in unequal abundance (e.g. 2:1 ratio). The
relative abundance of each gene copy in genomic DNA is also measured as a 1:1 
control.
In the absence of cis-acting influences that differentially affect expression of each
chromosomal copy of a gene, both copies of that gene will be expressed equally (Figure
1.5 A). In contrast, if an individual is heterozygous for any cis-acting variant that affects a 
gene’s transcription or its mRNA’s stability, or if a gene is subject to allele-specific 
epigenetic modification (e.g. imprinting effects), then each copy of that gene will be 
expressed at different levels. Accordingly, by measuring the relative expression of each 
copy of a gene in tissue samples from a series of individuals, the presence of c/s-regulatory 
genetic or epigenetic variation can be inferred on the basis of a significant departure from a 
1:1 ratio in any one sample (Figure 1.5B). In this ‘within samples’ approach, the mRNA 
from each gene copy serves as the perfect internal control for the other, as both are
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subjected to identical conditions and trans-acting influences. Thus, assays of relative 
allelic expression do not incur any of the described confounding factors that afflict 
‘between samples' comparisons, meaning that even modest c/s-regulatory effects can be 
detected.
To distinguish mRNAs from each gene copy, assays o f relative allelic expression typically 
make use of a SNP within the transcribed sequence of the gene (as shown in Figure 1.5).
Most often the SNP is located in an exon, although SNPs in introns can also be used 
(Pastinen et al., 2004), in which case pre-mRNA instead of mRNA will be assayed. The 
first step in any relative allelic expression assay is to genotype the tissue samples for the 
SNP to identify heterozygotes. The relative abundance of mRNAs from each gene copy is 
then measured in those samples using a quantitative method of allele discrimination. 
Examples of such methods used previously include real-time PCR assays (Zhu et al., 
2004), polymerase colonies (Butz et al., 2004), microarrays (Lo et al., 2003), and RT-PCR 
followed by a variety of methods based on single base primer extension (Singer-Sam et al.,
1992; Cowles et al., 2002; Yan et al., 2002; Bray et al., 2003a; Pastinen et al., 2004). A 
primer extension method that uses fluorescent dideoxynucleotides is particularly robust, 
capable of quantifying very small percentage differences in allelic representation (Norton 
et al., 2002).
By assessing relative allelic expression in a series of individuals, it is possible to screen a 
gene for the presence of common c/s-regulatory variation, at least as this affects gene 
expression in the assayed tissue. Studies involving a limited number of individuals 
(typically less than 20 per gene) have found that around 50% of genes analysed show 
evidence o f unequal allelic expression in tissue or cells from at least one individual (Yan et
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al., 2002; Bray et al., 2003; Lo et al., 2003; Pant ef a/., 2006), demonstrating that c/s- 
regulatory variation is common in the human genome. These studies have revealed that 
allelic expression differences are typically o f modest magnitude (<2 fold), and, for some 
genes, tissue-specific (Lo et al., 2003). Furthermore, analysis of human lymphoblastoid 
cell lines derived from families has confirmed that differences in allelic expression are 
heritable (Yan et al., 2002; Pastinen et al., 2004).
The utility o f relative allelic expression assays extends beyond their capacity to simply 
screen a gene for c/s-regulatory variation. Since they expose only the variance in 
expression resulting from c/s-acting effects, they also provide a particularly powerful 
method for examining the influence of specific genotypes or haplotypes on a given gene’s 
expression (e.g. Bray et al., 2003b, 2005). This makes them particularly useful for 
investigating regulatory effects associated with variants implicated in disease.
1.12: Pathogenic Variants in Monogenic Human Disease
Mutations that disrupt gene expression, especially transcription, are known to cause several 
human genetic disorders (Maston, Evans & Green, 2006). Examples include a- and le­
thal assaemia (Antonarakis et al., 1984; Driscoll et al., 1999; Hatton et al., 1990), Gilbert’s 
syndrome (Bosma et al., 1995), and fragile X syndrome (Sutcliffe et al., 1992), each of 
which involve transcriptional disruption by a different mechanism. However, the majority 
o f identified high penetrance mutations known to cause genetic disease impart their 
pathogenic effect by altering protein structure. For instance, as of December 2008, the 
Human Gene Mutation Database (Stenson et al., 2009) lists 35,545 missense and nonsense 
mutations, but only 817 regulatory mutations. The larger number of mutations in the 
former class may in part be due to the fact that such mutations are more readily
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identifiable. However, the considerably smaller number of regulatory mutations more 
likely indicates that variants that influence gene expression typically have more subtle 
phenotypic effects that, independently, are insufficient to cause disease.
1.13: Pathogenic Variants In Complex Human Disease
In contrast to rare dominant Mendelian disorders where the effect of a single mutation is 
often large enough to cause disease, the genetic architecture of more common disorders 
such as diabetes, cardiovascular disease, and the major mental illnesses, is generally 
thought to be considerably more complex. While these disorders often show high 
heritability (e.g. Hyttinen et al., 2003; Zdravkovic et al., 2002; Cardno et al., 1999; 
Sullivan, Kendler & Neale, 2003), transmission is not usually consistent with a Mendelian 
model. Rather, the majority o f cases of these conditions are thought by many to be largely 
attributable to the co-action of variants in multiple genes, as well as environmental factors 
(Reich & Lander, 2001; Pritchard, 2001; Dean, 2003). According to the common disease / 
common variant hypothesis (Reich & Lander, 2001) the variants underlying complex 
disorders are most likely to be common, with each conferring only a small increase in 
disease risk (e.g. odds ratios [OR] of less than 2). However, this hypothesis has recently 
been challenged by findings of an increased frequency of rare copy number variants in 
complex diseases such as autism and schizophrenia (e.g. Sebat et al., 2007; Walsh et al.,
2008; Stefansson et al., 2008; International Schizophrenia Consortium, 2008).
There are many examples o f variants associated with a complex disease that have been 
demonstrated to have a cis-regulatory effect (Knight, 2005). Among the earliest examples 
are a variable number tandem repeat (VNTR) polymorphism associated with type 1 
diabetes that regulates transcription of the gene encoding insulin (Kennedy et al., 1995), a
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SNP in exon 4 of PTPRC, which modulates splicing (Lynch & Weiss, 2001) and is 
associated in some studies with multiple sclerosis, and a SNP in the 5’ UTR of F I2 that 
predisposes to cardiovascular disorders by reducing the translation efficiency of 
coagulating factor XII (Kanaji et al., 1998). The widespread involvement of variants 
affecting gene expression in complex diseases is suggested in that many of the most 
significant genome-wide association hits related to such disorders do not appear explicable 
in terms non-synonymous changes (e.g. O’Donovan et al., 2008; Stefansson et al., 2009; 
Newton-Cheh et al., 2009; Song et al., 2009).
1.14: Psychiatric and Neurodegenerative Disease
Psychiatric and certain types of neurodegenerative diseases are prime examples o f complex 
diseases that are currently being tackled by molecular genetics research. Psychiatric 
diseases have as their defining features disturbances of perception, cognition, mood and 
behaviour. As their name suggests, neurodegenerative diseases are characterised by the 
degeneration of neural tissue, and these disorders also frequently have psychiatric as well 
as neurological manifestations. Pertinent examples of both types o f disease, as well as 
epilepsy, a neurological disorder, are listed in Table 1.1 with brief details of core 
symptoms, heritability, and lifetime population prevalence.
Microarray studies have found that many psychiatric and neurodegenerative disorders are 
associated with widespread gene expression changes in brain (Ricciarelli et al., 2004; 
Hauser et al., 2005; Katsel et al., 2005; Iwamoto & Kato, 2006). However, it is difficult on 
the basis o f gene expression assays alone to distinguish between changes that reflect 
primary disease mechanisms and secondary manifestations of the disease (Bray, 2008).
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Disorder Core Clinical Features Heritability Prevalence (%)
Schizophrenia
Delusions, hallucinations, and cognitive and 
emotional deficits.
X).80a 1
Bipolar Disorder
Episodes of mania, with or without episodes of 
depression.
0.85b 1
Major Depression
Episodes of clinically significant depression in 
the absence of mania.
0-29(m> 0.42(f)C 10-20
Generalised Anxiety 
Disorder
Recurrent, ongoing, prominent and 
pathological anxiety.
0.32d 5
Alcohol / Drug 
Dependence
Inappropriate or excessive use of alcohol or 
drugs leading to social, psychological or 
physical impairment and physical dependence.
0.50—0.60(A)e 
0.45-0.79(D)e
10
Autism
Delayed social-communicative development 
with restricted patterns of interest or behaviour.
>0.90f 0.05
Alzheimer's Disease
Progressive deterioration of memory 
accompanied by cognitive impairments.
0.60-0.80*
5
(over age 65)
Idiopathic Epilepsy Recurrent seizures and loss of consciousness. 0.80h 0.5-1
Tabic 1.1: The core clinical features, heritability and approximate lifetime population prevalence of several
psychiatric and neurodegenerative disorders and the neurological disorder, epilepsy. Heritability estimates 
for major depression are given separately for males (M) and females (F), and separately for alcohol (A) and 
other drug (D) dependences. Heritability estimates are from “Cardno & Gottesman (2000); bMcGuffin et al. 
(2003); cKendler et al. (2006); dHettema, Neale & Kendler (2001); *Dick & Agrawal (2008); fFreitag 
(2007); *Gatz et al. (2006); “Kjeldsen et al. (2003).
There is now strong evidence implicating particular susceptibility genes in many 
psychiatric and neurodegenerative disorders including schizophrenia (International 
Schizophrenia Consortium, 2008; Stefansson et al., 2009), bipolar disorder (Craddock et 
al., 2008; Ferreira et al., 2008), autism (Wang et al., 2009), and Alzheimer’s disease 
(Corder et al., 1993; Harold et al., 2009). However, in the vast majority o f cases, the true 
functional variants involved have not been characterised, and the mechanisms by which
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they increase susceptibility is unclear. One of the few notable exceptions is the e4 allele o f 
the APOE gene, which is thought to increase risk for Alzheimer’s disease through changes 
in protein structure (Strittmatter et al., 1993a, 1993b) and non-coding variation in SLC6A4, 
which has been found to alter transcription of the serotonin transporter and to be associated 
with anxiety-related traits (Lesch et al., 1996).
None of the associations between schizophrenia and bipolar disorder and their best 
supported susceptibility genes that have emerged in the past though positional cloning, for 
example NRG I, DTNBPJ and DAO A (reviewed in Norton, Williams & Owen, 2006) 
appear to be mediated by variants that affect protein structure. Moreover, unpublished data 
generated in the Department of Psychological Medicine suggest that the same is also true 
for the leading candidate genes for these disorders that have been identified more recently 
by genome-wide association (e.g. ANK3, Ferreira et al., 2008; CACNA1C, Ferreira et al.,
2008; NRGN, Stefansson et al., 2009; and ZNF804A, O’Donovan et al., 2008). Therefore, 
if these associations are genuine, it is likely that they are mediated by variants that alter 
gene expression.
For several of the leading (pre-genome-wide association) schizophrenia susceptibility 
genes, there is now evidence that this might indeed be the case. For example, using assays 
of relative allelic expression, it has been found that a haplotype in the DTNBP1 gene that 
showed association with schizophrenia in UK and Irish samples (Williams et al., 2004) is 
associated with reduced expression of that gene’s mRNA in human cerebral cortex (Bray 
et al., 2005). Using real time PCR, a SNP within a haplotype of the NRG1 gene that shows 
association with schizophrenia (Stefansson et al., 2002, 2003) was found to be associated 
with increased expression of a novel NRG1 mRNA isoform in human hippocampus (Law
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et al., 2006). In a subsequent study, a reporter gene assay provided evidence that this SNP 
in the 5’ region of NRG I influences transcriptional activity (Tan et al., 2007).
1.15: The Present Series of Studies
There are numerous other examples of genes implicated in psychiatric or 
neurodegenerative disease where reported associations are not entirely explicable by 
variants that alter protein structure. A selection of these genes forms the basis for this 
thesis, which tested the hypothesis that the putative associations between these genes and 
disease may be mediated by variants that have c/s-regulatory effects on mRNA abundance.
The genes analysed were as follows:
•  DISCI : This gene was originally identified as the breakpoint site of a chromosomal 
translocation in a large family with multiple cases of mental illness. It has since 
emerged as promising susceptibility candidate for schizophrenia as well as bipolar 
disorder.
•  RELN: This gene encodes a large protein that is critical for proper neuronal 
migration. Reduced RELN expression in brain has been reported in schizophrenia 
and bipolar disorder as well as autism. Genetic association between this gene and 
autism and schizophrenia has also been reported.
• NOS JAP: A  positional and plausible functional susceptibility candidate for 
schizophrenia, with evidence of genetic association and altered expression in 
schizophrenic and bipolar disorder post-mortem brain.
•  MAPT: This gene encodes tau, the major constituent of neuronal protein aggregates 
that are characteristic of several neurodegenerative diseases, including Alzheimer’s 
disease and rare disorders such as progressive supranuclear palsy.
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•  A selection o f six GABAa receptor subunit genes: The Department of 
Psychological Medicine, Cardiff University, recently generated strong genetic 
evidence that implicates several members o f this family o f genes in the aetiology o f 
a particular subtype of bipolar disorder.
1.16: Aims
The general aims of the present series of studies were as follows:
•  To determine whether or not the expression of each of the above genes in human 
brain is influenced by c/s-regulatory variation. This was achieved by applying 
assays of relative allelic expression to a large number of human post-mortem brain 
tissue samples.
•  For genes that showed evidence of unequal allelic expression (and thereby cis- 
regulatory variation), to attempt to link that phenomenon to susceptibility to 
relevant psychiatric or neurodegenerative diseases. This was achieved by:
o Genotyping the assayed brain samples for specific variants or haplotypes 
that have been reported to show association with disease to test whether or 
not they are also associated with regulation of gene expression in brain, 
o Or, where relative allelic expression assays pointed to an association 
between specific variants and gene expression, by testing those variants for 
evidence of association with disease.
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This chapter describes in detail the general materials and methods used in the present 
series of studies. Specific details of materials and methods used for each study are 
described in relevant chapters.
2.1: Brain Samples
2.1.1: Demographic Data
Post-mortem brain samples used in the present studies were obtained by Dr NJ Bray / Prof 
MC O’Donovan from three reputable sources with ethical permission to collect and 
distribute the samples: 1) the MRC London Brain Bank for Neurodegenerative Diseases 
(London, UK); 2) the Stanley Medical Research Institute (Maryland, USA); and 3) the 
Karolinska Institute (Stockholm, Sweden). Demographic characteristics of samples from 
each source are summarised in Table 2.1. All tissue samples were stored in a '80°C freezer 
prior to extraction.
2-1-2: A Note on DNA and RNA Processing
At the commencement o f the present work, brain samples from all subjects had already 
been processed by Dr Bray. However, as stocks of DNA, RNA and cDNA became 
depleted, it was necessary to obtain further brain tissue from certain subjects for DNA / 
RNA extraction and subsequent cDNA synthesis. This replenishment of samples was 
carried out by the author.
29
Chapter 2: Materials and Methods
Source N
Sex 
M F
Age at Death 
M R
Ethnicity
C A B N
Diagnosis 
S B M A
Brain Region 
F T P
MRC 67 33 34 73 20-105 67 0 0 44 1 0 0 22 45 22 0
Stanley 71 44 27 45 19-70 66 3 2 23 17 15 16 0 60 0 11
Karolinska 10 6 4 52 35-61 10 0 0 10 0 0 0 0 0 10 0
All 148 83 65 58 19-105 143 3 2 77 18 15 16 22 105 32 11
Table 2.1: Details of brain samples used in the present series of studies. Sex: M = male, F = female; Age at 
Death: M = mean average (whole years), R = range (whole years); Ethnicity: C = Caucasian, A = Asian, B 
= Black; Diagnosis: N = normal (no known psychiatric or neurological disease), S = schizophrenia, B = 
bipolar affective disorder, M = major depressive disorder, A = Alzheimer’s disease; Brain Region: F = 
frontal lobe, T = temporal lobe, P = parietal lobe. Except for Age at Death, numbers in each cell represent 
the frequency o f  individual brain samples obtained from each source that fall in each demographic category.
2.13: Genomic DNA Extraction
For each brain sample, up to -1,000 mg o f tissue was taken from a 80°C freezer and 
freeze-fractured using a hammer and a pie-frozen stainless steel pulveriser. Approximately 
half o f the freeze-fractured tissue was used for DNA extraction, and half for RNA 
extraction (see later). To obtain DNA, the pulverised sample was loaded into a 2 ml Lysing 
Matrix D tube (Qbiogene) with 1 ml o f STE buffer (Fisher Scientific), and homogenised 
on a FastPrep® FP120 Cell Disrupter (Qbiogene) for 40 seconds at speed setting 4. The 
tube was then centrifuged at 13,000 rpm for five minutes at 4°C. The supernatant was 
transferred to a fresh microcentrifuge tube to which 100 pi of 10% sodium dodecyl 
sulphate (Sigma-Aldrich) and 100 pi (2 mg) of proteinase K (Sigma-Aldrich) was added.
The tube was then vortexed and incubated at 50°C overnight in a water bath.
The following morning, the digested tissue was divided and transferred in equal volumes 
(-600 pi) to two microcentrifuge tubes. 1 ml of phenol (Sigma-Aldrich) was added to each
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tube. The tubes were then vortexed, incubated at room temperature for five minutes, and 
centrifuged at 3,300 rpm for four minutes at 10°C. The upper aqueous phases of each tube 
were transferred to fresh tubes to which 400 pi of phenol (Sigma-Aldrich) and 400 pi of 
24:1 chloroform / isoamyl alcohol (Sigma-Aldrich) were added. The tubes were vortexed 
and centrifuged at 3,300 rpm for four minutes at 10°C. The upper aqueous phases of each 
tube were again transferred to fresh tubes, this time with 1 ml of 24:1 chloroform / isoamyl 
alcohol (Sigma-Aldrich). The tubes were vortexed and centrifuged at 3,300 rpm for four 
minutes at 10°C. To precipitate the DNA, the upper aqueous phases of each tube were 
transferred to two fresh tubes to which 1 ml o f 100% ethanol (Sigma-Aldrich) was added.
The precipitated DNA from both tubes was then removed and pooled into a fresh tube and 
suspended in 1 ml of TE buffer. Extracted DNA samples were left overnight in a fridge to 
dissolve, and then stored at "20°C.
2.1.4: Total RNA Extraction
TMTotal RNA was originally extracted using the RNAwiz isolation reagent (Ambion). Due 
to the discontinuation of this product, replenishment of RNA samples was instead carried 
out using Tri Reagent® Solution (Ambion).
For each brain sample, up to -1,000 mg of tissue was taken from a ‘80°C freezer and 
freeze-fractured using a hammer and a pre-frozen stainless steel pulveriser. Approximately 
half of the freeze-fractured tissue was used for DNA extraction (see above), and half for 
RNA extraction. To obtain RNA, the pulverised sample was loaded into a 2 ml Lysing 
Matrix D tube (Qbiogene) with 1 ml of Tri Reagent® Solution (Ambion), and homogenised 
on a FastPrep® FP120 Cell Disrupter (Qbiogene) for 40 seconds at speed setting 4. Once
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homogenised in Tri Reagent, the sample was incubated at room temperature for 10 
minutes. The tube was then centrifuged at 13,000 rpm for five minutes at 4°C.
The supernatant was transferred to a fresh microcentrifuge tube to which 200 pi of 
chloroform (Sigma-Aldrich) was added. The tube was vigorously vortexed, incubated at 
room temperature for 10 minutes, and centrifuged at 13,000 rpm for 10 minutes at 4°C.
The upper aqueous phase was transferred to a second microcentrifuge tube to which 500 pi 
o f isopropanol (Sigma-Aldrich) was added to precipitate the RNA. The tube was vortexed, 
incubated at room temperature for 10 minutes, and centrifuged at 13,000 rpm for eight 
minutes at 4°C. The supernatant was discarded and the pellet was washed by adding 1 ml 
of 75% ethanol (Sigma-Aldrich) and centrifuging at 8,000 rpm for five minutes at 4°C.
The ethanol was discarded and the pellet was air-dried for five minutes before being 
suspended in 40-100 pi of nuclease-free water (Ambion) and stored at '80°C.
2.1.5: DNase Treatment of Extracted RNA Samples
To remove genomic DNA, extracted RNA samples were treated using the DNA-free™ Kit 
(Ambion). This kit contains a recombinant DNase I (rDNasel) enzyme in addition to 
DNase Inactivation Reagent. 40 pi of extracted total RNA was transferred to a 0.6 ml 
microcentrifuge tube to which 4 pi o f 10x DNase I Buffer and 1 pi (2 U) of rDNase I was 
added. The mixture was gently tapped and then incubated at 37°C for 30 minutes. 
Following this, 5 pi of DNase Inactivation Reagent was added, and the mixture was 
incubated at room temperature for two minutes whilst being gently tapped intermittently.
To pellet the DNase and Inactivation Reagent, the mixture was centrifuged at 13,000 rpm 
for two minutes. The supernatant, containing DNA-free RNA, was then transferred to a 
fresh 0.6 ml tube and stored at '80°C.
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1 pi of each DNase-treated RNA sample was diluted in 140 pi of water, which is a dilution 
factor that is equivalent to that achieved during reverse transcription (described in section 
2.1.7) to generate cDNA for the relative allelic expression assay (described in section 
2.2.2). This diluted RNA sample was then tested for residual genomic DNA contamination 
(alongside genomic DNA and water as positive and negative controls) by PCR using 
primers and conditions that were optimised for the amplification of a genomic DNA 
sequence. The absence of contaminating genomic DNA was confirmed by the failure of the 
dilute RNA sample to produce a PCR amplicon detectable by agarose gel electrophoresis.
2.1.6: Spectrophotometry and Dilution of Extracted DNA and RNA Samples
The concentration and purity of extracted DNA and RNA samples was measured by
TMspectrophotometry using a NanoDrop 1000 Spectrophotometer (Thermo Scientific). A 
260/280 ratio of >1.7 was required for DNA and of >1.8 for RNA. Working aliquots of 1 
ml o f genomic DNA at a concentration of 8 ng/pl were then prepared and stored at '20°C. 
Where RNA concentrations were above 1 pg/pl, samples were diluted to 1 pg/pl before 
being stored at *80°C.
2.1.7: Reverse Transcription
Reverse transcription (RT) involves the use o f a reverse transcriptase enzyme to copy RNA 
into its complementary DNA (cDNA) sequence, which can then be used as a template for 
PCR Amplification (described in section 2.3.1). For each DNase-treated RNA sample, two 
separate RT reactions were carried out simultaneously.
Prior to conducting RT reactions, all work surfaces, pipettes and gloves were thoroughly 
cleaned with RNaseZap® (Ambion) to minimise the potential for RNase contamination. RT
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reactions were carried out in a total volume of 20 pi containing 1 pg of total RNA. All 
reagents were supplied as part of the RETROscript Kit® (Ambion). Table 2.2 shows the 
volume and concentration of each reagent used in a single reaction, which was carried out 
in two steps.
Reagent Supplier Concentration Volume (pi)
H20  (nuclease-free) - 9.0
Random Decamer Primers 50 pM 2.0
RT Buffer
Ambion
10* 2.0
dNTPs (dATP, dCTP, dGTP, dTTP) 10 mM 4.0
MMLV-RT 100 U/pl 1.0
RNase Inhibitor lOU/pl 1.0
RNA Template - 1 Pg/pl 1.0
Total - - 20
Table 2 J2: Details o f reagents used in RT reactions.
In the first step, the RNA template was mixed with the random decamer primers and 
nuclease-free water, heated to 85°C for 3-5 minutes, and then immediately placed on ice. 
This step was necessary to denature the secondary structure of mRNA to facilitate 
annealing of primers to the template and was done prior to the second step to prevent the 
reverse transcriptase and RNase inhibitor enzymes from being denatured. In the second 
step, all other reagents in Table 2.2 were added to the reaction mix. The reaction was 
incubated at 44°C for 40 minutes, 55°C for 20 minutes, and then heated to 92°C for 10 
minutes to inactivate the enzymes.
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2.1.8: Dilution of cPNA Samples
Following completion of RT reactions, 120 pi of sterile water (Phoenix Pharma) was 
added to each cDNA product (20 pi) to create working samples at what is hereafter 
referred to as the 'standard cDNA concentration’. These cDNA samples were then stored 
at *20°C.
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2.2: Molecular Analysis Techniques 
2.2.1: Genotvping
Samples were primarily genotyped for single nucleotide polymorphisms (SNPs), but other 
polymorphisms, such as microsatellites, were also genotyped. Genotyping of SNPs was a 
necessary step in the relative allelic expression assay (described in section 2.2.2) in order 
to identify informative samples. Additional variants were genotyped to identify carriers of 
particular alleles or haplotypes of interest.
Genotyping of SNPs
TMGenotyping of SNPs was performed by single base primer extension using the SNaPshot 
Multiplex Kit (Applied Biosystems). This involved the following five steps: 1) PCR 
Amplification, 2) Post-PCR Cleanup, 3) SNaPshot Primer Extension, 4) Post-SNaPshot 
Cleanup, and 5) Capillary Gel Electrophoresis. Each of these steps is described in detail in 
section 2.3. SNP genotype data were processed in GeneScan® Analysis 3.7 (Applied 
Biosystems) and analysed in Genotyper® 2.5 (Applied Biosystems) as described in section 
2.4.1.
Genotyping of Microsatellites
Genotyping of microsatellites was performed by PCR-amplifying the sequence using a 5’ 
fluorescently-labelled forward primer and then measuring the size (in bp) of amplicons by 
coelectrophoresis with a fluorescent size standard by capillary gel electrophoresis. PCR 
Amplification and Capillary Gel Electrophoresis are described in detail in section 2.3. 
Amplicon size data were processed in Gene Scan® Analysis 3.7 (Applied Biosystems) and 
analysed in Genotyper® 2.5 (Applied Biosystems) as described in section 2.4.1.
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2.2.2: Relative Allelic Expression Assay
The relative allelic expression assay was the main technique used to address the major 
questions posed in the present research; hence the bulk of data presented in following 
chapters was generated by this assay. As described in Chapter 1, the relative allelic 
expression assay is a method to detect the influence of c/s-regulatory genetic or epigenetic 
variation on gene expression at the RNA level. In brief: the relative expression of each 
parental copy of a gene is measured in brain tissue by quantifying each allele of an exonic 
SNP in cDNA derived from heterozygous brain samples. If departure from a 1:1 ratio is 
detected, it is assumed that this reflects the influence of c/s-acting regulatory variation.
In addition to simply screening a gene for cw-regulatory variants, the relative allelic 
expression assay was also used to investigate potential effects on expression of individual 
polymorphisms or haplotypes that have been found to be associated with disease. Such 
effects were tested for by comparing allele ratios from brain samples that are heterozygous 
for the polymorphism or haplotype with ratios from samples that are homozygous or that 
do not carry the haplotype.
Three key aspects of the assay are the choice o f SNP to analyse, the design of PCR 
primers, and the application of a correction factor derived from genomic DNA.
SNP Selection
The SNP chosen for analysis was used primarily to distinguish transcripts derived from 
each of the two parental copies of a gene (i.e. the SNP was not chosen based on hypotheses 
regarding its functionality). An absolute requirement was that the SNP must be expressed 
at the RNA level; hence only SNPs within an exon of the gene of interest were selected. It
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was preferable to choose a SNP with a high minor allele frequency to maximise the 
number of informative (i.e. heterozygous) brain samples. In addition, it was important to 
choose a SNP that is sufficiently distant from the splice junction to allow the design of 
single-exon primers that are capable of amplifying cDNA and genomic DNA templates 
(described below). When choosing a SNP for a gene that is alternatively spliced or that has 
multiple promoters, the exon in which the SNP was located was considered carefully, as 
this determined the particular transcripts that would be assayed.
Primer Design
PCR primers flanking the SNP were designed to produce the same amplicon from both 
genomic DNA and cDNA, and were therefore based on sequences from a single exon. The 
use of single-exon primers meant that genomic DNA could be assayed under identical 
conditions to cDNA, to serve as a control for potential allelic biases that may arise during 
PCR amplification or SNaPshot primer extension. More details on primer design are 
described under PCR Amplification in section 2.3.1.
Genomic DNA Correction Factor
In single base primer extension assays that employ SNaPshot chemistry, the two alleles of 
a SNP are not equally represented -  not even in genomic DNA where alleles are usually 
present in equimolar concentrations. Instead, there is a bias towards specific nucleotides 
(Moskvina et al., 2005). Given this fact, and that the used assay employed SNaPshot 
chemistry, it was crucial that raw cDNA allelic ratios were corrected for this bias to obtain 
an accurate measurement o f relative allelic expression. In the absence of copy number 
variation, null alleles or paralogous sequences, allelic ratios obtained from genomic DNA 
should reflect a perfect 1:1 ratio of the two alleles. Therefore, where possible, genomic
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DNA was always assayed in parallel with cDNA so that allelic ratios obtained from the 
former could be used to correct those from the latter. How the correction factor was 
applied is described in section 2.5.1.
Assay Outline
Genomic DNA samples were initially genotyped for the chosen SNP to identify 
heterozygotes, informative for analysis. Genotyping of SNPs is described in section 2.2.1.
For each heterozygote, genomic DNA and two corresponding cDNA samples (i.e. products 
of two separate RT reactions) were assayed on two separate occasions under identical 
conditions according to the following five steps: 1) PCR Amplification, 2) Post-PCR 
Cleanup, 3) SNaPshot Primer Extension, 4) Post-SNaPshot Cleanup, and 5) Capillary Gel 
Electrophoresis. Each of these steps is described in detail in section 2.3. Raw data were 
processed in GeneScan® Analysis 3.7 (Applied Biosystems) and analysed in Genotyper®
2.5 (Applied Biosystems) as described in section 2.4.1. Raw allelic ratios were then 
statistically analysed in Excel 2003 (Microsoft) as described in section 2.5.
Investigation of Effects of Polymorphisms or Haplotypes
When testing for potential cz's-regulatory effects o f disease-associated polymorphisms or 
haplotypes, the relevant polymorphisms were genotyped in each brain sample. However, 
since parental DNA samples were not available, unless the individual was homozygous at 
all other genotyped loci, the precise haplotypes carried on each gene copy (i.e. phased 
diplotypes) by each assayed brain sample could not be definitively determined. For this 
reason, the relevant polymorphisms were genotyped in the entire collection of brain 
samples (i.e. assayed and non-assayed samples) so that the most likely phased diplotype 
carried by each of the assayed samples with respect to the assayed SNP could be predicted
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based on observed patterns of linkage disequilibrium (LD). The analysis of LD and 
prediction of phased diplotype probabilities are described in section 2.5.
2.23: 3^RACE
3’ rapid amplification of cDNA ends (3’ RACE) is a technique that allows 3’ ends 
(including the poly-A tail) of mRNAs transcribed from a particular gene to be PCR- 
amplified from cDNA. In the present work it was used to search for novel mRNA isoforms 
and to verify the 3’ exon makeup of known isoforms. The technique involved two steps: 1) 
reverse transcription using a specially designed primer, and 2) PCR amplification.
Using FirstChoice® Total RNA (Ambion) derived from human brain as template, a RT 
reaction was carried out as described in section 2.1.7, except that an oligo(dT)i7 adapter 
primer, as shown in Table 2.3, was used instead of random decamers. The oligo(dT) 
portion of the primer is designed to hybridise to the poly(A) tails of mRNAs, thereby 
facilitating the production of cDNA enriched for 3’ ends. Following the RT reaction, a 
PCR is carried out using a gene-specific forward primer and the adapter primer shown in 
Table 2.3 as the reverse primer. PCR Amplification is described in detail in section 2.3.1.
To increase gene-specificity, PCR products were diluted 1 in 1,000 and then used as 
template in a nested PCR using a second gene-specific primer. The nested PCR products
Primer Sequence (5’- 3 ’)
01igo(dT)i7 Adapter GAG ICCAG1CGACACAGAGCATTTTTTTTTTTTTTTTT
Adapter GAGTCCAGTCGACACAGAGC
Table 23: Details o f primers used in 3’ RACE.
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could then be analysed by agarose gel electrophoresis, excised and extracted from the gel, 
and then sequenced as described in section 2.3.
22.4: Sequence Analysis
If a relative allelic expression assay indicated the presence of c/s-regulatory variation, 
sequencing was carried out to search for novel variants in functionally important regulatory 
domains (e.g. promoters). Sequencing was also employed following 3’ RACE to determine 
the exon makeup of amplified transcripts. Sequencing was performed by the fluorescent 
dideoxy method using the BigDye® Terminator Kit (Applied Biosystems). This involved 
the following five steps: 1) PCR Amplification, 2) Post-PCR Cleanup, 3) Sequencing, 4) 
Post-Sequencing Cleanup, and 5) Capillary Gel Electrophoresis. Each of these steps is 
described in detail in section 2.3. Sequence chromatograms were analysed in Sequence 
Navigator™ 1.0.1 (Applied Biosystems) as described in section 2.4.2.
41
Chapter 2: Materials and Methods
23: Core Molecular Methods 
23.1: PCR Amplification
The first step in all the molecular analyses conducted (e.g. genotyping, relative allelic 
expression assay, sequencing) was the polymerase chain reaction (PCR). PCR is an in vitro 
method that enables short stretches of DNA sequence (typically 100-500 bp) to be rapidly 
amplified for further analysis. The method relies on the specific design of two 
oligonucleotide primers (typically 20-30 bases long) that are complementary to the 
sequences that flank the stretch of DNA of interest.
PCR Primer Design
All PCR primers were designed by use of the Primer3 program (Rozen & Skaletsky, 2000) 
available online (http://frodo.wi.mit.edu), unless otherwise specified. Input sequences were 
obtained from the Ensembl Genome Browser website (http://www.ensembl.org). Care was 
taken to avoid variants in the primer binding sequence of the template. Primers intended to 
amplify a SNP for the purpose of relative allelic expression analysis were designed to also 
avoid, where possible, the inclusion of additional variants in the amplicon. For these 
primers, the input parameter ‘product size ranges’ was set at 100-300 bp. For all primers, 
the ‘optimal primer Tm’ was set at 58°C. All other input parameters were left at default 
settings. To ensure that the primer pair suggested by Primer3 would specifically amplify 
the intended sequence, an in silico PCR was carried out using the program on the 
University of California, Santa Cruz Genome Bioinformatics website 
(http://genome.ucsc.edu/cgi-bin/hgPcr), which searches for the primer sequences in the 
latest assembly of the human genome database, and displays the sequence of the predicted 
amplicon(s).
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PCR Protocol
PCRs were carried out in a total volume of 12 pi containing either 6 pi of genomic DNA at 
a concentration of 8 ng/pl or 6 pi of cDNA at the standard cDNA concentration (see 
section 2.1.8). The volume and concentration of each reagent used in a single PCR is 
shown in Table 2.4. Blank PCRs, containing sterile water instead of DNA, were always 
carried out alongside live PCRs so that any potential bias or inaccuracy that might later 
result from the presence of contaminating templates (e.g. products of earlier PCRs) could 
be detected and resolved at an early stage.
Reagent Supplier Concentration Volume (pi)
Sterile H2O Phoenix Pharma - 2.8
PCR Buffer (inc. 15 mM MgCl2) Qiagen 10x 1.2
Forward Primer
Sigma-Aldrich
10 pM 0.5
Reverse Primer 10 pM 0.5
dNTPs (dATP, dCTP, dGTP, dTTP) Bioline 9.52 mM 0.9
TM
HotStar Taq Polymerase Qiagen 5 U/pl 0.1
DNA Template -
t
6
Total - - 12
Table 2.4: Details o f reagents used in most PCRs. ’Genomic DNA was at 8 ng/pl, cDNA 
was at the standard cDNA concentration (see section 2.1.8).
Thermal cycling was carried out by either a MJ Research PTC-225 DNA Engine Tetrad™ 
or PTC-220 DNA Engine Dyad™ thermal cycler. A total of 35 cycles were carried out 
using a thermal cycling program as depicted in Figure 2.1.
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95°C (15:00) 95°C (00:45)
72°C (10:00)
2°C (00:30) 
4°C (00:3d)
4°C (10:00)
Initial I I I I Final I
Denaturation Denaturation Annealing Extension Extension Cool Down
Figure 2.1: Thermal cycling conditions used in PCRs. Incubation time at each
temperature is indicated in parentheses in minutes and seconds.
Using the reagent mix shown in Table 2.4 and the thermal cycling program shown in 
Figure 2.1, the only condition that required optimisation was the annealing temperature. 
This was achieved by carrying out test PCRs using a thermal cycling program that included 
an annealing temperature gradient from 54°C to 62°C. Optimal temperatures were then 
determined by agarose gel electrophoresis and visualisation with an ultraviolet 
transilluminator. Electrophoresis and transillumination were also used to confirm 
amplification and absence of contamination whenever PCR was performed.
Variant PCR Protocols
Small variations on the above protocol were sometimes required. When the sequence to be 
amplified was GC-rich, dimethyl sulfoxide (Sigma-Aldrich) was added to the reaction at 
7% volume (i.e. 0.84 pi in a 12 pi reaction) with an adjusted volume of water. For 
amplification of microsatellites, the volume of genomic DNA template was reduced to 4 pi 
(i.e. 32 ng) with an adjusted volume of water.
23.2: Agarose Gel Electrophoresis
Agarose gel electrophoresis in conjunction with ultraviolet transillumination was mainly 
used to assess a number of factors related to the quality of a PCR. For instance, it was used
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to find the optimal annealing temperature for new PCRs, to confirm that only amplicons of 
expected sizes were produced, and, most frequently, to simply check that PCRs had 
worked and that contamination was absent. Less frequently, the method was also employed 
as part of techniques to identify novel genetic variants or alternatively spliced transcripts 
(e.g. following 3’ RACE PCR). If a PCR produced more than one amplicon, agarose gel 
electrophoresis was used to separate them by size so that they could be measured and 
extracted from the gel for further analysis (e.g. sequencing).
Agarose Gels
Agarose gels were made with 2-3% electrophoresis grade agarose (Invitrogen) and either 
100 or 200 ml of 1* TBE buffer. Each gel was treated with 3 pi (30 pg) of ethidium 
bromide (Sigma-Aldrich) per 100 ml of agarose solution.
TBE Buffer
TBE buffer was prepared at 10* concentration. It contained Tris (Fisher Scientific), boric 
acid (Fisher Scientific), and EDTA (Sigma-Aldrich) at concentrations of 0.97, 0.89, and 
0.02 M respectively, in Millipore-purified water. It was diluted 1 in 10 as required.
Size Standard DNA Ladders
Two size standard DNA ladders were used: a 100 bp DNA ladder (Promega) and a 1 Kb 
Plus DNA ladder (Invitrogen). The 100 bp DNA ladder consists of 11 fragments that range 
in size from 100-1,000 bp in 100 bp increments, plus an additional fragment at 1,500 bp.
The 1 Kb Plus DNA ladder consists of 12 fragments that range in size from 1,000-12,000 
bp in 1,000 bp increments, plus eight bands that range in size from 100-1,650 bp (i.e. 100,
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200, 300, 400, 500, 650, 850, and 1,650 bp). Each ladder was diluted to -0.1 pg/pl using 
the supplied buffer.
Loading Buffer
A stock of loading buffer was prepared at working concentration. It contained 12 ml of 1 x 
TBE buffer, 8 ml of laboratory reagent grade glycerol (Fisher Scientific), and 300 mg of 
general purpose grade Orange G sodium salt (Fisher Scientific).
Agarose Gel Electrophoresis Protocol
PCR products were mixed with 4 pi of loading buffer per up to 12 pi of product and loaded 
into pre-formed wells in the agarose gel. When sizing of PCR products was necessary, 5 pi 
of size standard DNA ladder was loaded into one well. In all electrophoreses, TBE buffer 
was used. To check that PCRs had worked and that contamination was absent, 4 pi of 
product was electrophoresed at 120 volts for -20  minutes. When multiple PCR amplicons 
were being separated and sized (e.g. following 3’ RACE PCR), the entire product was 
electrophoresed at 80 volts for up to 4 hours as required. Gels were visualised by 
ultraviolet transillumination using an AutoChemi™ (UVP) imaging system and 
photographed using the in-built camera.
23 3 :  Extraction of PCR Products from Agarose Gel
Where a PCR reaction gave rise to multiple bands on an agarose gel (e.g. following 
3’RACE), specific bands were sometimes excised from the gel following electrophoresis, 
and the DNA recovered so that it could be sequenced. The extraction procedure was 
carried out using the QIAquick® Gel Extraction Kit (Qiagen) in conjunction with a 
microcentrifuge according to the manufacturer’s protocol.
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Discrete bands were excised from the gel (up to 400 mg) using a clean, sharp scalpel and 
placed in a microcentrifuge tube. 300 pi of Buffer QG (which contains guanidine 
thiocyanate) per 100 mg of agarose was then added. The tube was incubated in a water 
bath at 50°C for 10 minutes whilst being vortexed intermittently. 100 pi of isopropanol 
(Sigma-Aldrich) per 100 mg of agarose was added, and the tube was vortexed again. The 
dissolved agarose was then applied to a QIAquick® spin column inside a collection tube 
and centrifuged at 13,000 rpm for one minute. Following this, 500 pi of Buffer QG was 
added to the spin column, and the tube was centrifuged again at 13,000 rpm for one 
minute. 750 pi of ethanol-containing Buffer PE was added to the spin column, which was 
then allowed to stand for five minutes. The tube was then centrifuged twice at 13,000 rpm 
for one minute. 30 pi o f Buffer EB (10 mM Tris-Cl, pH 8.5) that had been pre-heated to 
70°C was added to the spin column, which was then allowed to stand for one minute. The 
PCR product was eluted by a final centrifugation at 13,000 rpm for one minute. The eluted 
product was stored at ‘20°C.
23.4: Post-PCR Cleanup
Some post-PCR molecular analyses (e.g. genotyping, relative allelic expression assay, and 
sequencing) require unincorporated primer or dNTPs present in the PCR product to be 
deactivated to avoid potential interference with primer extension reactions. This can be 
achieved by treatment with shrimp alkaline phosphatase (SAP) and exonuclease I (Exol).
SAP dephosphorylates free nucleotides, rendering them incapable of polymerisation. Exol 
degrades unbound primer into free nucleotides which can then be dephosphorylated by 
SAP.
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To each PCR product, 1 pi (1 U) of SAP (GE Healthcare), 0.25 pi (2.5 U) of Exol (GE 
Healthcare), and 1.75 pi of sterile water (Phoenix Pharma) was added. The reaction was 
incubated at 37°C for 60 minutes, and then heated to 80°C for 20 minutes to inactivate the 
enzymes.
23.5: SNaPshot Primer Extension
SNaPshot primer extension involves use of the SNaPshot™ Multiplex Kit (Applied 
Biosystems) to perform a single base extension reaction. In this reaction, an 
oligonucleotide primer, specifically designed to anneal immediately adjacent to a known 
SNP site, is extended by one base with a fluorescently labelled ddNTP (F-ddNTP). Using 
the kit it is possible to extend multiple primers in a single multiplex reaction. Although 
originally designed for allele discrimination purposes (e.g. SNP genotyping), SNaPshot 
chemistry also has excellent quantitative properties (Norton et al., 2002). Hence, SNaPshot 
was used not just for SNP genotyping, but also for relative allelic expression analysis.
SNaPshot Extension Primer Design
All extension primers were designed by use of the FP Primer program (Ivanov et al., 2004) 
available online (http://m034.pc.uwcm.ac.uk/FP_Primer.html). If there were known 
variants in the amplicon in addition to the SNP to be genotyped or analysed, care was 
taken to avoid them. The input parameter ‘minimum length of the primers’ was set to 17.
AJ1 other input parameters were left at default settings. From the list of suggested primer 
sequences, a primer with low secondary structure and a Tm close to 60°C was used. For 
multiplex reactions, each primer was designed either a) so that it was at least two bases 
different in length from the others, or, if the same length as another, b) so that it would be 
extended with a different option of allelic nucleotides.
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SNaPshot Protocol
SNaPshot reactions were carried out in a total volume of 10 pi. Table 2.5 shows the 
volume and concentration of each reagent used in a singleplex reaction. For multiplex 
reactions, total extension primer volume remained at 1 pi with the concentration of each 
primer increased accordingly. Moreover, total PCR product volume increased to a 
maximum of 4.75 pi with the volume of sterile water reduced accordingly. Multiplex 
reactions were only carried out for genotyping purposes. All reactions for relative allelic 
expression analysis were carried out as singleplex.
Reagent Supplier Concentration Volume (pi)
Sterile H2O Phoenix Pharma - 2.75
SNaPshot Buffer - 3x* 3
Extension Primer Sigma-Aldrich 1 pM 1
SNaPshot Mix Applied Biosystems - 1.25
Clean PCR Product - - 2
Total - - 10
Table 2.5: Details o f reagents used in SNaPshot reactions. *SNaPshot buffer 
at 3* concentration contained 160 mM Tris-HCl at pH 8 (Fisher Scientific) 
and 4 mM MgCh (Qiagen) in Millipore-purified water.
  Till
Thermal cycling was carried out by either a MJ Research PTC-225 DNA Engine Tetrad 
or PTC-220 DNA Engine Dyad™ thermal cycler. A total of 25 cycles were carried out 
using the thermal cycling program depicted in Figure 2.2.
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95°C (02:00) 95°C (00:05)
3°C (00:05)
(4°C (10:00)
Initial
Denaturation Denaturation Annealing Extension Cool Down
Figure 2.2: Thermal cycling conditions used in SNaPshot primer extension reactions.
Incubation time at each temperature is indicated in parentheses in minutes and 
seconds.
23 .6 : Post-SNaPshot Cleanup
Left untreated, unincorporated F-ddNTPs present in SNaPshot products will comigrate 
with the ffagment(s) of interest during capillary gel electrophoresis and may interfere with 
base calling. To prevent this, SNaPshot products were treated with shrimp alkaline 
phosphatase (SAP), which alters the migratory properties of free F-ddNTPs by the removal 
of 5’ phosphoryl groups.
To each SNaPshot product, 0.5 pi (0.5 U) of SAP (GE Healthcare) and 2 pi of dH20  
(Phoenix Pharma) was added. The reaction was incubated at 37°C for 60 minutes, and then 
heated to 80°C for 20 minutes to inactivate the enzyme.
2.3.7: Sequencing
Sequencing was carried out using the BigDye® Terminator 3.1 Cycle Sequencing Kit 
(Applied Biosystems), which is based on the chain-terminating dideoxy method. In a 
sequencing reaction using this kit, an oligonucleotide primer, usually the forward or 
reverse PCR primer, anneals to a template and is extended in the presence of a high 
concentration of dNTPs and a lower concentration of fluorescently labelled ddNTPs (F- 
ddNTPs). The incorporation of a F-ddNTP after a random number of dNTPs into
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elongating DNA strands terminates their extension, which thus produces a set of 
fluorescently labelled DNA fragments that differ in length by a single nucleotide. When 
separated by size by capillary gel electrophoresis, the different fluorophores for each 
nucleotide are detected in the order they appear in the DNA fragment, which thereby 
reveals the sequence.
Sequencing Protocol
Sequencing reactions were carried out in a total volume of 10 pi. Table 2.6 shows the 
volume and concentration of each reagent used in a single reaction. Sequencing of PCR 
amplicons was carried out in both directions in two separate reactions: one with the 
forward PCR primer, and one with the reverse PCR primer.
Reagent Supplier Concentration Volume (pi)
BigDye Sequencing Buffer Applied Biosystems 5x 2
Primer (F or R) Sigma-Aldrich 3.2 pM 1
BigDye Terminator Mix Applied Biosystems 2.5* 2
Clean PCR Product - - 5
Total - - 10
Table 2.6: Details o f reagents used in sequencing reactions.
Thermal cycling was carried out by either a MJ Research PTC-225 DNA Engine Tetrad™
  TM
or PTC-220 DNA Engine Dyad thermal cycler. A total o f 26 cycles were carried out 
using the thermal cycling program depicted in Figure 2.3.
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96°C (02:00) 96°C (00:
Denaturation Denaturation Annealing Extension Cool Down 
Figure 23: Thermal cycling conditions used in sequencing reactions. Incubation time 
at each temperature is indicated in parentheses in minutes and seconds.
23 .8 : Post-Sequencing Cleanup
Left untreated, unincorporated F-ddNTPs present in sequencing products will comigrate 
with the fragments of interest during capillary gel electrophoresis and may interfere with 
base calling. To prevent this, sequencing products were purified using the Agencourt® 
CleanSEQ® purification system (Beckman Coulter). The CleanSEQ system works by the 
binding of sequencing products to specially designed paramagnetic beads, which, when 
exposed to a magnetic field, separates the products from unincorporated dyes, nucleotides, 
salts and other contaminants that are present in the supernatant. Following removal of the 
supernatant, the beads are washed in 85% ethanol and eluted into water, which causes the 
products to be released.
The post-sequencing cleanup procedure was fully automated using a Biomek® NX MC 
Laboratory Automation Workstation (Beckman Coulter). The Biomek robot was 
programmed using Biomek® Software 3.2 (Beckman Coulter) to follow the CleanSEQ 
manufacturer’s protocol for dye-terminator removal (Agencourt Bioscience Corp, 2006). 
Clean sequencing products were eluted into 10 pi of water.
52
Chapter 2: Materials and Methods
23.9: Capillary Gel Electrophoresis
Capillary gel electrophoresis was the end-stage method by which nearly all raw data 
presented in this work was generated. Fluorescent products of PCR, SNaPshot and 
sequencing reactions were separated, detected and quantified by an ABI Prism® 3100 
(Applied Biosystems) capillary gel electrophoresis machine controlled by Data Collection 
Software 2.0 (Applied Biosystems). The particular conditions and settings used during 
electrophoresis varied according to the type of product analysed. The majority of sample 
products were loaded onto the ABI 3100 by Miss Jennifer Turner.
Electrophoresis of SNaPshot Products
TM1-2 pi of clean product was mixed with 8-9 pi of Hi-Di Formamide (Applied 
Biosystems) and loaded on to the ABI 3100 machine. The products were electrophoresed 
on a 36 cm capillary array with POP-4™ Polymer (Applied Biosystems) at 60°C.
Electrophoresis of Fluorescent Microsatellite PCR Products
TM2 pi of product was mixed with 7.5 pi of Hi-Di Formamide (Applied Biosystems) and 0.5 
pi of GeneScan™ 500 ROX™ Size Standard (Applied Biosystems) and loaded on to the 
ABI 3100 machine. The products were electrophoresed on a 36 cm capillary array with 
POP-4™ Polymer (Applied Biosystems) at 60°C.
Electrophoresis of Sequencing Products
10 pi of clean product was loaded on to the ABI 3100 machine and electrophoresed on a 
36 cm capillary array with POP-6™ Polymer (Applied Biosystems) at 55°C.
53
Chapter 2: Materials and Methods
2.4: Data Analysis
Following capillary gel electrophoresis, data output files for fluorescent PCR assays (i.e. 
for microsatellite genotyping) and SNaPshot assays (i.e. for SNP genotyping and relative 
allelic expression) were processed by GeneScan® Analysis 3.7 and analysed in Genotyper® 
2.5. Data output files for sequencing assays were analysed in Sequence Navigator™ 1.0.1 
(Applied Biosystems).
2.4.1: GeneScan® Analysis 3.7 and Genotyper® 2.5
GeneScan® Analysis 3.7 (Applied Biosystems) is a program that assigns size to detected 
DNA fragments and quantifies their fluorescent signal. Detected DNA fragments can then 
be viewed in Genotyper 2.5 (Applied Biosystems) as peaks in an electropherogram, 
which can be labelled according to either size (if a size standard was used in the 
electrophoresis) or height. The height of each peak is proportional to the amount of the 
DNA fragment that was detected. To ensure only true signals were analysed, a minimum 
peak height value of 500 was required.
Analysis of Microsatellite Genotype Data
When genotyping microsatellites, peaks were labelled according to size (i.e. length in bp). 
The size of each peak was proportional to the number of repeats. The number of repeats for 
each allele was approximately calculated by dividing the size by the number of bases in a 
single repeat unit after the length of the PCR primers and the non-polymorphic portion of 
the amplicon was subtracted. The exact numbering of repeats was guided by reported 
population allele frequencies.
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Analysis of SNP Genotype Data
In Genotyper® 2.5, each allele of a SNP is depicted as a peak of a different colour 
according to the fluorophore attached to each ddNTP in the SNaPshot™ Multiplex Kit (A = 
green; C = black; G = blue; T = red). Genotypes for each SNP were determined by the 
presence of peaks in the appropriate colour.
Analysis of Relative Allelic Expression Data
To quantify allelic ratios, peaks were labelled in Genotyper® 2.5 according to height. Peaks 
heights were required to be in the approximate range of 1,000-6,000 as peak heights 
outside this range are generally less quantitative. Height data were appended to a table and 
copied into an Excel 2003 (Microsoft) spreadsheet for statistical analysis.
2.4.2: Analysis of Sequence Data in Sequence Navigator™ 1.0.1
TMSequence data output files were analysed in Sequence Navigator 1.0.1 (Applied 
Biosystems). In this program, sequence data is presented as a series of peaks in an 
electropherogram that differ in colour according to the fluorophore attached to each ddNTP 
in the BigDye® Terminator Kit (A = green; C = blue; G = black; T = red). The sequence 
was determined by simply reading from left to right.
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2.5: Statistical Analysis 
2.5.1: Statistical Correction of Allelic Ratios
Raw peak height data copied from Genotyper 2.5 (Applied Biosystems) were pasted into 
an Excel 2003 (Microsoft) data sheet that was pre-formulated to calculate a corrected 
measure o f relative allelic expression for each brain sample assayed. The main calculations 
executed in the data sheet to generate corrected allelic expression ratios are summarised in 
the equation in Figure 2.4.
[Ac/Bc]
CDNArati°“r= [(Z | f ) /n ]
Figure 2.4: Calculation o f corrected cDNA allelic ratios. Ac, Be = peak height values 
for alleles A and B in cDNA. Ag, Bg = peak height values for alleles A and B in 
genomic DNA. n -  the number o f genomic DNA samples assayed.
In essence, raw cDNA ratios were each divided by the mean of all ratios derived from 
genomic DNA, since, in the absence of any outliers, this was likely to represent the most 
precise equimolar ratio. Raw genomic DNA ratios were also corrected by the same factor, 
so that corrected genomic DNA ratios averaged 1:1. Once corrected, replicate cDNA and 
genomic DNA ratios for each brain sample were averaged, and these average values were 
subjected to further statistical analyses.
2.5.2: Statistical Power of the Relative Allelic Expression Assay
The power of the relative allelic expression assay to detect effects of unknown cis- 
regulatory variants is based on the binomial distribution, Hardy-Weinberg equilibrium at 
the regulatory variant, and no LD with the assayed SNP. The probability o f a brain sample 
being homozygous at a putative regulatory variant with alleles in Hardy-Weinberg
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equilibrium is p 2 + q1, where p  and q are the two allele frequencies. The probability that, of 
n individuals, all are homozygous (and therefore undetectable by the assay) for the 
regulatory polymorphism is then (p2 + q2)n. This also applies for n individuals selected for 
heterozygosity at the assayed SNP if there is no LD between the genotypes at each 
polymorphism. The power to detect at least one heterozygote is then 1 -  (p2 + q2)n. If the 
assayed and regulatory SNPs are in LD, then a higher proportion of samples selected for 
heterozygosity at the assayed SNP will also be heterozygous for the regulatory SNP and 
the power will be increased.
2 i 3 :  Statistical Comparison of Allele Ratios
Evidence for cw-regulatory polymorphism is obtained when cDNA ratios are significantly 
different from 1:1, as represented by ratios obtained from genomic DNA. To test whether 
or not cDNA ratios were significantly different from genomic DNA ratios, the independent 
samples t-test was used. The t-test was also used to test for potential c/s-regulatory effects 
of disease-associated polymorphisms or haplotypes by comparing cDNA ratios from brain 
samples that are heterozygous for the polymorphism or haplotype with ratios from samples 
that are homozygous, or that do not carry the haplotype. All t-tests were two-tailed, 
assumed unequal variance, and were performed using Excel 2003 (Microsoft). The power 
to detect a significant difference in cDNA ratios between heterozygotes and homozygotes 
for disease-associated polymorphisms or haplotypes was calculated using the Statistical 
Power Calculator available on the DSS Research website (http://www.dssresearch.com/ 
toolkit/spcalc/po wer_a2 .asp).
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2.5.4: Prediction of Phased Diplotypes
To determine the most likely phased diplotype carried by each brain sample, and phase 
with respect to the assayed SNP, unphased genotype data from all brain samples were first 
analysed in EH Plus (Zhao, Curtis & Sham, 2000) to predict the frequency of each possible 
haplotype. The probability that each brain sample carries a specific phased diplotype was 
then calculated using an in-house program (designed by Dr V Moskvina) by first 
reconstructing all possible phased diplotypes for each brain sample based on their observed 
genotypes at each locus. The expected distribution of phased diplotype frequencies, given 
the predicted haplotype frequencies in the entire brain sample collection, was then used to 
identify the most probable phased diplotype for each brain sample. The probability that a 
brain sample carries a particular phased diplotype is then the frequency of that diplotype 
divided by the sum of the frequencies for all possible diplotypes.
2.5.5: Linkage Disequilibrium Analysis
D * and r2 measures of linkage disequilibrium (LD) between two polymorphisms (e.g. an 
assayed SNP and a disease-associated variant) were calculated using Haploview 4.0 
(Barrett et al., 2005).
2.5.6: Other Statistical Analyses
Other statistical analyses, such as linear regression analysis, were performed using SPSS 
for Windows 14.0 (SPSS Inc.).
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3.1: Introduction 
3.1.1: The DISCI Gene and Protein
The DISCI gene (OMIM: 605210) was originally identified in a large Scottish family in 
which a balanced chromosomal translocation t( l;l lXq42.1;ql4.3) cosegregated with 
schizophrenia, bipolar disorder and other major mental illnesses (St Clair et al., 1990). The 
breakpoint on chromosome 1 directly interrupted two novel genes, which were named 
Disrupted in Schizophrenia 1 (DISCI) and 2 (DISC2) (Millar et al., 2000a). The DISCI 
gene spans —414 kb of chromosome lq42, includes 13 exons, and encodes a full length 
protein of 854 amino acids. The translocation interrupted the coding sequence, potentially 
resulting in a truncated protein that lacks the C-terminal 257 amino acids (Millar et al., 
2000a). DISC2 appears to specify a non-coding RNA that is transcribed from the antisense 
strand, and which may regulate DISCI expression (Millar et al., 2000a).
DISCI is expressed in both the embryonic and adult brain, and is particularly prominent in 
the hippocampus throughout all stages of life (Austin et al., 2003, 2004; Schurov et al., 
2004; Lipska et al., 2006). In mice, significant peaks in protein expression are detectable 
during embryonic neurogenesis and at puberty (Schurov et al., 2004), suggesting that 
DISCI plays an important role in brain development and maturation. The amino acid 
sequence of DISCI predicts a scaffold protein, and protein-protein interaction assays have 
identified >50 potential binding partners (Millar et al., 2003, 2005; Miyoshi et al., 2003, 
2004; Morris et al., 2003; Ozeki et al., 2003; Brandon et al., 2004; Ogawa et al., 2005) 
several of which are indeed involved in neurodevelopmental processes. Two of the most 
studied are fasciculation and elongation protein £ 1 (FEZI), linking DISCI with axon
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guidance and outgrowth (Miyoshi et al., 2003), and nuclear distribution gene E 
homologue-like 1 (NUDEL), which is known to form a complex with lissencephaly 1 
(LISI) (Sasaki et al., 2000; Niethammer et al., 2000), mutations in which cause severe 
disorders of neuronal migration (Pilz et al., 1998; Cardoso et al., 2002). More recently 
DISCI was also found to interact with, and thereby inhibit, phosphodiesterase 4B (PDE4B) 
(Millar et al., 2005). This is a potentially important finding since PDE4B inactivates 
cAMP, a second messenger molecule that plays a key role in learning, memory and mood 
(Davis et al., 1995; Lamprecht, 1999; Bauman, Goehring & Scott, 2004).
3.1.2: The DISCI Gene in Psychiatric Populations
Following the initial report on the Scottish family, a number of genetic linkage and 
association studies have suggested that DISCI may operate more generally as a 
susceptibility gene for mental illness. Chromosome lq42 has been reported to show 
linkage to schizophrenia (Ekelund et al., 2001; Ekelund et al., 2003; Hwu et al., 2003), 
schizoaffective disorder (Hamshere et al., 2005), bipolar disorder (Curtis et al., 2003; 
Macgregor et al., 2004) and autism (Buxbaum et al., 2004). Furthermore, SNPs and 
haplotypes in DISCI have shown association with schizophrenia, schizoaffective disorder 
and bipolar disorder in several independent populations (Hennah et al., 2003; Hodgkinson 
et al., 2004; Callicott et al., 2005; Cannon et al., 2005; Thomson et al., 2005a; Chen et al.,
2007; Qu et al., 2007). Association with major depressive disorder (Hashimoto et al.,
2006) and autistic spectrum disorders (Kilpinen et al., 2008) has also been reported. There 
have, however, been many negative association reports in schizophrenia and bipolar 
disorder (e.g. Devon et al., 2001; Kockelkom et al., 2004; Zhang et al., 2005b, Sanders et 
al., 2008). However, even large negative studies do not exclude the involvement of a gene 
given the presumed genetic complexity o f these disorders and the expected small effect
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sizes involved for many risk alleles (International Schizophrenia Consortium, 2009). It 
should also be noted that across the diverse populations, not all of the associated 
haplotypes overlap, indeed when put together they span the entire gene (Hennah et al.,
2006; Chubb, 2008). This may reflect a mixture of true and false associations, population 
differences in linkage disequilibrium (LD) structure, or, more likely given the distance 
across which the signals span, the presence of multiple susceptibility variants.
In order for DISCI to increase susceptibility to mental illness in the general population, it 
must contain sequence variants that either alter the structure of the encoded protein or 
influence the temporal, spatial or quantitative aspects of its expression. A common non- 
synonymous base substitution, which encodes Ser704Cys, has been reported to be 
associated with mental illness, and has also been shown to influence hippocampal and 
cingulate grey matter volume (Callicott et al., 2005; Hashimoto et al., 2006) and various 
measures of cognitive function (Callicott et al., 2005; Thomson et al., 2005b). Two other 
non-synonymous polymorphisms in DISCI, which encode Arg264Gln and Phe607Leu, 
also form parts of haplotypes that have been reported to show altered representation in 
schizophrenia (Hennah et al., 2003; Cannon et al., 2005). However, these and other 
associated haplotypes include non-coding variants that do not appear to tag polymorphism 
with obvious effects on DISCI protein structure. Although screening of DISCI has 
identified a small number of rare frameshift and missense mutations (Devon et al., 2001;
Sachs et al., 2005), in every case the variant either did not segregate with illness, or has 
been found in similar frequency in healthy control individuals (Devon et al., 2001; Green 
et al., 2006). Taken as a whole, these findings raise the possibility that the reported 
associations between DISCI and mental illness are mediated, at least in part, by variants 
that affect DISCI expression.
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One prominent example of a haplotype that might influence DISCI expression is HEP3, a 
common two SNP haplotype (comprising alleles T and A at SNPs rs751229 and rs3738401 
respectively) spanning -62 kb from intron 1 to exon 2 of DISCI. In a sample from Finland, 
this haplotype was originally reported to be under-transmitted to schizophrenic females 
(Hennah et al., 2003), but the finding was later interpreted to reflect over-transmission to 
schizophrenic males when population frequency was taken into account (Hennah et al., 
2005). It was also reported to be associated with cognitive endophenotypes related to 
schizophrenia such as deficits in visual working memory and visual attention (Hennah et 
al., 2005). The association between this haplotype and males with psychotic disorder has 
also been observed in a second Finnish sample (Palo et al., 2007). Moreover, an 
overlapping haplotype (which also includes the A allele at SNP rs3738401) was found to 
be under-represented in schizoaffective disorder patients in a study involving a North 
American white population (Hodgkinson et al., 2004).
3.13: Altered DISCI Expression as a Potential Pathogenic Mechanism in Psychiatric 
Disease
The potential pathogenic importance of altered DISCI expression is suggested by the 
observation that lymphoblastoid cell lines derived from family members carrying the 
t( 1; 11) translocation show -50% lower DISCI expression than cell lines from family 
members without the translocation (Millar et al., 2005). Since no truncated protein could 
be detected, the authors concluded that increased susceptibility of translocation carriers to 
mental illness was probably due to haploinsufficiency of DISCI.
Consistent with this view are findings that down-regulation of DISCI in vivo and in vitro 
give rise to developmental anomalies that are of potential relevance to schizophrenia. For
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example, down-regulation of Disci by RNA interference (RNAi) has been found, in 
embryonic mice, to impair neuronal migration and dendritic arborisation (Kamiya et al., 
2005), and in adult mice, to lead to cellular positioning defects in the hippocampus (Duan 
et al., 2007). Moreover, in cell culture, down-regulation of DISCI by RNAi has been 
reported to inhibit neurite outgrowth (Kamiya et al., 2005; Shinoda et al., 2007; Taya et 
al., 2007), and promote premature neuronal differentiation accompanied by reduced neural 
progenitor proliferation (Mao et al., 2009). Although these results all support decreased 
expression of DISCI as the pathogenic mechanism, it should, however, be noted that 
similar and additional phenotypes are also reported to result from expression of the 
putative truncated DISCI protein product acting in a dominant-negative manner (Kamiya 
et al., 2005; Hikida et al., 2007; Taya et al., 2007).
Whether or not brain DISCI expression is altered in psychiatric patients is not clear. One 
study did not find a difference in DISCI mRNA abundance in prefrontal cortex between 
subjects with schizophrenia or bipolar disorder and control subjects (Dean et al., 2007). 
However, in the hippocampus, a modest (-20%) increase in DISCI protein was observed 
in schizophrenic subjects compared with controls (Lipska et al., 2006). The hypothesis that 
DISCI contains common regulatory variation, and that this contributes to susceptibility to 
mental illness, is suggested by a recent study in which a putative risk haplotype for bipolar 
disorder was associated with reduced DISCI expression in lymphoblastoid cell lines 
(Maeda et al., 2006). However, a further study did not find a correlation between SNPs 
that showed association with schizophrenia and DISCI mRNA abundance in human brain 
(Lipska et al., 2006). The existence of regulatory variation in DISCI, and its relevance to 
psychiatric illness, therefore remains open to question.
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3.1.4: The Present Study
The reports of association between DISCI and various psychiatric disorders are currently 
not explicable by variants that alter protein structure, and there is evidence compatible with 
the hypothesis that alterations in DISCI expression could be relevant to disease. The 
primary aim of the present study was to investigate the possibility that DISCI contains 
common regulatory polymorphism. To this end, 65 informative individuals were screened 
for altered allelic expression. Samples were also genotyped for the HEP3 haplotype to test 
for a potential cis effect of this haplotype on DISCI expression. In selected individuals, the 
proximal DISCI promoter region was also sequenced in an effort to identify potential 
regulatory variants.
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3.2: Materials and Methods
Brain samples and the general methods used for DNA and RNA processing, 
genotyping, and the relative allelic expression assay are described in more detail in 
Chapter 2. 
3.2.1: Samples
Post-mortem brain tissue derived from frontal, temporal or parietal cortex of 148 unrelated 
anonymised individuals obtained from three sources (the MRC London Brain Bank for 
Neurodegenerative Diseases, the Stanley Medical Research Institute, and the Karolinska 
Institute) were used in this study. For each tissue sample, genomic DNA and total RNA 
were extracted by standard procedures. RNA was then treated with DNAse and reverse 
transcribed to cDNA.
3.2.2: Genotyping
PCR primers for the primary SNP used for relative allelic expression analysis (rs3738401), 
and for SNPs rs821616 and rs751229, were designed by use of the Primer3 program 
(Rozen & Skaletsky, 2000). PCR was carried out in a total reaction volume of 12 pi 
containing 48 ng of genomic DNA, and consisted of 35 cycles. Genotyping was carried out
TMby primer extension using the SNaPshot Multiplex Kit (Applied Biosystems) and primers 
designed by use of the FP Primer program (Ivanov et al., 2004). All primer sequences are 
shown in Table 3.1, which, where relevant, also shows the annealing temperature used 
during PCR cycling.
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Polymorphism Primer Sequence (5’-3 ’) Ta (°C)
F: GAACGTGGAGAAGCAGAAGG
58
rs3738401* R: AGAATGCATGTCACGCTCTG
EXT: ACCCGCGATGTCTCTCTC -
F: ACTTGGAAGCTTGTCGATTG
58
rs821616* R: CATCCATCTGCCTCTCATCT
EXT: CTTCCTGGAGCTGTAGGC -
F: TGAATTGAACTGAATCCCTTTTT
60
rs751229 R: GAGATGGGTTTCTGCCATGT
EXT: CTTAAAAACTTAGA TriTCAGCC -
Table 3.1: Details o f primers used in the study o f the DISCI gene. Asterisks 
indicate SNPs used for relative allelic expression analysis. F = forward primer, R 
= reverse primer, EXT = extension primer, Ta = annealing temperature used 
during PCR cycling.
3.23: Linkage Disequilibrium Analysis and Phased Diplotvpe Prediction
Linkage disequilibrium (LD) analyses were performed using Haploview 4.00 (Barrett et 
al., 2005) and were based on genotype data for the entire collection of 148 brain samples. 
The probability that each brain sample carried the HEP3 haplotype comprised of SNPs 
rs751229 and rs3738401 was calculated using EH Plus (Zhao, Curtis & Sham, 2000) and 
an in-house program, as described in Chapter 2 (section 2.5.4).
3.2.4: Relative Allelic Expression Assay
The SNP chosen for the primary relative allelic expression analysis was rs3738401. This 
SNP has a minor allele frequency of 0.30 in the HapMap CEU sample, is located in exon 2 
of the DISCI gene, and is present on all four principal DISCI mRNAs known to be 
transcribed in human brain (see Figure 3.1). The SNP is also present on low abundance
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hybrid transcripts formed through intergenic splicing of DISCI and the adjacent gene 
translin-associated factor X (TSNAX) (Millar et al., 2000b).
Genomic DNA from all brain samples was initially genotyped, as described, for the SNP to 
identify heterozygotes. For each heterozygous sample, cDNA produced ffom two separate 
reverse transcription reactions, alongside corresponding genomic DNA, was assayed on 
two separate occasions (i.e. 2 x {2 cDNA + 1 genomic DNA}). Genomic DNA and cDNA 
were assayed under identical conditions. This allowed the average allelic ratio obtained 
ffom genomic DNA (representing a 1:1 ratio) to be used to correct allelic ratios obtained 
ffom cDNA for any inequalities in allelic representation specific to the assay.
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Figure 3.1: The organisation of the DISCI gene and its four major mRNA transcripts. 
L = Long isoform (NM_018662), Lv = Long variant isoform (NM 001012957), S = 
Short isoform (NM 001012959), Es = Extremely short isoform (NM 001012958). 
Yellow rectangles represent 5’ and 3’ untranslated regions (UTRs), blue rectangles 
represent protein-coding exons, and the red rectangle represents the alternatively 
spliced 66 bp portion of exon 11. Asterisks indicate the positions of assayed SNPs 
rs3738401 in exon 2 and rs821616 in exon 11.
PCR consisted of 35 cycles and was carried out in a total reaction volume of 12 pi 
containing 48 ng of genomic DNA or 6 pi of cDNA at the standard cDNA concentration 
(see Chapter 2, section 2.1.8). Primers, shown in Table 3.1, were located in a single exon 
and therefore amplified an identical sequence from both templates. Allelic representation
TM • • •was measured by primer extension using the SNaPshot Multiplex Kit (Applied
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Biosystems) and the primer shown in Table 3.1. Peak heights of allele-specific extended 
primers were determined using Genotyper 2.5 (Applied Biosystems). The ratio of cDNA 
peak heights, corrected using the average ratio of genomic DNA peak heights, was then 
used to calculate the relative expression of mRNAs transcribed from each parental 
chromosome in each individual sample.
To confirm altered allelic expression, individuals showing expression of one allele at a 
level 20% or more than the other were assayed on four further occasions (i.e. 4 x {2 cDNA 
+ 1 genomic DNA}). In line with previous studies (Yan et al., 2002; Bray et al., 2003), an 
allelic expression difference >20% for any individual sample was chosen as indicative of 
the influence of cw-acting regulatory polymorphism since measurements surpassing this 
threshold are generally reproducible. Furthermore, where an average difference in allelic 
expression of >20% was maintained over the subsequent eight reactions, allelic expression 
was assessed, if heterozygous, at a second expressed SNP to test for effects on specific 
mRNA transcripts. The second SNP was rs821616, which, as shown in Figure 3.1, is 
located on exon 11 and present on the L and Lv transcripts only. The procedure for this 
SNP was identical to that used for rs3738401, but the primers used were those shown in 
Table 3.1.
3.2.5: Sequencing
In selected individuals, approximately 1 kb 5’ to the DISCI transcription start site was 
sequenced to determine the presence or absence of putative regulatory variants in the 
proximal promoter region. Primers used for PCR and sequencing are shown in Table 3.2.
PCR was carried out in a total reaction volume of 12 pi containing 48 ng of genomic DNA, 
and consisted of 35 cycles. Sequencing was performed in both directions by the fluorescent
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dideoxy method using the BigDye® Terminator Kit (Applied Biosystems). Where PCR 
generated two products of different sizes, the products were electrophoresed, excised from 
the gel, purified, and then sequenced.
Target Sequence Primer Sequence (5’- 3 ’) Ta (°C)
1045-795
F:
R:
GAACTCCTGGACTCAAGCAA 
TC AGGG AT AGG AGGG AG AAC
60
970-612
F:
R:
GGGC AAAC AC ACTG ATTTT A 
GCACCCCCTAGGTAGCAC
60
“668-348
F:
R:
CATGTGTAGCCCTTCCTTGT
GTGACCACACAGTGATGGAG
60
“451-103
F:
R:
TCTCTTTCCAGGGTCATCAG
CTGTTTCCTTTCCAGCATTG
60
“233-+146
F:
R:
AGCAGCGTGTGTGTGTATGT
CTAGGACTCTGTGGCAGCTC
60
Table 3.2: Details o f primers used to PCR amplify and sequence the DISCI
proximal promoter region. F = forward primer, R = reverse primer, Ta = 
annealing temperature used during PCR cycling. Target sequence positions are 
relative to the transcription start site.
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33: Results
33.1: Assayed Samples
A total of 65 genotyped individuals were heterozygous for the expressed SNP rs3738401 
and therefore informative for allelic expression analysis. Their mean age at death was 57 
years (SD = 19.69), 36 were male, and 29 were female. Over half (n = 33) had no known 
history of psychiatric or neurological disease, 10 had schizophrenia, eight had bipolar 
disorder, four had major depression, and 10 had Alzheimer’s disease. Samples were 
derived from frontal (n = 45), temporal (n = 14), and parietal (n = 6) brain tissue.
3 3 3 :  Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.09. No correlation was observed with sex, age, diagnostic status 
or brain region assayed. In the primary analysis, transcripts tagged by the G allele at SNP 
rs3738401 were on average 8.8% more abundant than those tagged by the A allele (Figure 
3.2). The difference between allelic ratios obtained with cDNA and genomic DNA was 
significant (P = 6.3 x 10**). Four samples displayed an allelic expression difference >20% 
(Figure 3.2). However, when these samples were assayed a further four times, this level of 
allelic expression difference was maintained by just one individual (Figure 3.3). The 
individual (Individual A, Figure 3.3) was a 57-year-old anonymous male with no known 
history of psychiatric or neurological disorder. For this individual, the average G:A ratio 
over eight replicate cDNA measurements was 1.53:1 (95% C.I. = 1.37-1.68:1). Thus, in 
this individual, expression of the G allele was increased by 53% (using the A allele as an 
arbitrary reference point), or expression of the A allele reduced by 34% (using the G allele
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as an arbitrary reference point). Observed cDNA ratios ffom this individual were 
significantly different ffom ratios derived ffom genomic DNA (P = 9.86 x 10‘5).
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Figure 3.2: Scatter plot showing allelic ratios for 
genomic DNA and cDNA derived ffom 65 
individuals heterozygous for SNP rs3738401. 
Data are presented as the G allele relative to the 
A allele (G:A). Each data point represents the 
average of four measurements. Ratios have been 
corrected by the average ratio obtained with 
genomic DNA.
A B C D 
Figure 33:  Bar chart comparing average allelic 
ratios obtained in the initial assay (red) with 
ratios obtained in the repeat assay (yellow) for 
four individuals (A, B, C, D) that showed an 
initial allelic expression difference >20%. The 
initial assay average is based on four 
measurements; the repeat assay average is based 
on eight measurements.
Relative allelic expression was assessed in this individual at a second exonic SNP, 
rs821616, for which the individual was also heterozygous. When assayed at this SNP, the 
average T:A ratio in cDNA ffom this individual was 1.60:1 (95% C.I. = 1.34-1.87:1).
33 3 :  Sequencing o f the DISCI Promoter Region
Sequencing of approximately 1 kb immediately upstream of the DISCI transcription start 
site in the individual that showed a robust allelic expression difference of >20% 
(Individual A) and in three individuals that showed close to equal allelic expression 
identified a novel insertion polymorphism (Figure 3.4). The insertion was a duplication of 
the 22 nucleotides at positions 168 to 147 relative to the DISCI transcription start site
Chapter 3: DISCI
(nucleotides 675-696 in reference sequence AF222982). The duplication was inserted in 
tandem with the reference sequence. The individual that showed a robust allelic expression 
difference was heterozygous for this duplication. However, after screening a further eight 
samples, two additional individuals that did not show allelic expression differences (G:A 
ratio = 0.95:1 and 0.97:1) were also found to be heterozygous for the duplication.
' i n v i i i
T ATG TC TG TG TG TG TG TG TG TG T G C G C G C G C G C G C G C G C G  
TA TG TC TG TG TG TG TG TG TG TG T A T G T C  T G T G T G T G T G T G
Figure 3.4: Sequencing trace showing the heterozygous duplication of the 22 
nucleotides at positions T 68-147 relative to the DISCI transcription start site in the 
individual that showed a consistent allelic expression difference. The sequence on the 
chromosome without the duplication is shown on the upper line; the duplicated 
sequence on the other chromosome is shown on the lower line. The arrow indicates the 
start of the duplicated sequence. The reference sequence is shown in italics.
The duplicated sequence includes a TG repeat that has previously been reported to be 
polymorphic (Devon et al., 2001; Kockelkom et al., 2004). In the present study, all 
chromosomes carrying the duplicated sequence carried one (TG)s repeat unit and one 
(TG)io unit. On the chromosome without the insertion, the individual that showed a 
consistent allelic expression difference carried a (TG)9 unit. Some individuals that showed 
no allelic expression differences were heterozygous for two repeat units that differed in 
length to a greater extent (e.g. (TG)9 and (TG)h).
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3.3.4: Effect of SNP rs751229 and the HEP3 haplotype
The HEP3 haplotype is comprised of alleles A and T respectively of SNPs rs3738401 (the 
assayed SNP) and rs751229, which were found to be in moderate LD (D’ = 0.70, r2 =
0.32). In the 148 brain samples genotyped in this study, the estimated frequency of this 
haplotype is 0.06. The probability that the 65 assayed brain samples (all of which were 
heterozygous at SNP rs3738401) carried the HEP3 haplotype based on their genotype at
Genotype P of HEP3 Class
C/C 0 Definite HEP3 non-carriers
C/T 0.06 Probable HEP3 non-carriers
T/T 1 Definite HEP3 carriers
Table 3.3: The estimated probability that the 65 assayed 
brain samples carry the HEP3 haplotype based on their 
genotype at SNP rs751229.
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Figure 3.5: Scatter plot showing allelic ratios for cDNA derived from 65 individuals 
heterozygous for SNP rs3738401 stratified by genotype for SNP rs751229. Data are 
presented as the G allele relative to the A allele (G:A). Individuals with genotype T/T 
(i.e. definite HEP3 carriers) are separated according to sex (dark green = males, light 
green = females). Each data point represents the average of four measurements. Ratios 
have been corrected by the average ratio obtained with genomic DNA.
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SNP rs751229 is shown in Table 3.3. As indicated in Table 3.3, assayed brain samples that 
were heterozygous for SNP rs751229 most likely do not carry the HEP3 haplotype (P of 
not carrying HEP3 = 0.94).
In the 65 brain samples assayed, cDNA ratios did not significantly differ between 
homozygotes and heterozygotes for SNP rs751229 (P = 0.49; Figure 3.5). Similarly, 
cDNA ratios did not significantly differ between definite HEP3 carriers (i.e. T/T at SNP 
rs751229) and definite or probably non-carriers (i.e. C/C or C/T at SNP rs751229; P =
0.20). There was also no significant difference between male and female HEP3 carriers (P 
= 0.89). These analyses had 80% power to detect a ratio difference of 0.08 between SNP 
rs751229 homozygotes and heterozygotes, 0.11 between HEP3 carriers and non-carriers, 
and 0.20 between male and female HEP3 carriers (P = 0.05).
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3.4: Discussion
The present study sought to test the hypothesis that DISCI contains common regulatory 
polymorphism, which might underlie reported genetic associations between DISCI and 
psychiatric disorders in general populations. An assay of relative allelic expression applied 
to a total o f 65 post-mortem brain samples revealed just one that showed a robust allelic 
expression difference of >20%. In that sample, derived from a 57-year-old male with no 
known psychiatric or neurological diagnosis, expression of one gene copy was -50%  
greater than expression of the other. The identified cis effect on expression was found to 
apply to the L and Lv DISCI transcripts, although an effect on the S and Es transcripts 
could not be excluded.
Overall, the data suggest that polymorphisms or haplotypes that have moderately large (i.e. 
>20%) effects on DISCI expression in brain are, at least in Caucasian populations, rare 
with a frequency o f <0.01 in the samples screened. This frequency is much lower than that 
o f most haplotypes that have been reported to be associated with psychiatric illness in such 
populations. Thus, while the present study supports the existence in rare cases of cis-acting 
variation with a moderately large influence on DISCI expression in adult brain, it does not 
support the hypothesis that the relatively common haplotypes associated with 
schizophrenia and bipolar disorder tag functional variants that act through this mechanism. 
It is, however, possible that the rare observation of allelic expression difference is relevant 
to one of the many rare haplotypes that have been reported to be associated with illness 
(e.g. Thomson et al., 2005), although this hypothesis cannot be tested using inferred 
haplotypes from a single subject. Furthermore, it is difficult to speculate as to whether the 
as yet unknown functional variant is a risk or protective factor, as it is not known if its
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effect is to suppress or enhance DISCI expression. A decrease in DISCI expression has 
been found to impair neurite outgrowth and cerebral cortex development (Kamiya et al.,
2005; Shinoda et al., 2007; Taya et al., 2007) and, consistent with the likely effect of the 
DISCI translocation, would presumably confer risk. An increase in DISCI expression in 
response to atypical antipsychotic drug treatment has been observed (Chiba et al., 2006), 
and, therefore, might be protective.
The search in the DISCI proximal promoter region for variation that may have given rise 
to the single observation of substantial allelic expression difference uncovered two 
potential candidates: a novel 22 bp duplication variant and a TG repeat polymorphism, 
which was also included in the duplicated sequence. The individual that showed an allelic 
expression difference was heterozygous for the duplication. However, two further 
individuals that did not show allelic expression differences were also heterozygous for it, 
suggesting the variant is a frequent polymorphism which, at least alone, does not affect 
DISCI expression. The individual was also heterozygous for the TG repeat polymorphism 
but this is also probably not a functional variant, as the difference in repeat length between 
the duplicated and non-duplicated chromosomes was very small, and a number of 
individuals that did not show allelic expression differences were heterozygous for two 
alleles of more different lengths. To identify the true functional variant, further mutation 
screening of DISCI would be required. It is also possible, however, that the allelic 
expression difference might be due to heterozygosity at multiple common variants 
(including the duplication) comprising a haplotype, none of which alone are unique to the 
individual screened.
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In addition to the single observation of a moderately large allelic expression difference, 
mRNAs tagged by the G allele at assayed SNP rs3738401 were generally slightly (8.8% on 
average) more abundant than mRNAs tagged by the A allele. This finding is consistent 
with the presence of a c/s-acting regulatory variant of small effect that is in high LD with 
the assayed SNP. Although this has the potential to promote susceptibility to psychiatric 
disease, high quality imputed data (average maximum posterior call probability >0.99; 
missing data proportion <3%) generated in the Department of Psychological Medicine as 
part o f recent genome-wide association studies (Wellcome Trust Case Control Consortium,
2007; Craddock et al., 2008; O’Donovan et al., 2008) -  with which the author was not 
involved -  did not indicate an association with schizophrenia (P = 0.85) or bipolar disorder 
(P = 0.99).
The comparison of cDNA ratios between brain samples with different genotypes at SNP 
rs751229 did not reveal any significant differences. The T allele of this SNP along with the 
A allele of the assayed SNP rs3738401 comprise the HEP3 haplotype that has previously 
been found to be over-transmitted to Finnish males with psychotic disorder (Hennah et al.,
2003, 2005; Palo et al., 2007). That cDNA ratios from definite HEP3 carriers were not 
significantly different from definite or probable HEP3 non-carriers suggests that if the 
association of this haplotype with psychosis is genuine, it unlikely to be mediated by 
effects on DISCI mRNA abundance in brain. However, given the power of this 
comparison (80% to detect a difference of 11%), small effects of this haplotype on mRNA 
abundance cannot be excluded.
It is important to highlight that DISCI plays a major a role in brain development and its 
expression is developmentally regulated. For instance, in mice, DISCI expression peaks
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during periods of active neurogenesis (Schurov et al., 2004), peaks again at puberty 
(Schurov et al., 2004), and is expressed in some regions of the developing brain that do not 
express DISCI in adulthood (Austin et al., 2004). Similarly, in humans, DISCI is more 
prominently expressed during prenatal, neonatal and pubertal stages of life than in 
adulthood (Lipska et al., 2006). It is therefore possible that risk alleles or haplotypes may 
exert effects on DISCI expression exclusively in a developmental context; in which case, 
their existence would not have been detected in the present study as only adult brain tissue 
was assayed. Similarly, the present study cannot rule out variants that might exert effects in 
specific brain regions not studied. A noteworthy example is the dentate gyrus, the region of 
highest DISCI expression in the adult brain (Austin et al., 2003, 2004), and where recent 
evidence suggests the gene plays an important role in adult neurogenesis (Duan et al., 
2007). Finally, the present study does not address quantitative or qualitative post- 
transcriptional effects, for example in the abundance of the protein or its subcellular 
distribution. Both may be of importance as, in schizophrenic subjects, a 20% increase in 
DISCI protein in the hippocampus (Lipska et al., 2006), and an altered subcellular 
distribution of the protein in the orbitofrontal cortex (Sawamura et al., 2005) has been 
found.
3.4.1: Conclusions
The results of the present study do not provide evidence that reports of genetic association 
between DISCI and psychiatric disorder can be explained by variants that result in changes 
in DISCI mRNA abundance in adult brain. Future investigations of the functional variants 
underlying disease association with DISCI should focus on post-transcriptional 
mechanisms and / or earlier developmental stages.
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C h a p te r  4: R e e lin  {RELN)
4.1: Introduction
4.1.1: The RELN Gene and Reelin
The human RELN gene (OMIM: 600514) spans -518 kb of chromosome 7q22, includes 65 
exons and encodes the large (3,460 amino acids) extracellular matrix protein reelin. During 
brain development, reelin is secreted by Cajal-Retzius cells located in the marginal zone, 
and plays a key role in the determining the final position of neurons radially migrating 
from the subventricular zone (Jossin, 2004). It was originally identified as the defective 
gene product in reeler mice, which exhibit severe cerebellar and cortical malformations 
and widespread neuronal ectopia (D’Arcangelo et al., 1995). It binds two low density 
lipoprotein receptors, apolipoprotein E receptor 2 (APOER2) and very low density 
lipoprotein receptor ( VLDLR) (D’Arcangelo et al., 1999), and initiates a signal cascade that 
involves phosphorylation of disabled 1 (DAB1) (Howell, Herrick, & Cooper, 1999) and 
activation of Src family protein tyrosine kinases (Amaud et al., 2003). In the adult brain, it 
is largely synthesised by a subset of GABAergic intemeurons in the neocortex and 
hippocampus, and glutamatergic neurons in the cerebellum (Pesold et al., 1998). In 
addition to its role in brain development, recent evidence suggests that reelin signalling is 
also important for synaptic plasticity and cognitive functions such as learning and memory 
(Herz & Chen, 2006).
4.1.2: RELN Expression in Human Disease
RELN and its protein product have been implicated in the aetiology and pathology of 
several psychiatric and neurodegenerative diseases. While null mutations in RELN cause 
an autosomal recessive form of lissencephaly (Hong et al., 2000; Chang et al., 2007; Zaki
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et al., 2007), altered reelin expression has been reported in several other psychiatric and 
neurodegenerative disorders, including schizophrenia, bipolar disorder, autism and 
Alzheimer’s disease.
In schizophrenia and bipolar disorder, RELN mRNA and reelin protein have been reported 
to be reduced by -50% in prefrontal cortex, temporal cortex, hippocampus, caudate nuclei 
and cerebellum (Impagnatiello et al., 1998; Guidotti et al., 2000; Fatemi, Earle & 
McMenomy, 2000; Fatemi et al., 2005b). The origin of this reduction, at least in 
schizophrenia, has been localised to interstitial white matter neurons in hippocampus, and 
in prefrontal cortex, to these same neuron types as well as layer I neurons and intemeurons 
(Eastwood & Harrison, 2003, 2006). Furthermore, in a recent meta-analysis of -100 post­
mortem neurochemical markers analysed in the Stanley Consortium brain sample 
(including tissue from 15 each of individuals with schizophrenia, bipolar disorder and 
major depression, and 15 healthy controls), a decreased level o f reelin mRNA and protein 
was found to be among the most striking neuropathological findings (Torrey et al., 2005). 
Importantly, the decrease in brain reelin levels was not related to post-mortem interval, the 
use of medication, nor a reduction in neuronal number (Impagnatiello et al., 1998; Guidotti 
et al., 2000; Fatemi, Earle & McMenomy, 2000; Eastwood & Harrison, 2003, 2006; 
Torrey et al., 2005), suggesting that it constitutes part of the disease process.
Reelin protein has been found to be significantly decreased by -70%  in superior frontal 
cortex, by 40% in the cerebellum, and non-significantly by -70% in the parietal cortex of 
adults with autism, compared with tissue from healthy controls (Fatemi et al., 2005a). In 
the superior frontal cortex and cerebellum, reductions in reelin protein were accompanied 
by 4.7 and 3.9 fold reductions in RELN mRNA and 14.2 and 2.8 fold increases in VLDLR
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mRNA respectively. Significant reductions in DAB1 mRNA were also observed. In a study 
that measured blood levels of reelin in 28 monozygotic autistic twins, their parents and six 
normal siblings, reelin levels were found to be 60-70% decreased in all family members 
when compared with levels in eight unrelated controls (Fatemi, Stary & Egan, 2002).
Reelin has also been implicated in the neuropathology of Alzheimer’s and other 
neurodegenerative diseases. There is evidence to suggest that the reelin signal pathway 
regulates phosphorylation of the microtubule associated protein tau (MAPT) (Hiesberger et 
al., 1999), and hyperphosphorylated tau is the major constituent of neurofibrillary tangles 
(a pathologic hallmark of Alzheimer’s and other neurodegenerative diseases). Increased 
levels of reelin have been found in cerebrospinal fluid of patients with Alzheimer’s 
disease, ffontotemporal dementia, progressive supranuclear palsy and Parkinson’s disease 
(Botella-Lopez et al., 2006). RELN mRNA and reelin protein are also reported to be 40% 
increased in frontal cortex of Alzheimer’s patients compared with controls (Botella-Lopez 
et al., 2006).
4.13: Epigenetic Regulation of the RELN Promoter
The RELN promoter is embedded within a CpG island, which extends from -1200 bp 
upstream ("1200) to -200 bp downstream (*200) of the transcription start site (Chen et al., 
2002b). This CpG island is controlled by several regulatory proteins (Grayson et al., 2005).
Most notable is DNA methyltransferase 1 (DNMT1), which, by methylation of CpG 
dinucleotides and subsequent recruitment of further proteins, has the effect of silencing 
RELN transcription (Noh et al., 2005; Dong et al., 2005; Kundakovic et al., 2007).
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In post-mortem brains of individuals with schizophrenia and bipolar disorder, over- 
expression of DNMTJ and increased levels of the methyl donor S-adenosyl methionine 
(SAM) have been observed in the same neurons that show reduced expression of reelin 
(Veldic et al., 2004, 2005, 2007; Guidotti et al., 2007). Furthermore, particular CpG 
dinucleotides between positions ”444 and ”259 and non-standard CpNpG trinucleotides at 
positions “139 and “134 have been found to be hypermethylated in schizophrenia 
(Abdolmaleky et al., 2005; Grayson et al., 2005). However, a subsequent report did not 
confirm these findings and presented additional data to highlight possible methodological 
errors in the previous two studies (Tochigi et al., 2008). Aberrant epigenetic regulation of 
the RELN 5’ region in schizophrenia and bipolar disorder is still suggested, however, by a 
study that employed a different methodology. Although no significant difference in 
methylation was observed at positions +131, +227 and +229 between schizophrenia, bipolar 
and control subjects, a correlation between age and methylation status was detected in the 
control subjects but not in the psychiatric subjects (Tamura et al., 2007).
4.1.4: RELN  in the Genetics of Psychiatric Disease
Genome-wide linkage scans and meta-analysis have consistently identified chromosome 
7q21-q36 as a region likely to harbour susceptibility variants for autism (Badner & 
Gershon, 2002; Trikalinos et al., 2006; Freitag, 2007; Yang & Gill, 2007). The q22 region 
in particular, to which the RELN gene maps, has shown significant linkage not only with 
autism (IMGSAC, 2001a, 2001b; Lamb et al., 2005; Schellenberg et al., 2006; Trikalinos 
et al., 2006; AGPC, 2007), but also with schizophrenia (Ekelund et al., 2000; Wedenoja et 
al., 2008). RELN has therefore been the subject of several candidate gene association 
studies for both disorders.
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Most association studies of RELN have focussed on a variable length CGG repeat located 
in the 5’ UTR of the gene immediately upstream of the start codon. In the first analysis of 
this polymorphism in a Caucasian population, eight alleles were identified, ranging from 4 
to 23 repeats, with 8 and 10 repeats being the most frequent (Persico et al., 2001). In both 
case-control and family-based analyses, long alleles (>11 repeats) were associated with 
increased risk for autism (Persico et al., 2001). In a second study of autism, cases and 
controls did not differ in allelic or genotypic frequencies, but a more powerful family- 
based association test showed that long alleles were transmitted more often than expected 
to autistic children (Zhang et al. 2002). The authors also noted that they found no evidence 
for instability of the repeat during transmission. A further seven studies have analysed the 
repeat with respect to autism. One found association with the 10 repeat allele (Skaar et al., 
2005), one showed distorted paternal transmission of the 10 and 11 repeat alleles in an 
Indian population (Dutta et al., 2007), and the remainder were negative (Krebs et al., 2002; 
Bonora et al., 2003; Devlin et al., 2004; Li et al., 2004; Ashley-Koch et al., 2007).
The 5’UTR repeat has been less thoroughly assessed in the context of schizophrenia. In 
two small studies of Japanese and Chinese Han populations, no association was found 
(Akahane et al. 2002; Huang & Chen, 2006). In a Caucasian sample, a higher frequency of 
the homozygous 8 repeat genotype was observed in controls compared with cases and the 
10 repeat allele was significantly more frequent in patients that did not respond to 
antipsychotic drug treatment than in patients that did or normal controls (Goldberger et al.,
2005).
There is evidence to suggest that the CGG repeat may be functional. In a comparison 
between 10 pairs of age-matched autistic male individuals it was found that those carrying
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at least one long (>12 repeats) allele had on average 25% less reelin in their plasma than 
those carrying two short (<10 repeats) alleles (Lugli et al 2003). Furthermore, in neuronal 
and non-neuronal cell lines transfected with constructs encompassing the RELN 5’ UTR 
upstream of the luciferase gene it was found that luciferase activity declined as the number 
of repeats increased (Persico et al. 2006). This finding was explained in terms of predicted 
mRNA folding and translational efficiency. However, given the location of the repeat 
within the same CpG island as the RELN promoter, an effect of the repeat on transcription 
by a methylation-related mechanism is an equally plausible explanation.
Several polymorphisms within RELN other than the CGG repeat have been reported to 
show association with autism (Skaar et al., 2005; Serajee et al., 2006; Ashley-Koch et al.,
2007; Li et al., 2008). With the possible exception of one SNP which may affect splicing 
of exon 6 (Persico et al., 2001), none of the associated polymorphisms are predicted to 
have a significant effect on protein structure. Although a small number of rare non­
conservative missense mutations in RELN that cosegregate with autism have been found 
(Bonora et al., 2003), these variants were too infrequent to account for the strong linkage 
signal observed at the 7q22 locus (IMGSAC, 2001a, 2001b). Furthermore, despite 
extensive mutation screening, only one relatively frequent non-conservative SNP 
(encoding Ser630Arg) in RELN has been identified, and both alleles were found to have 
similar frequencies in autistic individuals and controls (Bonora et al., 2003). Taken 
together, these findings strongly suggest that if the reported associations are genuine, they 
are most likely mediated by sequence variants that alter RELN expression.
A mutation screen of ~1 kb of the RELN promoter region in 100 Chinese Han 
schizophrenic patients identified a SNP at position ~728, which was predicted to alter a
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transcription factor binding site (Chen et al., 2002a). In a small case-control study this SNP 
showed a non-significant (P = 0.08) trend for association with schizophrenia (Chen et al.,
2002). In a Finnish population, a number of non-coding variants showed significant 
associations with various neuropsychological endophenotypes related to memory and 
executive functions (Wedenoja et al., 2007). In an Ashkenazi Jewish population, a 
genome-wide association scan identified a female-specific association of SNP rs7341475 
in intron 4 of RELN with schizophrenia (Shifman et al., 2008). The SNP was then tested in 
a further four case-control sample sets: three of European ancestry (UK, Ireland and USA) 
and one from China. The UK sample set was that collected by the Department of 
Psychological Medicine. In total there were 2,274 cases (768 females, 1,506 males) and 
4,401 controls (2,194 females, 2,207 males). The female-specific association of the same 
allele was replicated in the UK sample set, and was replicated again when data from the 
other three populations were combined. When data from all five populations was 
combined, the estimated female-specific odds ratio (OR) for carrying the common G/G 
genotype was 1.58 (P = 8.8 x 10'7) (Shifman et al., 2008). The replicated association of the 
same SNP in the same allelic direction with the same disorder in several populations 
provides strong, though not genome-wide significant, evidence that the SNP is or tags a 
true pathogenic variant. How the sex-specificity of the risk allele can be explained is, 
however, unclear.
4.1.5: The Present Study
The altered expression of reelin in psychiatric and neurodegenerative disease may be due, 
at least in part, to czs-regulatory variation within or nearby the RELN gene itself. This 
hypothesis is supported by the reviewed genetic evidence, the putative functional effect of 
the 5’ UTR repeat, and the equivocal findings relating to the methylation status of the
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promoter in psychosis. The present study formally tested this hypothesis by employment of 
a relative allelic expression assay. Putative effects of the 5’ UTR repeat and SNP 
rs7341475 polymorphisms on RELN expression were also investigated. Moreover, the 
repeat polymorphism was also tested for association with schizophrenia and bipolar 
disorder in a case-control analysis.
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4J2: Materials and Methods
Brain samples and the general methods used for DNA and RNA processing, 
genotyping, and the relative allelic expression assay are described in more detail in 
Chapter 2. 
4.2.1: Samples
Post-mortem brain tissue derived from frontal, temporal or parietal cortex of 148 unrelated 
anonymised individuals obtained from three sources (the MRC London Brain Bank for 
Neurodegenerative Diseases, the Stanley Medical Research Institute, and the Karolinska 
Institute) were used in this study. For each tissue sample, genomic DNA and total RNA 
were extracted by standard procedures. RNA was then treated with DNAse and reverse 
transcribed to cDNA.
4.2.2: Genotyping
PCR primers for the SNP used for relative allelic expression analysis (rs2229864), and for 
SNP rs7341475, were designed by use of the Primer3 program (Rozen & Skaletsky, 2000). 
PCR was carried out in a total reaction volume of 12 pi containing 48 ng of genomic DNA, 
and consisted of 35 cycles. Genotyping was carried out by primer extension using the 
SNaPshot™ Multiplex Kit (Applied Biosystems) and primers designed by use o f the FP 
Primer program (Ivanov et al., 2004). For the 5’ UTR repeat polymorphism, primers were 
as described previously (Persico et al., 2001), with a 5’ FAM label on the forward primer. 
PCR was performed as it was for the SNPs, but with a 12 pi reaction volume that included 
7% DMSO. Amplicons were then sized by coelectrophoresis with a size standard on a
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capillary electrophoresis machine. All primer sequences are shown in Table 4.1, which, 
where relevant, also shows the annealing temperature used during PCR cycling.
Polymorphism Primer 5’ Label Sequence (5’-3’) Ta (°C)
F: _ AGGACCGTTATGCTGGACAC
58
rs2229864* R: - AAACATGTCAAAGGCGATCC
EXT: - CCCCAGTACCCCAGCA -
F: _ CTGCTCTGGCACTTTCTAGC
58
rs7341475 R: - TCTTGGGAATGGTATGCAGT
EXT: - GGC ACTTTCT AGCC ATG AAAT -
F: FAM CGGCGTCTCCAAAACTGAAT
5’ UTR CGG 58
R: - AAC AGCGCT AGG AGG AAAGT
Table 4.1: Details o f primers used in the study o f the RELN gene. The asterisk indicates 
the SNP used for relative allelic expression analysis. F = forward primer, R = reverse 
primer, EXT = extension primer, Ta = annealing temperature used during PCR cycling.
4.23: Relative Allelic Expression Assay
The SNP chosen for relative allelic expression analysis was rs2229864. This SNP has a 
minor allele frequency of 0.30 in the HapMap CEU sample, is located in exon 50 of the 
RELN gene, and is present on both principal RELN mRNAs known to be transcribed in 
human brain (see Figure 4.1). The SNP may also be present on more minor transcripts that 
are generated by alternative polyadenylation signals in an extension of exon 63 (Rouvroit 
etal ., 1999).
Genomic DNA from all brain samples was initially genotyped, as described, for the SNP to 
identify heterozygotes. For each heterozygous sample, cDNA produced from two separate 
reverse transcription reactions, alongside corresponding genomic DNA, was assayed on
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two separate occasions (i.e. 2 x {2 cDNA + 1 genomic DNA}). Genomic DNA and cDNA 
were assayed under identical conditions. This allowed the average allelic ratio obtained 
from genomic DNA (representing a 1:1 ratio) to be used to correct allelic ratios obtained 
from cDNA for any inequalities in allelic representation specific to the assay.
1 2 3 4 5 7 9 11 13 17 20 23 26 29 33 36 40 43 46 49^ 52 56 60 6465
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Figure 4.1: The organisation of the RELN gene and its two major mRNA transcripts.
A = full length mRNA (NM 005045), B = alternatively spliced mRNA 
(NM_173054). Yellow rectangles represent 5’ and 3’ untranslated regions (UTRs), 
blue rectangles represent protein-coding exons, and the red rectangle represents the 
alternatively spliced microexon 64. The asterisk indicates the position of assayed SNP 
rs2229864 in exon 50.
PCR consisted of 35 cycles and was carried out in a total reaction volume of 12 pi 
containing 48 ng of genomic DNA or 6 pi of cDNA at the standard cDNA concentration 
(see Chapter 2, section 2.1.8). Primers, shown in Table 4.1, were based on a single exon 
and therefore amplified an identical sequence from both templates. Allelic representation 
was measured by primer extension using the SNaPshot™ Multiplex Kit (Applied 
Biosystems) and the primer shown in Table 4.1. Peak heights of allele-specific extended 
primers were determined using Genotyper 2.5 (Applied Biosystems). The ratio of cDNA 
peak heights, corrected using the average ratio of genomic DNA peak heights, was then 
used to calculate the relative expression of mRNAs transcribed from each parental 
chromosome in each individual sample.
To confirm altered allelic expression, select individuals showing expression of one allele at 
a level 20% or more than the other were assayed on four further occasions (i.e. 4 x {2
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cDNA + 1 genomic DNA}). In line with previous studies (Yan et al., 2002; Bray et al.,
2003), an allelic expression difference >20% for any individual sample was chosen as 
indicative of the influence of c/s-acting regulatory polymorphism since measurements 
surpassing this threshold are generally reproducible.
4.2.4: Linear Regression Analysis
A step-wise linear regression analysis was carried out using SPSS 14.0 (SPSS Inc.) to 
investigate potential effects of the 5’ UTR CGG repeat polymorphism and other factors on 
RELN expression. Predictor variables included the difference in repeat number between the 
two alleles carried by an individual (i.e. CGG difference), rs7341475 genotype, age, sex, 
diagnosis, and brain region assayed. The dependent variable was the expression ratio of the 
highest relative to the lowest expressed allele (i.e. H:L cDNA ratio) for each individual.
4.2.5: Linkage Disequilibrium Analysis
Linkage disequilibrium (LD) analyses were performed using Haploview 4.00 (Barrett et 
al., 2005) and were based on genotype data for the entire collection of 148 brain samples.
4.2.6: Case-Control Association Analysis of the 5’ UTR CGG Polymorphism
The 5’ UTR CGG repeat polymorphism was indirectly tested for association with 
schizophrenia and bipolar disorder by a case-control association analysis. The Department 
of Psychological Medicine recently contributed to genome-wide case-control association 
studies of schizophrenia and bipolar disorder, which were comprised of 479 individuals 
with schizophrenia, 1,868 individuals with bipolar disorder, and 2,939 control individuals 
(Wellcome Trust Case-Control Consortium, 2007; O’Donovan et al., 2008). Imputed 
genotype data were generated for these cases and controls by Dr J Marchini (Oxford
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University) using IMPUTE (Marchini et al., 2007). It should be noted that imputed 
genotype data for the schizophrenia and bipolar disorder case-control datasets were 
generated using slightly different versions of IMPUTE, resulting in minor differences in 
the estimated allele frequencies. The samples analysed and the genesis of the datasets (with 
which the author was not involved) are described in detail in the source publications.
Rather than genotyping the repeat polymorphism in these individuals, it was instead 
genotyped in the 90 European individuals (consisting of 30 trios) that comprise the 
HapMap CEU samples. Patterns of LD in these samples were found to be representative of 
that in the individuals analysed in the case-control studies (WTCCC, 2007). Based on 
previous association findings (Persico et al., 2001; Goldberger et al., 2005), genotypes for 
the repeat polymorphism were biallelically coded as short (<10 repeats) versus long (>11 
repeats) and 8 repeats versus >10 repeats and merged with HapMap SNP data. Using 
Haploview 4.00 (Barrett et al., 2005), SNPs in high LD (i.e. r2) with the polymorphism 
were then identified and examined for evidence of association with disease in the imputed 
data for those SNPs, which were not present on the genotyping arrays used in the genome- 
wide association studies.
4.2.7: Calculation of Statistical Power for Case-Control Association Analyses
The statistical power of the case-control analyses to detect association of the 5’ UTR repeat 
polymorphism with schizophrenia and bipolar disorder was calculated by use of Epi Info™
3.3 (Centers for Disease Control and Prevention). Since SNPs in LD with the 
polymorphism were tested for association as a surrogate for the polymorphism itself, the 
calculation was based on case and control samples sizes that had been adjusted by 
multiplication by the value of r2.
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43: Results
43.1: Assayed Samples
A total of 66 genotyped individuals were heterozygous for the expressed SNP rs2229864 
and therefore informative for allelic expression analysis. Their mean age at death was 60 
years (SD = 19.67), 34 were male, and 32 were female. More than half (n = 39) had no 
known history of psychiatric or neurological disease, eight had schizophrenia, five had 
bipolar disorder, three had major depression, and 11 had Alzheimer’s disease. Samples 
were derived from frontal (n = 45), temporal (n=  15), and parietal (n = 6) brain tissue.
4 3 3 : Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.07. No correlation was observed with sex, age, diagnostic status 
or brain region assayed. Three samples displayed an allelic expression difference of >20%, 
two of which were clear outliers (Figure 4.2). One was an 85-year-old anonymous male 
with no known history of neurological or psychiatric disorder. For this individual 
(individual A), the average C:T ratio over four replicate cDNA measurements was 1.30:1. 
The other outlier was an 83-year-old anonymous male with a history of Alzheimer’s 
disease. For this individual (individual B), the average C:T ratio over four replicate cDNA 
measurements was 0.60:1. When these individuals’ samples were assayed a further four 
times, the average C:T ratios over eight replicate cDNA measurements were 1.44:1 (95% 
C.I. = 1.31-1.57:1) and 0.68:1 (95% C.I. = 0.64-0.73:1) respectively (Figure 4.3). Thus, 
expression of the C allele was increased by 44% in individual A and reduced by 32% in 
individual B (using the T allele as an arbitrary reference point), or expression of the T 
allele was reduced by 31% in individual A or increased by 46% in individual B (using the
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C allele as an arbitrary reference point). Observed cDNA ratios from both individuals were 
significantly different from ratios obtained with genomic DNA (P = 6.89 x 10'5 and 3.85 x 
10’5 respectively).
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Figure 4.2: Scatter plot showing allelic ratios 
for genomic DNA and cDNA derived from 66 
individuals heterozygous for SNP rs2229864. 
Data are presented as the C allele relative to 
the T allele (C:T). Each data point represents 
the average of four measurements. Ratios have 
been corrected by the average ratio obtained 
with genomic DNA.
A B
Figure 43: Bar chart comparing average 
allelic ratios obtained in the initial assay (red) 
with ratios obtained in the repeat assay 
(yellow) for two individuals (A, B) that 
showed an initial allelic expression difference 
>20%. The initial assay average is based on 
four measurements; the repeat assay average is 
based on eight measurements.
4 3 3 : Effect of SNP rs7341475 in Males and Females
LD analyses showed that there was no LD between the assayed SNP rs2229864 and the 
putative schizophrenia risk SNP rs7341475 (D’ = 0.01, r2 = 0.00). cDNA ratios denoted as 
the more highly expressed allele relative to the lower expressed allele (i.e. H:L) did not 
significantly differ between homozygotes and heterozygotes for SNP rs7341475 (P = 0.96; 
Figure 4.4). This was also apparent when males and females were analysed separately (P = 
0.80 and 0.45 respectively). These analyses had 80% power to detect a ratio difference of 
0.08 in males and females combined, 0.11 in males, and 0.07 in females (P = 0.05).
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Figure 4.4: Scatter plot showing allelic ratios for cDNA derived from 66 individuals 
heterozygous for SNP rs2229864 stratified by sex and genotype for SNP rs7341475. 
cDNA ratios from individuals that are homozygous for SNP rs7341475 are shown in 
red, and ratios from heterozygotes are shown in yellow. Data are presented as the 
higher expressed allele relative to the lower expressed allele (H:L). Each data point 
represents the average of four measurements. Ratios have been corrected by the 
average ratio obtained with genomic DNA.
43  A: Effect of the 5’ UTR CGG Repeat
In a stepwise linear regression analysis, the difference in length of the two CGG repeat 
alleles carried by each individual (i.e. CGG difference) was a significant predictor of H:L
1.30
1.25
1.20
1.15
1.10
1.05
1.00
0.95
0.90
3 4 5 70 1 2 6
Figure 4.5: Scatter plot showing the regression of CGG difference (i.e. difference in 
length of the two CGG repeat alleles carried by each individual) with H:L cDNA 
ratios (adjusted r2 = +0.10, P = 0.006, n = 64). The regression equation is H:L cDNA 
ratio = 1.068 + (0.015 * CGG Difference). Outlying individuals (individuals A and B) 
were excluded.
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cDNA ratios (B = 0.015, 95% C.I.: 0.005-0.026, P = 0.006) and accounted for -10% of the 
variance (adjusted r2 = 0.10). The regression line is shown in Figure 4.5. No other 
variables, including sex, age, diagnostic status, brain region assayed, or coefficient of 
variation, displayed significant predictive value.
43.5: Genotyping and Linkage Disequilibrium Analysis of the 5’ UTR CGG Repeat 
Polymorphism in HapMap CEU Samples
The 5’ UTR CGG repeat polymorphism was successfully genotyped in 89 of the 90 
(98.89%) HapMap CEU samples. Samples genotyped in duplicate yielded concordant 
genotypes and all genotypes were confirmed by a second, more experienced, researcher.
Six alleles were observed, ranging from 8 to 15 repeats, with 8 and 10 repeat alleles being 
the most frequent. All genotypes were consistent with Mendelian expectations.
LD analysis revealed that when biallelically coded as short (<10 repeats) versus long (>11 
repeats), the CGG repeat polymorphism exhibited highest LD (r2 = 0.80) with SNP 
rs l0273035. When coded as 8 repeats versus >10 repeats, highest LD (r2 = 0.89) was 
observed with SNP rs6951875. These SNPs map -26.5 kb and -2.5 kb 5’ of the CGG 
repeat respectively. In the HapMap CEU samples they have minor allele frequencies of 
0.08 and 0.34, and genotyping success of 96.7% and 97.8% respectively. No deviation 
from Hardy-Weinberg equilibrium was observed for either SNP (P > 0.05).
43.6: Association Analysis of SNPs rsl0273035 and rs6951875 in Schizophrenia 
Cases and Controls
Imputed genotype and allele frequency data for SNPs rs l0273035 and rs6951875 were 
obtained for 479 schizophrenia cases and 2,939 controls (Table 4.2). Missing data
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proportions were 1.84% (8 cases, 55 controls) and 27.94% (131 cases, 824 controls) for 
each SNP respectively. The average maximum posterior genotype call probabilities were 
0.99 and 0.91 respectively. No deviation from Hardy-Weinberg equilibrium was observed 
for either SNP in cases or controls (P > 0.05).
SNP
Allele or 
Genotype
Freq
Cases
uency
Controls
P
C 898 (0.95) 5,550 (0.96)
0.19
1 44 (0.05) 218(0.04)
rsl0273035 C/C 428 (0.91) 2,671 (0.93)
c/1 42 (0.09) 208 (0.07) 0.42
I/I 1 (0.00) 5 (0.00)
A 257 (0.37) 1,630(0.39)
0.42
G 439 (0.63) 2,600(0.61)
rs6951875 A/A 44(0.13) 328 (0.16)
A/G 169 (0.49) 974 (0.46) 0.36
G/G 135(0.39) 813(0.38)
Table 4J2: Summary o f schizophrenia case-control data for SNPs rsl0273035 and 
rs6951875. SNP alleles associated with longer CGG repeat alleles (i.e. >11 repeats for 
SNP rsl027303 or >10 repeats for rs6951875) in HapMap CEU samples are 
underlined. Genotype and allele frequencies are based on imputed data. Frequencies 
expressed as fractions o f total number o f cases or controls are shown in parentheses.
The significance P value for allelic and genotypic tests o f association is indicated.
Imputation did not reveal any allelic or genotypic association between SNP rs l0273035 
and schizophrenia (Table 4.2). Similarly, no association was observed with SNP rs6951875 
(Table 4.2). Based on the frequency of longer alleles of the CGG repeat (i.e. >11 repeats =
11.9% or >10 repeats = 63.6%) and allowing for its LD with the tested SNPs (i.e. r2 = 0.80
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or 0.89) in the HapMap CEU samples, it was calculated that these analyses had 80% power 
to detect association of the CGG repeat polymorphism with schizophrenia with ORs of 
>1.38 or >1.37 respectively.
43.7: Association Analysis of SNPs rsl0273035 and rs6951875 in Bipolar Disorder 
Cases and Controls
Imputed genotype and allele frequency data for SNPs rs l0273035 and rs6951875 were 
obtained for 1,868 bipolar disorder cases and 2,938 controls (Table 4.3). Missing data 
proportions were 4.02% (85 cases, 108 controls) and 24.34% (452 cases, 718 controls) for 
each SNP respectively. The average maximum posterior genotype call probabilities were 
0.99 and 0.92 respectively. No deviation from Hardy-Weinberg equilibrium was observed 
for SNP rs l0273035 in cases or controls (P > 0.05), or for SNP rs6951875 in controls. In 
cases, genotypes for the latter SNP deviated significantly from Hardy-Weinberg 
equilibrium (P < 0.001).
Imputation did not reveal any allelic or genotypic association between SNP rs l0273035 
and bipolar disorder (Table 4.3). Similarly, no association was observed with SNP 
rs6951875 (Table 4.3). Based on the frequency of longer alleles of the CGG repeat (i.e.
>11 repeats = 11.9% or >10 repeats = 63.6%) and allowing for its LD with the tested SNPs 
(i.e. r2 = 0.80 or 0.89) in the HapMap CEU samples, it was calculated that these analyses 
had 80% power to detect association of the CGG repeat polymorphism with bipolar 
disorder with ORs of >1.22 or >1.16 respectively.
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SNP
Allele or 
Genotype
Freqi
Cases
uency
Controls
P
C 3,451 (0.97) 5,469 (0.97)
0.70
I 115(0.03) 191 (0.03)
rsl 0273035 C/C 1,669 (0.94) 2,644 (0.94)
c/1 113(0.06) 181 (0.06) 0.54
I/I 1 (0.00) 5 (0.00)
A 1,158(0.41) 1,774 (0.40)
0.44
G 1,674 (0.59) 2,666 (0.60)
rs6951875 A/A 267 (0.19) 372 (0.17)
A/G 624 (0.44) 1,030 (0.46) 0.20
G/G 525 (0.37) 818(0.37)
Table 43: Summary o f bipolar disorder case-control data for SNPs rsl0273035 and 
rs6951875. SNP alleles associated with longer CGG repeat alleles (i.e. >11 repeats for 
SNP rsl027303 or >10 repeats for rs6951875) in HapMap CEU samples are 
underlined. Genotype and allele frequencies are based on imputed data. Frequencies 
expressed as fractions o f total number o f cases or controls are shown in parentheses. 
The significance P value for allelic and genotypic tests o f association is indicated.
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4.4: Discussion
The present study had four main objectives: 1) to determine whether or not the RELN gene 
contains common regulatory polymorphism, which could potentially influence risk for 
several psychiatric disorders; 2) to test whether or not SNP rs7341475, identified as a risk 
factor for schizophrenia in women, is associated with altered RELN expression; 3) to test 
whether or not a 5’ UTR CGG repeat polymorphism, previously reported to be associated 
with autism, influences RELN expression at the mRNA level; and 4) if the CGG repeat was 
indeed found to influence RELN expression, to identify SNPs in high LD with it and to test 
those SNPs for association with schizophrenia and bipolar disorder using imputed 
genotype data obtained in a large genome-wide case-control study. To achieve these 
objectives, an assay of relative allelic expression was applied to a total of 66 post-mortem 
brain samples, which were also genotyped for SNP rs7341475 and the CGG repeat 
polymorphism.
Of the 66 heterozygotes assayed, three showed an allelic expression difference of >20%, 
two of which were clear outliers. Repeat assays of these individuals showed a robust allelic 
expression difference of -45% in both individuals. The higher expressed allele was 
different in each individual. Hence, if the two individuals carried the same putative 
regulatory variant, which is suggested by their similar allelic difference, then the lower 
expressed allele is in phase with different alleles at the assayed SNP. The putative variant 
is, therefore, unlikely to be in high LD (i.e. D ’) with the assayed SNP.
These data suggest that polymorphisms or haplotypes that have moderately large effects 
(i.e. >20%) on RELN expression in brain exist but are, at least in Caucasian populations,
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relatively rare with a frequency of <0.02 in the samples screened. This frequency is much 
lower than that of most SNPs that have been reported to be associated with autism in such 
populations. Thus, while the present study supports the existence in rare cases of c/s-acting 
variation that has a moderately large influence on RELN expression in adult brain, it does 
not support the hypothesis that the relatively common SNPs associated with autism tag 
functional variants that act through this mechanism. Nonetheless, it remains a distinct 
possibility that the putative regulatory variants) detected in the present study may 
influence risk of psychiatric disorders in which expression of RELN in brain is altered. 
Indeed, for autism, it is perhaps even likely, given the previous (Lugli et al., 2003; Persico,
Levitt & Pimenta, 2006) and present work (discussed later) that suggests that the 5’ UTR 
repeat polymorphism reported to be associated with the disorder has functional effects on 
RELN expression.
The comparison of H:L cDNA ratios between homozygotes and heterozygotes for SNP 
rs7341475 did not reveal any significant differences in males and females combined, nor in 
each sex separately. This finding suggests that the reported association of the SNP with 
schizophrenia in women is not mediated by an alteration in RELN mRNA abundance. It is 
of note, however, that these analyses did not have sufficient power to detect a significant 
ratio difference of <0.08 in both sexes combined, or <0.07 in females, hence the present 
study cannot exclude the possibility that SNP rs7341475 influences risk by very small 
effects on expression. Furthermore, it is possible that SNP rs7341475 is not a functional 
variant, but merely serves as proxy for a separate variant that is in high LD with it. In this 
case, and if the variant indeed has effects on mRNA abundance, only a fraction of SNP 
rs7341475 heterozygotes, and even some homozygotes for the risk allele, would be 
expected to show a significant allelic expression difference. Consistent with this was that
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one of the outlying male individuals with a H:L cDNA ratio of 1.44:1 was a SNP 
rs7341475 heterozygote. However, one other male individual with a similar ratio was 
homozygous for the non-risk allele, which suggests that cw-regulatory variants with effects 
on mRNA abundance are not exclusive to haplotypes tagged by the risk allele.
In the test of whether or not the CGG repeat polymorphism has functional effects on RELN 
mRNA abundance, it was assumed that if it did, then the difference in repeat number of the 
two alleles carried by each individual (i.e. CGG difference) should account for some of the 
inter-individual variation in allelic expression imbalance. Genotyping of the repeat 
polymorphism in the assayed individuals identified genotypes with CGG differences 
ranging from zero (i.e. homozygotes) to six repeats (i.e. 8/14 repeat genotype). In a 
stepwise linear regression analysis it was found that CGG Difference was the only 
significant predictor of H:L cDNA ratio, and accounted for -10% of the measured inter­
individual variation in that variable. The regression equation was H:L cDNA ratio = 1.068 
+ (0.015 x CGG Difference), which indicates that as repeat number difference increases by 
one, allelic expression imbalance increases by 1.5%.
These data are in agreement with two previous studies, which also provided evidence that 
the CGG repeat polymorphism has functional effects on reelin expression (Lugli et al.,
2003; Persico, Levitt & Pimenta, 2006). In both studies, which only measured expression 
at the protein level, higher repeat numbers were associated with lower expression. The data 
from the present study do not distinguish the direction of the relationship between repeat 
number and mRNA expression level. While direct assay of the repeat is theoretically 
possible given its location within mRNA sequence, this was not performed because of 
unknown effects of repeat size on the efficiency of reverse transcription, which is not
103
Chapter 4: RELN
necessarily controlled for by assay of genomic DNA. However, given that the RELN 
promoter is known to be regulated by methylation, it is tempting to assume that higher 
repeat numbers are also associated with lower mRNA expression due to the extra potential 
methylation sites that the CGG repeats provide. It is of note that in comparison with 
reported effects on protein abundance (Lugli et al., 2003; Persico, Levitt & Pimenta, 2006), 
the effect of the repeat polymorphism on mRNA abundance is relatively small. This 
difference in effect size on expression at the two levels suggests that the effect previously 
observed on protein expression cannot be explained merely by an effect on mRNA 
abundance (e.g. transcriptional effects). Hence, while the present study provides the first 
evidence that the repeat polymorphism has functional effects on mRNA expression, it is 
also consistent with previous evidence, which suggests that it additionally influences 
protein levels by separate effects on mRNA folding and translational efficiency (Persico,
Levitt & Pimenta, 2006).
If the repeat is a true susceptibility variant for autism, then its pathogenicity may be 
mediated by a combination of all the above-described effects. The same can be proposed in 
relation to Alzheimer’s disease with which the polymorphism was also found to be 
associated after the present work was conducted (Seripa et al., 2008). Interestingly, in that 
study, genotypes containing shorter alleles (i.e. 8 /8  and 8 /1 0  repeat genotypes) were more 
frequent in female but not male patients with Alzheimer’s disease than controls, consistent 
with increased levels of reelin detected in affected brains (Botella-L6 pez et al., 2006). 
However, there is no obvious explanation for the sex-specific effect, which might be a 
chance observation resulting from multiple post-hoc testing and reduced power in the 
smaller subgroups.
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The longer alleles (>11 repeats) of the repeat are reported to confer susceptibility to autism 
(Persico et al., 2001; Zhang et al., 2002), which, given previous and present findings, is 
consistent with reduced levels of reelin found in brains of autistic individuals (Fatemi et 
al., 2005a). In view of this, it was reasoned that the polymorphism might similarly be a 
good candidate susceptibility variant for schizophrenia and bipolar disorder, in which 
reduced brain expression of reelin has proved to be a replicable finding (Torrey et al.,
2005). For the sake of efficiency, the polymorphism was genotyped in HapMap CEU 
samples to identify SNPs in high LD with it, which could then be tested for association 
with the disorders using imputed genotype data already generated as part of genome-wide 
association studies in the Department of Psychological Medicine. When biallelically coded 
as short (<10 repeats) versus long (>11 repeats) and 8  repeats versus >10 repeats, the CGG 
repeat polymorphism was found to exhibit highest LD with SNPs rs l0273035 (r2 = 0.80) 
and rs6951875 (r2 = 0.89) respectively. Imputation analyses of these SNPs did not reveal 
any significant allelic or genotypic association with schizophrenia or bipolar disorder.
The present association analyses represent, to the authors knowledge, the largest 
association study of the RELN 5’ UTR CGG polymorphism with schizophrenia to date, 
having 80% power to detect association with ORs of >1.37. That no significant association 
was detected is consistent with two previous, less powerful, studies of the same 
polymorphism that also did not detect any association with schizophrenia in Asian 
populations (Akahane et al. 2002; Huang & Chen, 2006). Patient data on responsiveness to 
antipsychotic drug treatment was not available in the present study, hence whether or not 
alleles of 1 0  repeats or longer were more frequent in non-responders than in responders, as 
previously observed in a Caucasian population (Goldberger et al., 2005), could not be 
determined. The present association analyses also represent the first time the
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polymorphism has been studied in relation to bipolar disorder, and had 80% power to 
detect association with ORs of >1.16. That no significant association was detected suggests 
that the polymorphism does not confer susceptibility to bipolar disorder either.
The above suggestion that the CGG repeat polymorphism does not confer susceptibility to 
schizophrenia or bipolar disorder is only valid given the described power of the analyses to 
detect effects of the stated sizes. It is also noteworthy that the calculated power levels did 
not take into consideration the LD relationship between the rare 4 repeat allele and the 
tested SNPs, as this allele was not detected in the HapMap CEU samples. Nonetheless, the 
present study strongly suggests that if the CGG repeat polymorphism does confer 
susceptibility to schizophrenia and bipolar disorder, then its effect is likely to be very 
small. Given that most common allele effect sizes are now expected to be substantially 
smaller than many previously expected (International Schizophrenia Consortium, 2009), 
this is an important caveat; hence, the present study certainly does not exclude the 
involvement of this polymorphism in these disorders.
The replicated finding that RELN expression is down-regulated in brains of patients with 
schizophrenia and bipolar disorder has led to the hypothesis that reduced levels of the 
protein increases vulnerability to development of those disorders (Guidotti et al., 2000; 
Fatemi, 2001, 2005; Costa et al., 2002). However, the previous and present evidence that 
the CGG repeat polymorphism has a functional effect on RELN expression and is not 
associated with either disorder does not support that hypothesis. Also arguing against it, is 
that o f all individuals reported to date to be heterozygous for null alleles of RELN (and that 
express 50% normal levels of reelin protein), none have demonstrated any clinical signs of 
psychosis (Hong et al., 2000; Chang et al., 2007; Zaki et al., 2007). Given that such null
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alleles have a larger effect on expression compared with the repeat polymorphism, these 
findings could collectively be interpreted to suggest that reduced brain levels of reelin in 
patients with schizophrenia and bipolar disorder may represent a benign consequence, or 
side-effect, of a true pathogenic process or of the disorders themselves. For example, 
according to one hypothesis, reduced expression of RELN is a consequence of the same 
pathogenic process that leads to down-regulation of the gene that encodes the 67 kDa form 
of glutamic acid decarboxylase (GAD67) in brains of the same patients (Noh et al., 2005; 
Veldic et al., 2004, 2005). Multiple studies have found that variants in the promoter region 
of that gene, GAD1, are associated with schizophrenia and bipolar disorder (Addington et 
al., 2005; Lundorf et al., 2005; Straub et al., 2007; Zhao et al., 2007; Du et al., 2008), 
although the data are not yet conclusive in favour of a true association.
An alternative hypothesis is that more important than the level of reelin in brain per se in 
determining vulnerability to psychosis is the capacity for reelin levels to change or be 
maintained as the brain matures. Under this hypothesis, the decreased brain level of reelin 
observed in patients with schizophrenia and bipolar disorder may be pathogenic not 
because it is lower than in healthy individuals, but either because it decreased with time or 
at a certain point, or failed to increase as might normally occur at appropriate stages of 
development. Possibly relevant to this hypothesis is the recent finding that the degree of 
methylation of the RELN promoter correlates with age in healthy individuals, but not in 
individuals with schizophrenia or bipolar disorder (Tamura et al., 2007).
4.4.1: Conclusions
The present study adds to previous evidence that the CGG repeat polymorphism in the 5’
UTR of the RELN gene has a functional effect on RELN expression in brain. Accordingly,
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altered brain levels of reelin in disorders with which the polymorphism is reportedly 
associated (e.g. autism, Alzheimer’s disease) potentially represents a primary pathogenic 
defect. However, SNPs tagging the repeat polymorphism were not found to be associated 
with schizophrenia or bipolar disorder, suggesting that the previously observed decrease in 
brain level of reelin may represent a secondary feature of those disorders. Also consistent 
with this view is that no effect on mRNA abundance of a SNP (rs7341745) associated with 
schizophrenia in women was detected. The pathogenic mechanism of this SNP requires 
further investigation. The present study also detected a low frequency variant with a larger 
c/s-regulatory effect on RELN expression. The contribution of this as yet unknown variant 
to psychiatric and neurodegenerative disease may also deserve further investigation.
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_____________ C h a p t e r  5: GABAa R e c e p t o r  S u b u n it  G e n e s_____________
5.1: Introduction 
5.1.1: GABA
The amino acid, y-aminobutyric acid (GABA) is the most widely distributed and abundant 
inhibitory neurotransmitter in the adult brain (Sivilotti & Nistri, 1991). An estimated 30- 
40% of all brain neurons and synapses utilise GABA (Bloom & Iversen, 1971; Roberts, 
1986). The majority of GABAergic neurons are intemeurons that modulate excitability of 
local neuronal circuits (Roberts, 1986). In addition, GABAergic neurons play a central role 
in nearly all stages of brain development including neuronal proliferation, migration, 
differentiation, and synapse formation and refinement (Owens & Kriegstein, 2002). Hence, 
given its widespread presence and utilisation, one could say that GABA is involved in all 
brain functions and all brain diseases (Olsen, 2002).
5.1.2: GABA^ Receptors
GABA acts via two classes of ionotropic and metabotropic receptors, GABAa and GABAb 
respectively (Barnard et al., 1998). Most of its neurobiological actions are mediated by the 
GABAa class (Sieghart & Sperk, 2 0 0 2 ). GABAa receptors are pentameric ligand-gated 
chloride ion (Cl-) channels (Sieghart et al., 1999; Olsen, 2002) that, in adult brain, mediate 
fast synaptic inhibition (Connors, Malenka & Silva, 1988). They are made up of various 
combinations of a  (aj to 0 6), p (Pi to P3), y (yi to y3), 6 , e, 0 , n, and p (pi to P3) subunits 
(Barnard et al., 1998; Bonnert et al. 1999), each encoded by separate genes. In the brain, 
the most abundant and widespread subtype assemblies are composed of two a, two p and 
one y subunits (Sieghart et al., 1999; MOhler, 2006). In less abundant and more localised 
receptors, the y subunit is substituted with a 6 , 8 , or ji subunit, whereas the p subunit can be
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replaced with the 0 subunit (Barnard et al., 1998; Whiting, 2003). The p subunits are 
believed to form pentamers only with other p subunits and are preferentially expressed in 
the retina (Barnard et al., 1998).
GABAa receptors can be modulated by a variety of pharmacologically and clinically 
important drugs including alcohol, anaesthetics, barbiturates, benzodiazepines, 
convulsants, and steroids (Sieghart, 1995, 2006, Olsen, 2002). Each class of drug acts at 
different sites of the channel; hence, each has varying affinities for receptors with different 
subunits (Sieghart, 1995; Korpi, Griinder & Luddens, 2002). In addition to regulating brain 
excitability, different GABAa receptor assemblies play significant roles in the control of 
anxiety, sleep, and cognition including learning, memory and sensorimotor processing 
(Mohler et al., 2004; Mohler, 2006). This has led to the use and ongoing development of 
GABAa receptor subtype-selective drugs in the treatment of a wide range of psychiatric 
and neurological conditions (Whiting, 2003; Guidotti et al., 2005; Korpi & Sinkkonen,
2006). Epilepsy, pain, sleep disorders, affective disorders, psychoses, and alcohol and 
substance abuse are a few examples.
5.13: GABAergic Dysfunction in Psychiatric Disease
Abnormalities in GABA neurotransmission, both pre- and post-synaptic, have been 
described in relation to several psychiatric disorders, particularly schizophrenia and bipolar 
disorder (Blum & Mann, 2002; Guidotti et al., 2005). In relation to these particular 
disorders, several studies have found a significant reduction (up to 70%), relative to 
controls, in cortical or cerebellar levels of glutamic acid decarboxylase (GAD), particularly 
the 67 kDa form (GAD67) (Akbarian et al., 1995b; Impagnatiello et al., 1998; Guidotti et 
al., 2000; Volk et al., 2000; Vawter et al., 2002; Hashimoto et al., 2003; Woo, Walsh &
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Benes, 2004; Fatemi et al., 2005b; Veldic et al., 2005), which is the main rate-limiting 
enzyme for GABA synthesis in the brain (Asada et al., 1997). According to a recent meta­
analysis of -100 post-mortem neurochemical markers analysed in the Stanley Consortium 
brain sample (including tissue from 15 each of individuals with schizophrenia, bipolar 
disorder and major depression, and 15 healthy controls), the reduction in this enzyme was 
among the most striking neuropathological findings (Torrey et al., 2005). Similar decreases 
in brain levels of GAD have also been described in relation to major depression (Fatemi et 
al., 2005b) and autism (Fatemi et al., 2002; Yip, Soghomonian & Blatt, 2007). In addition 
to reduced GAD, schizophrenia and bipolar disorder are also associated with other 
deficiencies in GABAergic function. These include decreases in reelin (see Chapter 4), the 
GABA membrane transporter (Woo et al., 1998), and parvalbumin (Lewis, Volk & 
Hashimoto, 2004).
5.1.4: Altered Expression of GABAa Receptor Subunits as a Pathophysiological 
Feature of Schizophrenia and Bipolar Disorder
A number of studies have suggested that expression of GABAa subunits, and hence the 
composition of GABAa receptors, is responsive to changes in intensity of GABAergic 
stimulation (Steiger & Russek, 2004; Guidotti et al., 2005). Consistent with this, changes 
in G ABAa subunit expression have been observed in the same disorders that are associated 
with reductions in GAD. In schizophrenia, binding assays using [ HJmuscimol (a potent 
GABAa receptor agonist that binds to the same site as GABA) on post-mortem brain tissue 
have shown increased binding in prefrontal cortex, cingulate cortex, hippocampus, and 
other brain regions when compared with normal controls (Hanada et al., 1987; Benes et al.,
1992, 1996a, 1996b; Dean et al., 1999; Deng & Huang, 2006; Newell et al., 2007). In 
bipolar disorder, increased binding of [3H]flumazenil (a benzodiazepine antagonist), but
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not [ HJmuscimol was observed in prefrontal cortex (Dean et al., 2001), and alterations in 
[ H]flumazenil binding were also observed in hippocampus (Dean et al., 2005). These 
latter findings suggest that in bipolar disorder, the up-regulation in receptor expression 
may be specific to subtypes that are sensitive to benzodiazepines.
Alterations in GABAa subunit expression associated with schizophrenia and bipolar 
disorder have also been examined at mRNA and individual protein levels. In an initial 
study, which utilised in situ hybridisation, expression levels of six subunits (ai, <12, as, Pi, 
p2 and 72) were not significantly different in prefrontal cortex from individuals with 
schizophrenia and controls (Akbarian et al., 1995a). In a number of subsequent reports, 
however, consistent with the binding assay data, ai and as subunit mRNAs, particularly the 
latter, were found by quantitative RT-PCR and in situ hybridisation to be significantly 
increased in prefrontal cortex of schizophrenic brains relative to controls (Impagnatiello et 
al., 1998; Ohnuma et al. 1999). Increased expression of these receptors in schizophrenia 
has also been detected by immunohistochemistry at the protein level (Ishikawa et al., 
2004b; Guidotti et al., 2005). Furthermore, according to one report, the density of 
postsynaptic neurons with a2-containing receptors is significantly increased in the brains of 
schizophrenic individuals, but not individuals with major depression (Volk et al., 2002). In 
a further study, expression of a* subunit mRNA was found to be 1.37 fold lower in 
peripheral blood leukocytes of schizophrenic patients, as compared with their unaffected 
siblings (Petryshen et al., 2005).
By immunohistochemistry, the P2/P3 subunits were found to be increased in both 
schizophrenia and bipolar disorder prefrontal cortex samples, although the antibody used 
could not distinguish between the two subunits (Ishikawa et al., 2004a). It was later found
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by real-time PCR that expression of the p2 subunit was reduced in schizophrenia (Zhao et 
al., 2006), which, if confirmed, suggests that the increased protein levels detected in the 
previous study may be specific to the f33 subunit.
The yi/y3 subunits have also been examined by immunohistochemistry and found to be 
significantly increased in bipolar disorder, but not schizophrenia (Ishikawa et al., 2004a).
With regards to the 72 subunit, one study that employed in situ hybridisation and semi- 
quantitative RT-PCR found that although overall expression levels were only modestly and 
non-significantly reduced in schizophrenia, the ratio of long and short splice forms of this 
subunit was significantly altered in patient samples when compared with controls 
(Huntsman et al., 1998).
The above described studies together suggest that changes in expression of GABAa 
subunits, particularly in prefrontal cortical areas, may play an important role in the 
pathophysiology of schizophrenia and bipolar disorder. However, alterations in expression 
of GABAa subunits may represent a compensatory response to diminished GABAergic 
neurotransmission. This is suggested by the observation that subunit expression is altered 
in the same brain samples that show reduced GAD levels (Impagnatiello et al., 1998) and 
GABA content (Ohnuma et al., 1999). That mRNA for the GABA transporter, which 
generally functions to remove GABA from the synapse, has been found at reduced levels 
concomitant with a reduction in GAD (Ohnuma et al., 1999; Volk et al., 2001) and 
increased receptor subunit expression (Volk et al., 2 0 0 2 ) is also consistent with this view. 
Furthermore, although increased [ HJmuscimol binding has been observed even in 
schizophrenic patients with little or no exposure to antipsychotic drugs (Benes et al.,
1992), it is possible that some reports of altered subunit gene expression reflect effects of
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medication. However, it is also possible that altered GABAa receptor expression plays a 
direct role in susceptibility to schizophrenia, bipolar disorder, and other psychiatric 
disorders. Thus, the genes encoding these receptors are plausible functional candidates for 
these conditions.
5.1.5: Genomic Organisation of GABAa Subunit Genes
The genes encoding GABAa subunits are genomically organised into clusters on different 
chromosomes. In most instances, these clusters include genes coding for a, p and y 
subunits consistent with the composition of most receptor subtypes. Phylogenetic tree 
analysis suggests that the different gene clusters arose from a single ancestral cluster 
following a series of duplication events (Russek, 1999; Darlison, Pahal & Thode, 2005). In 
the human genome, the major subunit gene clusters are located on chromosome 4pl2 (ot2,
0 4 , Pi and yi subunits), 5q31-q35 (ai, <X6, P2, J2 and it subunits), 15ql 1—ql3 (0 5 , p3 and 73 
subunits) and Xq28 (0 3 , e and 0 subunits). The remaining subunits are located on 
chromosome 6ql3-q l6  (pi and p2 subunits), lp36 ( 8  subunit) and 3ql 1 (p3 subunit).
5.1.6: GABAa Subunit Genes in Psychiatric and Neurological Populations
GABAa subunit genes have been tested for association with a variety of psychiatric and 
neurological disorders. Previous evidence supports their possible involvement in alcohol 
dependence (Parsian & Cloninger, 1997; Noble et al., 1998; Loh et al., 1999; Parsian & 
Zhang, 1999; Schuckit et al., 1999; Song et al., 2003; Covault et al., 2004; Dick et al.,
2004; Edenberg et al., 2004; Radel et al., 2005), schizophrenia (Lo et al., 2004; Liu et al.,
2005; Petryshen et al., 2005; Yu et al., 2006; Lo et al., 2007; Zhao et al., 2007), bipolar 
disorder (Papadimitriou et al., 1998; Massat et al., 2002; Yamada et al., 2003; Horiuchi et 
al., 2004), major depression (Yamada et al., 2003), autism (Cook et al., 1998; Martin et
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al., 2000; Menold et al., 2001; Buxbaum et al., 2002; Shao et al., 2003; McCauley e/ a/.,
2004; Ma et al., 2005; Ashley-Koch ef a/., 2006), and epilepsy (Mulley et al., 2003; Chou 
et al., 2003,2007; Audenaert et al., 2006; Maljevic et al., 2006).
Recently, the Department of Psychological Medicine contributed towards a large genome- 
wide association study of seven common diseases, one of which was bipolar disorder 
(Wellcome Trust Case Control Consortium, 2007). The study examined -2,000 cases for 
each disorder (1,868 for bipolar disorder) and a shared set of 2,938 controls, all of which 
were genotyped for -500,000 SNPs across the genome. In the bipolar data set, one of the 
higher ranked association signals was from SNP rs7680321 in the GABRB1 gene (encoding 
the GABAa Pi subunit), with the C allele being more frequent in cases than controls (OR =
1.36,/* = 6.2 x 10'5).
In an effort to increase biological homogeneity, a follow-up study sought to identify the 
phenotypic subset of cases that showed the strongest association signal at SNP rs7680321 
(Craddock et al., 2008). The association signal was found to be significantly enriched in 
the 279 cases that met Research Diagnostic Criteria (RDC; Spitzer et al., 1978) for 
schizoaffective disorder, bipolar type (OR = 1.80, P = 3.8 x 10-6). When individuals with 
this diagnosis were compared with the original set of controls, SNPs rs6414684 in 
GABRB1, rs3934674 in GABRA4 (0 4  subunit), rsl7561681 in GABRA5 (as subunit), 
rs890319 in GABRB3 (p3 subunit), and rs854579 in GABRR3 (p3 subunit) showed gene- 
wide significant evidence for association, independent of the signal at SNP rs7680321. 
Moreover, although not included in the final report, early statistical analyses also identified 
SNPs in GABRG3 (73 subunit) as showing association, albeit at more nominal levels of 
significance.
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A notable outcome of the study is that none of the most strongly associated SNPs in each 
gene are predicted to alter the amino acid sequence of an encoded protein. Indeed, 
according to online SNP databases and several published mutation screening efforts 
(Madia et al., 2003; Ma et al., 2006; Urak et al., 2006), such polymorphisms have not been 
identified in GABRA5, GABRB1, and GABRB3, at least not in Caucasian populations. 
Furthermore, although non-synonymous SNPs are known to exist in GABRA4, GABRG3, 
and GABRR3, those SNPs either showed no evidence of association or showed much 
weaker evidence than the top hit. Thus it may be hypothesised that the associations are 
mediated by sequence variants that alter gene expression, which in turn may modify the 
subunit composition of GABAa receptors, and thereby their physiological and 
pharmacological properties.
5.1.7: The Present Study
The association of GABAa subunit genes with bipolar disorder, especially RDC-defined 
schizoaffective disorder, bipolar type, does not appear to be explicable by variants that 
affect protein structure. It is likely, therefore, that the associations are mediated by cis- 
regulatory effects on gene expression, which may influence the brain’s capacity to 
compensate for a presynaptic deficit in GABAergic transmission. To test this hypothesis, 
assays of relative allelic expression targeted at several of the associated genes were applied 
to varying numbers of brain samples from heterozygous individuals. The genes assayed 
were GABRA4, GABRA5, GABRB1, GABRB3, and GABRG3. For a number of these genes, 
samples were also genotyped for the SNPs that showed association with RDC-defined 
schizoaffective disorder, bipolar type to test for putative cis effects on expression. 
Furthermore, given the widespread expression of the 72 subunit in the brain and its
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requirement for high-affinity benzodiazepine binding, which is altered in bipolar disorder, 
the GABRG2 gene was also assayed.
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5.2: Materials and Methods
Brain samples and the general methods used for DNA and RNA processing, 
genotyping, and the relative allelic expression assay are described in more detail in 
Chapter 2. 
5.2.1: Samples
Post-mortem brain tissue derived from frontal, temporal or parietal cortex of 6 6  unrelated 
anonymised individuals obtained from three sources (the MRC London Brain Bank for 
Neurodegenerative Diseases, the Stanley Medical Research Institute, and the Karolinska 
Institute) were used in this study. For each tissue sample, genomic DNA and total RNA 
were extracted by standard procedures. RNA was then treated with DNAse and reverse 
transcribed to cDNA.
5.2.2: Genotyping
PCR primers for the SNPs used for relative allelic expression analysis of each gene and for 
SNPs rs7680321 and rs6414684 in GABRB1 and rs l7561681 in GABRA5 were designed 
by use of the Primer3 program (Rozen & Skaletsky, 2000). PCR was carried out in a total 
reaction volume of 12 pi containing 48 ng of genomic DNA, and consisted of 35 cycles.
TMGenotyping was carried out by fluorescent primer extension using the SNaPshot 
Multiplex Kit (Applied Biosystems) and primers designed by use of the FP Primer 
program (Ivanov et al., 2004). Primer sequences for SNPs used for relative allelic 
expression analysis and for SNPs rs l7561681, rs7680321 and rs6414684 are shown in 
Tables 5.1 and 5.2 respectively, which, where relevant, also show the annealing 
temperature used during PCR cycling.
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Gene Polymorphism Primer Sequence (5’-3 ’) Ta (°C)
GABRA4 rs7660336
F:
R:
TGGCAAAAGGAAATGGAATA
GGCTCAGAGAACAAAATTTCA
56
EXT: AGCCAACATAAGAAAGGGAA -
GABRA5 rsl 40682
F:
R:
TGCGTACCCTAATTCTGAAGTC
CCATCAGGTGGTACTGGTTC
58
EXT: CGTACCCTAATTCTGAAGTCGT -
rsl0016388
F:
R:
AAAGGGGAGAGAAGCAAGAA
AGAGCCACCACTTTACATATCC
58
GABRB1
EXT: GGTGTCATATACTTATGAAGGTCTATTAC -
rsl 0028945
F:
R:
C AGCC ATCC AATTGGTTTT A 
CTGCTAAAGATCTACCTGTCTAACTTC
58
EXT: GCT AAAG ATCT ACCTGTCT AACTTCT -
GABRB3 rsl 1637141
F:
R:
CATCCCCAAATGTGTCTTGT
GATGAAAACAAACCCCATCA
58
EXT: AATGAGTCACTTACTTCATATCCTCTC -
GABRG2 rs418210
F:
R:
AAGAAAATTTCCTCCACATTCA 
GCCCAAGGACACAAAATAAA
57
EXT: TCTCTTTAGATCCAAAATAAATGGA -
GABRG3 rsl 40679
F:
R:
ACGCGTGTCCTACGTGAC 
CGTGGTGGTTGG1TTT CTAC
60
EXT: CCATGGACCTTTTTGTGAC -
Table 5.1: Details of primers used for relative allelic expression analysis of GABAa receptor subunit
genes. F = forward primer, R = reverse primer, EXT = extension primer, Ta = annealing temperature 
used during PCR cycling.
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Gene Polymorphism Primer Sequence (5’- 3 ’) Ta (°C)
GABRA5 rsl7561681
F:
R.
CAAAGACAGCCACTCCATTT
GTCACTCTCCCAGCAGAAAA
58
EXT: CACTCCATTTTAAGACCAGATGA -
rs7680321
F:
R:
ACGAAACTTAAAATATGCTGTGAA 
CAGGTGGAGGAAGCA1TTT A
58
GABRB1
EXT: G AAACTT AAAAT ATGCT GT G AACT AC A -
rs6414684
F:
R:
TGTTGTGATTTCCACAATGG
GAAGTGCAGCCTGAAAATGT
58
EXT: AGATGGAATTTATGCCAAATGAAAA -
Table 5.2: Details o f primers used for genotyping SNPs rsl 7561681, rs7680321, and rs6414684. F = 
forward primer, R = reverse primer, EXT = extension primer, Ta = annealing temperature used during 
PCR cycling.
5.23 :  Relative Allelic Expression Assay
Details of SNPs chosen for relative allelic expression analysis of each gene are described 
in Table 5.3. Their location on known mRNA transcripts of each gene is illustrated in 
Figures 5.1-5.6.
Genomic DNA from all brain samples was initially genotyped, as described, for all SNPs 
to identify heterozygotes. For each heterozygous sample, cDNA produced from two 
separate reverse transcription reactions, alongside corresponding genomic DNA, was 
assayed on two separate occasions (i.e. 2 x {2 cDNA + 1 genomic DNA}). Genomic DNA 
and cDNA were assayed under identical conditions. This allowed the average allelic ratio 
obtained from genomic DNA (representing a 1:1 ratio) to be used to correct allelic ratios 
obtained from cDNA for any inequalities in allelic representation specific to the assay.
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Gene Polymorphism Exon MAF
GABRB1
rsl0016388 
rsl 0028945
3’ UTR* 
3’ UTR*
0.08
0.28
GABRA4 rs7660336 3’ UTR 0.48
GABRA5 rsl 40682 8 0.07
GABRB3 rsl 1637141 3’ UTR 0.23
GABRG2 rs418210 3’ UTR 0.20
GABRG3 rsl 40679 8 0.49
Table 53: Details of SNPs chosen for relative allelic expression analysis of 
GABAa receptor subunit genes. Exon = the exon in which the SNP is located 
as shown in each gene figure (Figures 5.1-5.6). MAF = minor allele 
frequency in HapMap CEU samples. *SNPs rs l0016388 and rs l0028945 are 
present in UTRs of different GABRB1 mRNA transcripts (Figure 5.1).
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Figure 5.1: The organisation of the GABRB1 gene and its two mRNA transcripts. 
Transcript A is based on reference sequence NM_000812. Transcript B is based on 
cDNA clones DB172039 and AW301170 as indicated in AceView. Yellow rectangles 
represent 5’ and 3’ untranslated regions (UTRs), blue rectangles represent protein- 
coding exons. The green rectangle represents protein-coding sequence in transcript A, 
and UTR sequence in transcript B. Asterisks indicate the positions of assayed SNPs 
rs l0016388 in exon 4 and rs l0028945 in exon 9.
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Figure 5.2: The organisation of the GABRA4 gene and its one reference mRNA 
transcript (NM 00809). Yellow rectangles represent 5’ and 3’ untranslated regions 
(UTRs), blue rectangles represent protein-coding exons. The asterisk indicates the 
position of assayed SNP rs7660336 in exon 9.
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Figure 53: The organisation of the GABRA5 gene and its three mRNA transcripts. 
Transcript A is based on reference sequence NM 000810. Transcript B and C are 
based on descriptions provided by their discoverers (Kim et al., 1997). Yellow 
rectangles represent 5’ and 3’ untranslated regions (UTRs), blue rectangles represent 
protein-coding exons. The asterisk indicates the position of assayed SNP rs l40682 in 
exon 8.
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Figure 5.4: The organisation of the GABRB3 gene and its two mRNA transcripts. 
Transcript A is based on reference sequence NM 021912. Transcript B is based on 
reference sequence NM 000814. Yellow rectangles represent 5’ and 3’ untranslated 
regions (UTRs), blue rectangles represent protein-coding exons. The asterisk indicates 
the position of assayed SNP rsl 1637141 in exon 9.
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Figure 5.5: The organisation of the GABRG2 gene and its three mRNA transcripts. 
Transcript A is based on reference sequence NM_198904. Transcript B is based on 
reference sequence NM 000816. Transcript C is based on reference sequence 
NM 198903. Yellow rectangles represent 5’ and 3’ untranslated regions (UTRs), blue 
rectangles represent protein-coding exons. Green rectangles represent protein-coding 
sequence / exons in transcripts A and C, and UTR sequence in transcript B. Red 
rectangles represent an alternatively spliced portion of exon 4 and the alternatively 
spliced exon 9. The asterisk indicates the position of assayed SNP rs418210 in exon 
10.
2 3 4 5 6
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10
Figure 5.6: The organisation of the GABRG3 gene and its one reference mRNA 
transcript (NM 033223). Yellow rectangles represent 5’ and 3’ untranslated regions 
(UTRs), blue rectangles represent protein-coding exons. The asterisk indicates the 
position of assayed SNP rsl 40679 in exon 8.
PCR consisted of 35 cycles and was carried out in a total reaction volume of 12 pi 
containing 48 ng of genomic DNA or 6 pi of cDNA at the standard cDNA concentration 
(see Chapter 2, section 2.1.8). Primers, shown in Table 5.1, were based on single exons and 
therefore amplified an identical sequence from both templates. Allelic representation was
TMmeasured by primer extension using the SNaPshot Multiplex Kit (Applied Biosystems) 
and the primers shown in Table 5.1. Peak heights of allele-specific extended primers were 
determined using Genotyper 2.5 (Applied Biosystems). The ratio of cDNA peak heights, 
corrected using the average ratio of genomic DNA peak heights, was then used to calculate 
the relative expression of mRNAs transcribed from each parental chromosome in each 
individual sample.
To confirm altered allelic expression, select individuals showing expression of one allele at 
a level 20% or more than the other were assayed on four further occasions (i.e. 4 x {2 
cDNA + 1 genomic DNA}). In line with previous studies (Yan et al., 2002; Bray et al., 
2003), an allelic expression difference >20% for any individual sample was chosen as 
indicative of the influence of cfr-acting regulatory polymorphism since measurements 
surpassing this threshold are generally reproducible.
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5.2.4: Linkage Disequilibrium Analysis
Linkage disequilibrium (LD) analyses were performed using Haploview 4.00 (Barrett et 
al., 2005) and were based on genotype data for the entire collection of 6 6  brain samples.
5.2.5: Checking for Genetic Association
Where evidence for c/s-regulatory variation in high LD with the assayed SNP was obtained 
in any gene assay, that SNP was checked for evidence for association with schizophrenia, 
bipolar disorder and RDC-defined schizoaffective disorder, bipolar type in imputed 
datasets generated in the Department of Psychological Medicine. These were the datasets 
generated as part of the WTCCC genome-wide association study (WTCCC, 2007) and the 
bipolar disorder study that followed it (Craddock et al., 2008). The author was in no way 
involved in the genesis of either of these datasets.
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5J: Results 
53.1: GAB RBI
Assayed Samples
Individuals informative for allelic expression analysis included 18 heterozygotes for SNP 
rsl0028945, which is located within the 3’ UTR of the reference mRNA transcript 
(NM_000812; Figure 5.1), and 17 heterozygotes for SNP rsl0016388, which is located 
within the 3’ UTR of an alternative mRNA predicted by AceView based on two cDNA 
clones (DB172039 and AW301170; Figure 5.1). Five individuals were heterozygous at 
both SNPs. The mean age at death for the total of 30 informative individuals was 63 years 
(SD = 19.50), 19 were male, and 11 were female. A large proportion (n = 28) had no 
known history of psychiatric or neurological disease, one had schizophrenia, and one had 
major depression. Samples were derived from frontal (n = 19), temporal (n = 5), and 
parietal (n = 6) brain tissue.
Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility for the assay at SNP rs l0028945 
with an average coefficient of variation (SD / mean) of 0.06. The average coefficient of 
variation for the assay at SNP rs l0016388, located within the alternative mRNA, was 
higher at 0.19. However, this was largely due to a few samples showing very large within- 
sample variation. Samples with a coefficient of variation of >2 SDs from the mean (n = 4) 
were therefore excluded, resulting in a coefficient of variation 0.08. In neither assay was 
significant correlation observed with sex, age, diagnostic status or brain region assayed.
126
Chapter 5: GABR Genes
Reference mRNA Transcript
Analysis of the reference transcript (NM 000812) at SNP rsl0028945 did not reveal any 
samples that showed allelic expression differences of >20% and cDNA ratios were not 
significantly different from genomic DNA ratios (P = 0.57; Figure 5.7). LD analyses 
showed that SNP rsl0028945 was in low LD with putative risk SNP rs7680321 (D’ = 0.28, 
r2 = 0.00) and not in LD with putative risk SNP rs6414684 (£>’ = 0.03, r2 = 0.00). cDNA 
ratios for the two samples derived from heterozygotes for SNP rs7680321 were close to 1:1 
(Figure 5.7) and cDNA ratios denoted as the more highly expressed allele relative to the 
lower expressed allele (i.e. H:L) did not significantly differ between homozygotes and 
heterozygotes for SNPs rs7680321 (P = 0.13) or rs6414684 (P = 0.36) (Figure 5.8). These 
analyses had 80% power to detect a ratio difference of 0.06 and 0.09 respectively (P = 
0.05).
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Figure 5.7 (left) & 5.8 (right): Scatter plots showing allelic ratios for genomic DNA and cDNA 
derived from 18 individuals heterozygous for SNP rs l0028945. In Figure 5.7, cDNA ratios from 
individuals that are homozygous for SNP rs7680321 are shown in red, and ratios from 
heterozygotes are shown in yellow. In Figure 5.8, cDNA ratios from individuals that are 
homozygous for SNP rs6414684 are shown in red, and ratios from heterozygotes are shown in 
yellow. Data are presented as the C allele relative to the T allele (C:T) in Figure 5.7 and as the 
higher expressed allele relative to the lower expressed allele (H:L) in Figure 5.8. Each data point 
represents the average of four measurements. Ratios have been corrected by the average ratio 
obtained with genomic DNA.
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Alternative mRNA Transcript
Analysis of the alternative mRNA transcript (DB172039 and AW301170) at SNP 
rsl0016388 showed that transcripts tagged by the A allele were on average ~9% less 
abundant than those tagged by the T allele (Figure 5.9). The difference between allelic 
ratios obtained with cDNA and genomic DNA was significant (P = 0.005). LD analyses 
showed that SNP rsl0016388 was in high LD with putative risk SNP rs7680321 (D' =
1.00, r2 = 0.43) such that the C allele of the latter was predicted to always be in phase with 
the A allele of the former. LD between SNP rsl0016388 and putative risk SNP rs6414684 
was low (£>’ = 0.13, r2 = 0.00). cDNA ratios did not significantly differ according to 
homozygosity and heterozygosity for SNP rs7680321 (P = 0.67; Figure 5.9), and when 
denoted as the more highly expressed allele relative to the lower expressed allele (i.e. H:L)
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Figure 5.9 (left) & 5.10 (right): Scatter plots showing allelic ratios for genomic DNA and cDNA 
derived from 13 individuals heterozygous for SNP rsl0016388. In Figure 5.9, cDNA ratios from 
individuals that are homozygous for SNP rs7680321 are shown in red, and ratios from 
heterozygotes are shown in yellow. In Figure 5.10, cDNA ratios from individuals that are 
homozygous for SNP rs6414684 are shown in red, and ratios from heterozygotes are shown in 
yellow. Data are presented as the A allele relative to the T allele (A:T) in Figure 5.9, and as the 
higher expressed allele relative to the lower expressed allele (H:L) in Figure 5.10. Each data point 
represents the average of four measurements. Ratios have been corrected by the average ratio 
obtained with genomic DNA.
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they did not significantly differ between homozygotes and heterozygotes for SNP 
rs6414684 either (P = 0.80; Figure 5.10). These analyses had 80% power to detect a ratio 
difference of 0.14 and 0.11 respectively (P = 0.05).
5.3.2: GABRA4 
Assayed Samples
A total of 28 genotyped individuals were heterozygous for the expressed SNP rs7660336 
and therefore informative for allelic expression analysis. Their mean age at death was 63 
years (SD = 20.98), 15 were male, and 13 were female. None had a known history of 
psychiatric or neurological disease. Samples were derived from frontal (n = 20), temporal 
(n = 3), and parietal (n = 5) brain tissue.
Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.09. One sample with a coefficient of variation of 0.90, which 
was >2 SDs from the mean, was excluded, resulting in an average coefficient of variation 
of 0.07. No correlation was observed with sex, age, diagnostic status or brain region 
assayed. For the majority of individuals (i.e. excluding one outlier) transcripts tagged by 
the C allele were on average ~4% less abundant than those tagged by the G allele (Figure 
5.11). The difference between allelic ratios obtained with cDNA and genomic DNA was 
significant (P = 0.003). Only one sample displayed an allelic expression difference of 
>20% (Figure 5.11). This sample was derived from a 54-year-old anonymous female with 
no known history of psychiatric or neurological disorder. For this individual, the average 
C:G ratio over four replicate cDNA measurements was 1.43:1. When this individual’s
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Figure 5.11: Scatter plot showing allelic ratios 
for genomic DNA and cDNA derived from 27 
individuals heterozygous for SNP rs7660336. 
Data are presented as the C allele relative to the 
G allele (C:G). Each data point represents the 
average of four measurements. Ratios have been 
corrected by the average ratio obtained with 
genomic DNA.
Figure 5.12: Bar chart comparing average 
allelic ratios obtained in the initial assay (red) 
with ratios obtained in the repeat assay (yellow) 
for the individual that showed an initial allelic 
expression difference >20%. The initial assay 
average is based on four measurements; the 
repeat assay average is based on eight 
measurements.
sample was assayed a further four times, the average C:G ratio over eight replicate cDNA 
measurements was 1.50:1 (95% C.I. = 1.39-1.62:1; Figure 5.12). Thus, in this individual, 
expression of the C allele was increased by 50% (using the A allele as an arbitrary 
reference point), or expression of the G allele reduced by 34% (using the G allele as an 
arbitrary reference point). Observed cDNA ratios from this individual were significantly 
different from ratios obtained with genomic DNA (P = 5.29 x 10-6).
5.3.3: GABRA5
Transcript Characterisation
GABRA5 has one reference mRNA transcript (NM 000810), but three isoforms of this 
mRNA transcribed from different promoters and differing in their first exon (Figure 5.3) 
have previously been reported (Kim et al., 1997). RT-PCR using primers to amplify from
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exon 1A, IB and 1C to exon 8 of GABRA5 using brain cDNA as template showed that 
mRNA transcribed from the three GABRA5 promoters all include exon 8 in which the 
assayed SNP rsl40682 is located, and that all three isoforms are expressed in the assayed 
tissue (Figure 5.13).
Figure 5.13: Gel photograph showing a 1 Kb Plus DNA ladder 
(lane 1), and amplicons produced by PCR with forward primers 
complementary to exon 1A (lane 2), IB (lane 3), and 1C (lane 4) 
and a reverse primer complementary to exon 8.
Assayed Samples
A total of 28 genotyped individuals were heterozygous for the expressed SNP rsl40682 
and therefore informative for allelic expression analysis. Their mean age at death was 66 
years (SD = 19.22), 14 were male, and 14 were female. A large proportion (n = 27) had no 
known history of psychiatric or neurological disease, and one had major depression. 
Samples were derived from frontal (n = 20), temporal (n = 6), and parietal (n = 2) brain 
tissue.
Relative Allelic Expression
Analysis of cDNA ratios showed very good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.03. No correlation was observed with sex, age, diagnostic status
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or brain region assayed. A small number of samples (n = 4) displayed allelic expression 
differences of >20%, however there were no major outliers, and ratios ranged from 0.79:1 
to 1.25:1 (Figure 5.14).
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Figure 5.14 (left) & 5.15 (right): Scatter plots showing allelic ratios for genomic DNA and cDNA 
derived from 28 individuals heterozygous for SNP rs l40682. cDNA ratios from individuals that are 
homozygous for SNP rs l7561681 are shown in red, and ratios from heterozygotes are shown in 
yellow. Data are presented as the C allele relative to the T allele (C:T) in Figure 5.14, and as the 
higher expressed allele relative to the lower expressed allele (H:L) in Figure 5.15. Each data point 
represents the average of four measurements. Ratios have been corrected by the average ratio 
obtained with genomic DNA.
LD analyses showed that there was moderate LD between the assayed SNP rsl40682 and 
putative risk SNP rsl7561681 (£>’ = 0.62, r2 -  0.04). cDNA ratios denoted as the more 
highly expressed allele relative to the lower expressed allele (i.e. H:L) did not significantly 
differ between homozygotes and heterozygotes for SNP rsl7561681 (P = 0.60; Figure 
5.15). This analysis had 80% power to detect a ratio difference of 0.08 (P = 0.05).
5.3.4: GABRB3
Assayed Samples
A total of 25 genotyped individuals were heterozygous for the expressed SNP rsl 1637141 
and therefore informative for allelic expression analysis. Their age at death was 65 years
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(SD = 19.03), 13 were male, and 12 were female. A large proportion (n = 22) had no 
known history of psychiatric or neurological disease, and three had schizophrenia. Samples 
were derived from frontal (n = 17), temporal (n = 3), and parietal (n = 5) brain tissue.
Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.04. No correlation was observed with sex, age, diagnostic status 
or brain region assayed. Transcripts tagged by the G allele were on average -23% less 
abundant than those tagged by the A allele (Figure 5.16). The difference between allelic 
ratios obtained with cDNA and genomic DNA was significant (P = 5.29 x 10'19).
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
I
 1-------- 1—
Genomic DNA
t-----------r
cDNA
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00 i
Figure 5.16: Scatter plot showing allelic ratios 
for genomic DNA and cDNA derived from 25 
individuals heterozygous for SNP rsl 1637141. 
Data are presented as the G allele relative to the 
A allele (G:A). Each data point represents the 
average of four measurements. Ratios have been 
corrected by the average ratio obtained with 
genomic DNA.
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Figure 5.17: Bar chart comparing average 
allelic ratios obtained in the initial assay (red) 
with ratios obtained in the repeat assay (yellow) 
for the individual that showed the largest allelic 
expression difference. The initial assay average 
is based on four measurements; the repeat assay 
average is based on eight measurements.
One sample, derived from an 89-year-old anonymous female with no known history of 
neurological or psychiatric disorder, showed even more pronounced allelic expression
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difference. For this individual the average G:A ratio over four replicate cDNA 
measurements was 0.60:1. When this individual’s sample was assayed a further four times, 
the average G:A ratio over eight replicate cDNA measurements was 0.62:1 (95% C.I. = 
0.60-0.65:1; Figure 5.17). Thus, in this individual, expression of the G allele was reduced 
by 38% (using the A allele as an arbitrary reference point), or expression of the A allele 
increased by 60% (using the G allele as an arbitrary reference point). Observed cDNA 
ratios from this individual were significantly different from ratios obtained with genomic 
D N A (P= 1.66 x 10'12).
5.3.5: GABRG2 
Assayed Samples
A total of 23 genotyped individuals were heterozygous for the expressed SNP rs418210 
and therefore informative for allelic expression analysis. Their mean age at death was 60 
years (SD = 19.54), 14 were male, and nine were female. A large proportion (n = 22) had 
no known history of psychiatric or neurological disease, and one had schizophrenia. 
Samples were derived from frontal (n = 15), temporal (n = 5), and parietal (n = 3) brain 
tissue.
Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.07. No correlation was observed with sex, age, diagnostic status 
or brain region assayed. Transcripts tagged by the C allele were on average 10% more 
abundant than those tagged by the T allele (Figure 5.18). The difference between allelic 
ratios obtained with cDNA and genomic DNA was significant (P = 2.17 x 10*5).
134
Chapter 5: GABR Genes
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
Genomic DNA cDNA
Figure 5.18: Scatter plot showing allelic ratios for genomic DNA and cDNA derived 
from 23 individuals heterozygous for SNP rs418210. Data are presented as the C allele 
relative to the T allele (C:T). Each data point represents the average of four 
measurements. Ratios have been corrected by the average ratio obtained with genomic
DNA.
53 .6 : GABRG3
Assayed Samples
A total of 30 genotyped individuals were heterozygous for the expressed SNP rs140679
years (SD = 20.53), 16 were male, and 14 were female. A large proportion (n = 29) had no 
known history of psychiatric or neurological disease, and one had schizophrenia. Samples 
were derived from frontal (n = 20), temporal (n = 5), and parietal (n = 5) brain tissue.
Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with an average coefficient of 
variation (SD / mean) of 0.08. One sample with a coefficient of variation of 0.70, which 
was >2 SDs from the mean, was excluded, resulting in an average coefficient of variation 
of 0.06. No correlation was observed with sex, age, diagnostic status or brain region 
assayed. No samples displayed allelic expression differences of >20%, and cDNA ratios 
were not significantly different from genomic DNA ratios (P = 0.81; Figure 5.19).
and therefore informative for allelic expression analysis. Their mean age at death was 59
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Figure 5.19: Scatter plot showing allelic ratios for genomic DNA and cDNA derived 
from 29 individuals heterozygous for SNP rs 140679. Data are presented as the T allele 
relative to the C allele (T:C). Each data point represents the average of four 
measurements. Ratios have been corrected by the average ratio obtained with genomic 
DNA.
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5.4: Discussion
The present study had two main objectives: 1) to determine whether or not a selection of 
GABAa subunit genes contain common regulatory polymorphism, which might 
conceivably influence risk of several psychiatric disorders; and 2 ) to test whether or not 
particular SNPs within a subset of those genes, recently identified in the Department of 
Psychological Medicine as risk factors for bipolar disorder, are associated with altered 
gene expression. To achieve these objectives, assays of relative allelic expression were 
applied to a series of brain samples, which were also genotyped for the SNPs in question. 
The data for each assayed gene are discussed in turn.
5.4.1: GABRB1
GABRB1 was the index GABAa subunit gene that through its association with bipolar 
disorder in a genome-wide study (WTCCC, 2007), and more strongly with RDC-defined 
schizoaffective disorder, bipolar type in a follow-up study (Craddock et al., 2008), pointed 
to the possible involvement of the GABAa receptors in these disorders. Two independent 
association signals were detected in this gene: the index signal was with SNP rs7680321, 
and the second was with SNP rs6414684. In the present study, potential cis effects on 
GABRB1 expression in brain were investigated using assays of relative allelic expression 
targeted at two of this gene’s mRNAs, including the reference transcript (NM 000812) and 
an alternative transcript that was indicated in AceView (DB172039 and AW301170).
None of 18 heterozygotes assayed for the reference transcript at SNP rs 10028945 showed 
an allelic expression difference of >2 0 %, suggesting that polymorphisms or haplotypes that 
have large effects on expression of this mRNA in brain are not likely to be common, at
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least in Caucasian populations. Only two of the assayed samples were heterozygous for the 
risk SNP rs7680321. That both had cDNA ratios close to 1:1 suggests that the association 
of this variant with bipolar disorder is not mediated by a direct effect of this SNP on 
expression of the main GABRB1 transcript. Furthermore, that H:L cDNA ratios did not 
significantly differ between homozygotes and heterozygotes for SNP rs6414684 suggests 
that the association of that variant with RDC-defined schizoaffective disorder, bipolar type 
is also not mediated by a pathogenic alteration in expression of the main GABRB1 
transcript.
In the assay of the alternative GABRB1 transcript, mRNAs tagged by the A allele at SNP 
rsl0016388 were generally slightly (~9% on average) less abundant than mRNAs tagged 
by the T allele, with two samples showing an A allelic decrease of >20%. These findings 
are consistent with the presence of a c/s-acting regulatory variant of small effect that is in 
high LD with the assayed SNP. The assayed SNP rs l0016388 is not included in the dataset 
used in the WTCCC genome-wide association study (WTCCC, 2007). Given the 
association between this SNP and allelic expression in the present study, testing it for 
association with bipolar disorder may be warranted.
Although the assayed SNP was found to be in high LD with SNP rs7680321, cDNA ratios 
did not significantly differ between homozygotes and heterozygotes for this SNP, and 
neither did they for SNP rs6414684. These findings suggest that the association of those 
SNPs with bipolar disorder and RDC-defined schizoaffective disorder, bipolar type is not 
mediated by a pathogenic alteration in mRNA abundance. However, since mRNAs tagged 
by the risk C allele of SNP rs7680321 were generally under-expressed relative to those 
tagged by the non-risk T allele, the possibility that reduced expression of the alternative
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mRNA isoform is relevant to but not sufficient for the pathogenic effect of the SNP cannot 
be ruled out.
5.4.2: GABRA4
In the assay of the only known GABRA4 mRNA transcript at SNP rs7660336, only one of 
27 heterozygotes showed an allelic expression difference of >20%. In that sample, derived 
from a 54-year-old female with no known psychiatric or neurological diagnosis, expression 
of one gene copy was -50% greater than the other. Aside from that one sample, the present 
study also found that mRNAs tagged by the C allele at SNP rs7660336 were generally a 
little less (—4% on average) abundant than mRNAs tagged by the G allele.
The first of these findings suggests that polymorphisms or haplotypes that have large 
effects on GABRA4 expression in brain are, at least in Caucasian populations, rare with a 
frequency of <0.02. This frequency is much lower than that of the minor allele of SNP 
rs3934674, which was the variant in GABRA4 that was associated with RDC-defined 
schizoaffective disorder, bipolar type (Craddock et al., 2008). Although this SNP was not 
genotyped in any of the brain samples assayed, given its minor allele frequency of 0 .2 2  in 
HapMap CEU samples, it is expected that almost half the assayed samples would have 
been heterozygous for it. Hence, that only one sample showed an allelic expression 
difference of >20% suggests that SNP rs3934674 does not have a large c/s-regulatory 
effect on GABRA4 mRNA abundance.
In contrast, the present study cannot rule out the possibility that SNP rs3934674 has a 
small effect on GABRA4 mRNA abundance, as samples with a C:G cDNA ratio of <1:1 
may have been heterozygous for that SNP. However, LD between the assayed SNP
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rs7660336 and SNP rs3934674 in Caucasians is relatively low (£>’ = 0.261, r2 = 0.02 in 
HapMap CEU samples), whereas the allelic expression data are more suggestive of a cis- 
regulatory variant that is in high LD with the assayed SNP. In the datasets used in the 
WTCCC follow-up study (Craddock et al., 200), high quality imputed data (average 
maximum posterior call probability >0.99; missing data proportion <1%) for assayed SNP 
rs7660336 did not indicate an association with schizophrenia (P = 0.65), bipolar disorder 
(P = 0.36) or RDC-defined schizoaffective disorder, bipolar type (P = 0.79). Therefore, it 
is unlikely that the association between GABRA4 and RDC-defined schizoaffective 
disorder, bipolar type is mediated by a pathogenic alteration in GABRA4 mRNA 
abundance.
5.43: GABRA5
In the assay of GABRA5 at SNP rsl40682, cDNA ratios ranged from 0.79 to 1.25. A 
notable feature of the data is that, despite this large range of values, cDNA ratios for each 
sample were very highly replicable, with an unusually low average coefficient of variation 
of <0.03. A low coefficient of variation narrows the confidence intervals within which the 
‘true’ allelic expression ratio for each brain sample is likely to fall, thereby increasing 
confidence in the accuracy of the measurements. In view of this, the data, taken as whole, 
are suggestive of either multiple c/s-regulatory variants of small to moderate effect or a 
single variant of variable size effect in low LD with the assayed SNP.
cDNA ratios did not significantly differ between homozygotes and heterozygotes for SNP 
rsl 7561681, which was the variant in GABRA5 that was associated with RDC-defined 
schizoaffective disorder, bipolar type (Craddock et al., 2008). Although this may imply 
that the SNP does not influence mRNA abundance, in light of the suggestive evidence that
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GABRA5 may contain multiple cw-regulatory variants, the possibility remains that any 
regulatory effect of the SNP might be masked by regulatory effects of other variants.
GABRA5 has three mRNAs that are transcribed from separate promoters, and that differ 
only in their 5’ UTR sequence (Kim et al., 1997). The assayed SNP rsl40682 is located in 
exon 8 , which is included in all three mRNAs. RT-PCR using brain cDNA as template 
showed that all three promoters were active in the assayed brain tissue. Therefore, if 
GABRA5 has multiple cis-regulatory variants, it is plausible that their effects, including any 
putative effect of SNP rs l7561681, might be specific to mRNAs transcribed from a 
particular promoter. Hence, the possibility that the association of SNP rs l7561681 with 
RDC-defined schizoaffective disorder, bipolar type is mediated by an isoform-specific 
pathogenic alteration in mRNA abundance cannot be ruled out. Transcript-specific assays 
of allelic expression based on primers that span alternate exons and the assayed SNP would 
allow this possibility to be investigated.
5.4.4: GABRB3
In the assay of GABRB3 at SNP rsl 1637141, all brain samples exhibited an allelic 
expression difference in the same direction, such that mRNAs tagged by the G allele were 
on average 23% less abundant than mRNAs tagged by the A allele. In addition, one sample 
showed an even more pronounced difference of 40%. These findings are consistent with 
the presence of a c/s-acting regulatory variant of moderate effect that is in high LD with 
the assayed SNP, and plausibly with a second, less frequent variant of similar or larger 
effect. The data are also consistent with SNP rsl 1637141 having a c/s-regulatory effect 
itself.
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The SNP in GABRB3 associated with RDC-defined schizoaffective disorder, bipolar type 
was SNP rs890319 (Craddock et al., 2008). This SNP was not genotyped in any of the 
brain samples assayed. However, in Caucasians, LD between the assayed SNP rsl 1637141 
and SNP rs890319 is very low (D ’ = 0.085, r2 = 0.004 in HapMap CEU samples). 
Therefore, although not conclusive, the data from the present study do not support the 
hypothesis that the association of SNP rs890319 with RDC-defined schizoaffective 
disorder, bipolar type is mediated by a pathogenic alteration in GABRB3 mRNA 
abundance. It is important to note, however, that GABRB3 has two known mRNAs 
(Kirkness & Fraser, 1993), and that the assayed SNP rsl 1637141 is located in the 3’ UTR 
of both. Thus, the present study cannot rule out the possibility that SNP rs890319 has a cis- 
regulatory effect that is mRNA-specific. However, if SNP rsl 1637141 is functional, as the 
data may suggest, then, given its location in the 3’ UTR, it is likely that the detected allelic 
expression difference reflects an effect on mRNA degradation that influences the 
abundance of both isoforms.
Given the strong association between the assayed SNP and allelic expression in the present 
study, the potential importance of GABRB3 expression in bipolar disorder could be 
assessed by testing this SNP for genetic association with the disorder. However, in the 
datasets used in the WTCCC follow-up study (Craddock et al., 200), high quality imputed 
data (average maximum posterior call probability >0.98; missing data proportion <3.5%) 
for SNP rsl 1637141 did not indicate an association with bipolar disorder (P = 0.45) or 
RDC-defined schizoaffective disorder, bipolar type (P = 0.21). Similarly, the data did not 
indicate an association with schizophrenia either ([P = 0.78). This suggests that variation in 
GABRB3 mRNA abundance in brain probably does not influence susceptibility to any of 
these disorders.
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5.4.5: GABRG2
In the assay of GABRG2 at SNP rs418210, mRNAs tagged by the C allele were generally 
slightly (-10% on average) more abundant than mRNAs tagged by the T allele, with two 
samples showing a C allelic increase of >20%. These findings are consistent with the 
presence of a c/s-acting regulatory variant of small effect that is in high LD with the 
assayed SNP. However, GABRG2 is known to have three mRNA isoforms, and SNP 
rsl40682 is present on all of them. Thus which of these mRNAs the putative regulatory 
variant affects is unclear.
Variants in GABRG2 did not previously show any evidence for association with bipolar 
disorder or RDC-defined schizoaffective disorder, bipolar type (WTCCC, 2007, Craddock 
et al., 2008). In the datasets used in the WTCCC follow-up study (Craddock et al., 200), 
high quality imputed data (average maximum posterior call probability >0.98; missing data 
proportion <2%) for assayed SNP rs418210 did not indicate an association with 
schizophrenia (P = 0.55), bipolar disorder (P = 0.54) or RDC-defined schizoaffective 
disorder, bipolar type (P = 0.87). Therefore, it can be inferred that whatever small change 
(i.e. increase or decrease of one, two or all three mRNAs) in GABRG2 mRNA abundance 
in brain was detected in this study, it probably does not influence susceptibility to these 
disorders.
5.4.6: GABRG3
The assay of GABRG3 at SNP rsl40679 did not reveal any evidence of c/s-regulatory 
variation in the 29 brain samples analysed. This finding suggests that if polymorphisms or 
haplotypes with detectable effects on expression of this gene’s only known mRNA in brain 
exist, they are likely to be rare, at least in Caucasian populations. Hence, any association
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between common variants in this gene and psychiatric illness, including RDC-defined 
schizoaffective disorder, bipolar type, is unlikely to be mediated by a pathogenic alteration 
in GABRG3 mRNA abundance.
5.4.7: Further Discussion
The present studies do not support the hypothesis that the reported associations of SNPs in 
GABAa subunit genes with bipolar disorder and RDC-defined schizoaffective disorder, 
bipolar type are mediated by alterations in expression levels of those genes in brain. In 
fact, the results of each gene assay argue against this hypothesis in three different ways. 
Firstly, the GABRB1 and GABRA5 data clearly demonstrate that the risk SNPs have no 
more influence on mRNA abundance in the tissue assayed than any other variant within or 
nearby those genes. Secondly, the GABRA4, GABRB3, and GABRG2 data clearly suggest 
that c/s-acting variants that influence abundance of those genes’ mRNA do operate in 
brain; however, these variants do not appear to be associated with disease. And thirdly, the 
GABRG3 data suggest that the gene does not contain variants that influence mRNA 
abundance.
It is important to note that it is possible that the risk SNPs in each gene may each be 
serving as proxies for separate less frequent c/s-regulatory variants in high LD (as defined 
by D ’) with them. In this case, only a fraction of heterozygotes for the risk SNPs, and even 
some homozygotes for the risk alleles, would be expected to show a significant allelic 
expression difference. If such variants were of sufficiently low frequency, it is possible that 
too few brain samples were assayed in the present studies to detect them. However, the 
brain sample with the outlying cDNA ratio observed in the GABRA4 assay could 
potentially be one example.
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The assays of GABRB1 (alternative transcript), GABRA4, GABRA5, and particularly 
GABRB3 each provided evidence of cw-regulatory variation that was, or was very likely to 
be, unrelated to the risk SNPs identified in each gene. If a variant within a gene has a 
known functional effect, but does not increase risk for a disorder, it is a reasonable 
assumption that any susceptibility variants within the same gene likely act via a different 
mechanism. In view of this, the effects of risk SNPs identified in each of these genes may 
be more complex, or more specific, than simply altering expression levels in brain. For 
example, their effects may be specific to certain mRNA isoforms, brain regions or cell 
types, or may only occur at critical periods of development, or be dependent on one or 
more trans factors that are disease-specific.
The variants detected in the present studies, including the assay of GABRG2, may be of 
potential relevance to the aetiology or pathophysiology of several other psychiatric or 
neurological disorders. Their potential influence is likely dependent not only on whether 
they increase or decrease mRNA abundance, but also on the basal expression level of the 
gene in individual cells relative to other subunit genes that make up functional GABAa 
receptor channels. The assembly of multimeric channels such as GABAa receptors may, in 
theory, be constrained by whichever of the required subunits of the channel is least 
expressed (and therefore rate-limiting). Hence, in theory, the detected variants might only 
influence susceptibility if they affect or determine the least expressed subunit of at least 
one receptor subtype. With this and the logical potential for gene x gene interaction effects 
in mind, the variants underlying the allelic expression differences observed in these 
studies, if identified, could be reasonable functional candidates for case-control association 
studies of relevant psychiatric or neurological disorders.
145
Chapter 5: GABR Genes
The SNP assayed for GABRG2 (rs418210) is part of a haplotype that was previously found 
to be associated with schizophrenia in a Finnish family sample (Turunen et al., 2003). The 
detection of a c/s-regulatory variant in high LD with this SNP is, therefore, particularly 
intriguing and warrants further work to identify it. The present study also suggests that the 
SNP assayed for GABRB3 (SNP rsl 1637141) is, or is in perfect LD with, a functional cis- 
regulatory variant of moderate effect. In the two studies that have analysed this SNP in 
relation to autism (Tochigi et al., 2007; Kim et al., 2008), no evidence for association was 
found. This suggests that whatever influence this SNP has on GABRB3 mRNA expression 
in brain (i.e. increase or decrease in expression), it and other variants with a similar effect 
probably do not influence susceptibility to that disorder. In contrast, promoter variants in 
GABRB3 have previously been implicated in the aetiology of childhood absence epilepsy 
(Urak et al., 2006). Hence, analysis of SNP rsl 1637141 in relation to that disorder is 
warranted. The SNP is also a reasonable functional candidate for any other psychiatric or 
neurological disorder that GABRB3 might be implicated in.
GABRB3, GABRA5 and GABRG3 map to within the imprinted 15qll-ql3 region that is 
associated with Prader-Willi and Angelman syndromes. It is therefore noteworthy that the 
present studies demonstrate conclusively that none of these genes are imprinted in human 
brain, at least not in the regions assayed. This is in agreement with a recent study (Hogart 
et al., 2007), which also detected biallelic expression of these genes in frontal cortex of 
human control brain samples. Interestingly, this study also found highly skewed or 
monoallelic expression of these genes in brain samples from individuals with Rett 
syndrome or autistic spectrum disorders. The authors attributed these findings to 
dysregulation of epigenetic mechanisms in those disorders.
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5.4.8: Conclusions
The present studies do not support the hypothesis that the association of SNPs in GABAa 
subunit genes with bipolar disorder and RDC-defined schizoaffective disorder, bipolar type 
is mediated by c/s-regulatory influences on mRNA abundance. Czs-regulatory variants in a 
number of these genes do, however, exist and may be relevant to other psychiatric or 
neurological disorders.
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C h a p te r  6: N it r ic  O x id e  S y n th a s e  1 A d a p te r  P r o te in  (NOS1AP)
6.1: Introduction 
6.1.1: The NOS1AP Gene, the NOS1 Adapter Protein, and Nitric Oxide
The human NOS1AP gene (formerly CAPON; OMIM: 605551) encodes the neuronal nitric 
oxide synthase 1 (NOS1) adapter protein. This protein was originally identified in rat as a 
binding partner of neuronal nitric oxide synthase (nNOS) (Jaffrey et al., 1998), an enzyme 
that synthesises the gaseous transmitter, nitric oxide, in the brain (Huang et al., 1993). 
When bound to nNOS, the NOS1 adapter protein prevents the enzyme from associating 
with postsynaptic density proteins, PSD-93 and PSD-95 (Jaffrey et al., 1998). The 
interaction between nNOS and these proteins is important for targeting nNOS to the 
postsynaptic N-methyl-D-aspartate (NMD A) receptor complex and for subsequent NMD A 
receptor-mediated nitric oxide release (Brenman et al., 1996a, 1996b). Hence, the principal 
function of the NOS1 adapter protein is thought to be to negatively regulate the level of 
nitric oxide in the brain.
The primary function of nitric oxide is to stimulate guanylyl cyclase to catalyze the 
production of the second messenger, cyclic guanosine monophosphate (cGMP) (Friebe & 
Koesling, 2003). Through pathways dependent on and independent of this molecule, nitric 
oxide is known to play a wide range of roles in brain function. For example, it has been 
shown to regulate the release of numerous neurotransmitters (including glutamate, GABA, 
dopamine, and others), it modulates neurotransmitter receptor function, plays a key role in 
synaptic plasticity, and is involved in neuronal development and control of gene expression 
(Yun, Dawson & Dawson, 1996, 1997; Prast & Philippu, 2001). Since nitric oxide is an 
oxygen radical, at higher concentrations it is neurotoxic and thus may be involved in the
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pathophysiology of various neurological and neurodegenerative disorders (Dawson & 
Dawson, 1998; Boje, 2004). A role for nitric oxide in the pathophysiology of schizophrenia 
and other psychiatric disorders has also been proposed, although it is unclear whether an 
increase or decrease in nitric oxide levels is involved (Akyol et al., 2004; Bernstein, 
Bogerts & Keilhoff, 2005). Support for a role of nitric oxide in psychiatric disease is also 
provided by findings that non-coding variants in the NOS1 gene have been reported to be 
associated with schizophrenia in some samples (Shinkai et al., 2002; Fallin et al., 2005;
Reif et al., 2006; O’Donovan et al, 2008, Tang et al., 2008), although these studies have 
reported association to different alleles, making meta-analysis impossible.
6.1.2: The NOS1AP Gene in Psychiatric Populations
Given the diverse roles attributed to nitric oxide in the brain, its possible 
neuropathophysiological involvement, and the fact that the NOS1 adapter protein 
negatively regulates the activity of nNOS, the NOS1AP gene is an attractive functional 
candidate for psychiatric disease susceptibility. Moreover, the gene, which contains 10 
exons and spans -300 kb of chromosome lq23, is a good positional candidate, as linkage 
studies and meta-analysis have identified this region as a likely susceptibility locus for 
schizophrenia (Shaw et al., 1998; Brzustowicz et al., 2000, 2002; Gurling et al., 2001;
Hwu et al., 2003; Lewis et al., 2003, Ng et al., 2009) and autistic spectrum disorders 
(Auranen et al., 2002; Ylisaukko-oja et al., 2004, 2006).
In a study of 22 European-Canadian families multiply affected by schizophrenia, the 
maximum LOD score achieved at lq23 was 6.5 (Brzustowicz et al., 2000). The 
susceptibility locus was then fine-mapped to a 1 Mb region (Brzustowicz et al., 2002), in 
which several polymorphisms, all located within NOS JAP, were subsequently shown to be
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in significant linkage disequilibrium (LD) with the disease (Brzustowicz et al., 2004). Prior 
to the work presented here, association between polymorphisms within or nearby NOS1AP 
and schizophrenia had also been reported in Spanish (Rosa et al., 2002), Chinese Han 
(Zheng et al., 2005) and Colombian (Miranda et al., 2006) populations, although in a 
British sample no association was found (Puri et al., 2006). No meta-analyses of the 
association of NOS1AP with schizophrenia have, as of September 2008, been reported.
6.13: Altered NOS1AP Expression as a Potential Pathogenic Mechanism in 
Psychiatric Disease
Sequencing of the coding region of NOS1AP in individuals from the Canadian linkage 
sample did not identify any non-synonymous coding variants (Brzustowicz et al., 2004), 
suggesting that the association, if genuine, is mediated by variants that affect expression. 
Consistent with a pathological role for altered NOS1AP expression, a novel ‘short’ NOS1 
adapter protein isoform was recently reported to show -50% increased expression at the 
mRNA level in post-mortem brain samples from individuals with schizophrenia and 
bipolar disorder when compared with normal controls (Xu et al., 2005). The observed 
increase was associated with alleles of NOS1AP SNPs (rsl415263, rs4145621, rs2661818) 
that had previously been found to show association with schizophrenia (Brzustowicz et al., 
2004). No significant differences in expression of the full length isoform, which is 
controlled by a different promoter, were observed.
6.1.4: The Present Study
The NOS1AP gene does not contain common variants that affect protein structure, hence 
the association between polymorphisms in this gene and schizophrenia, if genuine, may be 
mediated by czs-acting variants that alter NOS JAP expression. This hypothesis is supported
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by one study, described above, which found an increase in expression associated with 
putative risk SNP alleles. In the present study, the hypothesis was tested again, this time 
using a relative allelic expression assay, which, whilst controlling for potential /rans-acting 
confounds, can detect genuine effects of cw-acting regulatory variation. As in the study 
described above, short and full length isoforms were assayed separately in order to detect 
transcript-specific effects. Samples were genotyped for the three SNPs that were reported 
to show genetic association with schizophrenia in the Canadian families to test for their 
proposed cis effect on expression.
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6.2: Materials and Methods
Brain samples and the general methods used for DNA and RNA processing, 
genotyping, and the relative allelic expression assay are described in more detail in 
Chapter 2. 
6.2.1: Samples
Post-mortem brain tissue derived from frontal, temporal or parietal cortex of 148 unrelated 
anonymised individuals obtained from three sources (MRC London Brain Bank for 
Neurodegenerative Diseases; Stanley Medical Research Institute; and Karolinska Institute) 
were used in this study. For each tissue sample, genomic DNA and total RNA were 
extracted by standard procedures. RNA was then treated with DNAse and reverse 
transcribed to cDNA.
6.2.2: Genotyping
PCR primers for the SNPs used for relative allelic expression analysis (rs3751284 and 
rs348624), and for SNPs rsl415263, rs4145621 and rs2661818, were designed by use of 
the Primer3 program (Rozen & Skaletsky, 2000). PCR was carried out in a total reaction 
volume of 12 pi containing 48 ng of genomic DNA, and consisted of 35 cycles.
TMGenotyping was carried out by fluorescent primer extension using the SNaPshot 
Multiplex Kit (Applied Biosystems) and primers designed by use of the FP Primer 
program (Ivanov et al., 2004). All primer sequences are shown in Table 6.1, which, where 
relevant, also shows the annealing temperature used during PCR cycling.
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Polymorphism Primer Sequence (5’- 3 ’) Ta (°C)
F: CCTTTGAGGTCTGCCACAAG
58
rs3751284* R: CCTGAGCTGTTGCTGTTCCT
EXT: GAGCTGTTGCTGTTCCTCTC -
F: CATTCATGTCCCTCTCTTCTCTC
58
rs348624* R: TGGAGCATGTCCTTGTTCTG
EXT: AGCAAAAGCTGATGCAC -
F: TGTTTGGAGGAAAATGTGGT
58
rsl415263 R: GAGCGTGGTATCAACCAAAC
EXT: ATTAGGC ATTCCC AATTCCTTT ATC -
F: TTTT ATTC ACCCC AACTCC A
58
rs4145621 R: CTATTGTCCATCACCCCTTG
EXT: TGACTTAAATCCAACTCTTCTTGTTTC -
F: GATCCTTGTCTCCTTGAGCA
58
rs2661818 R: AGATGGGATTGGAAGGAAAC
EXT: TTC AACCTCCTTCC ACT ATGA -
Table 6.1: Details o f primers used in the study o f  the NOS JAP gene. Asterisks 
indicate SNPs used for relative allelic expression analysis. F = forward primer, R = 
reverse primer, EXT = extension primer, Ta = annealing temperature used during PCR 
cycling.
6.23: Relative Allelic Expression Assay
The SNPs chosen for relative allelic expression analysis were rs3751284 and rs348624. In 
the HapMap CEU sample, frequency information for SNP rs3751284 is not available but 
the minor allele frequency for SNP rs348624 is 0.10. The two SNPs are located in exons 6  
and 9 of the NOS1AP gene respectively. Both SNPS are present on the full length brain- 
expressed mRNA transcript, but only the latter is present on the short transcript (see Figure 
6 .1).
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FL
Figure 6.1: The organisation of the NOS1AP gene and its two mRNA transcripts. The 
full length (FL) transcript is based on reference sequence NM_014697. The short (Sh) 
transcript is based on a description provided by its discoverers (Xu et al., 2005). 
Yellow rectangles represent 5’ and 3’ untranslated regions (UTRs), blue rectangles 
represent protein-coding exons, and the red rectangle represents the 5’ 54 bp coding 
portion of exon 9 that is unique to the short isoform. The black vertical line indicates a 
shorter 3’ UTR present in some transcripts. Asterisks indicate the positions of assayed 
SNPs rs3751284 in exon 6 and rs348624 in exon 9.
Genomic DNA from all brain samples was initially genotyped, as described, for both SNPs 
to identify heterozygotes. For each heterozygous sample, cDNA produced from two 
separate reverse transcription reactions, alongside corresponding genomic DNA, was 
assayed on two separate occasions (i.e. 2 * {2 cDNA + 1 genomic DNA}). Genomic DNA 
and cDNA were assayed under identical conditions. This allowed the average allelic ratio 
obtained from genomic DNA (representing a 1:1 ratio) to be used to correct allelic ratios 
obtained from cDNA for any inequalities in allelic representation specific to the assay.
PCR consisted of 35 cycles and was carried out in a total reaction volume of 12 pi 
containing 48 ng of genomic DNA or 6 pi of cDNA at the standard cDNA concentration 
(see Chapter 2, section 2.1.8). Primers, shown in Table 6.1, were based on single exons and 
therefore amplified an identical sequence from both templates. The forward primer for 
SNP rs348624 was based on a 5’ portion of exon 9 that was unique to the short transcript.
TMAllelic representation was measured by primer extension using the SNaPshot Multiplex 
Kit (Applied Biosystems) and the primers shown in Table 6.1. Peak heights of allele- 
specific extended primers were determined using Genotyper 2.5 (Applied Biosystems).
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The ratio of cDNA peak heights, corrected using the average ratio of genomic DNA peak 
heights, was then used to calculate the relative expression of mRNAs transcribed from 
each parental chromosome in each individual sample.
To confirm altered allelic expression, select individuals showing expression of one allele at 
a level 20% or more than the other were assayed on four further occasions (i.e. 4 x {2 
cDNA + 1 genomic DNA}). In line with previous studies (Yan et al., 2002; Bray et al., 
2003), an allelic expression difference >20% for any individual sample was chosen as 
indicative of the influence of cw-acting regulatory polymorphism since measurements 
surpassing this threshold are generally reproducible.
6.2.4: Linkage Disequilibrium Analysis and Diplotype Prediction
Linkage disequilibrium (LD) analyses were performed using Haploview 4.00 (Barrett et 
al., 2005) and were based on genotype data for the entire collection of 148 brain samples.
The probability that each brain sample carried a particular phased diplotype comprised of 
assayed SNPs rs3751284 and rs348624 was calculated using EH Plus (Zhao, Curtis & 
Sham, 2000) and an in-house program, as described in Chapter 2 (section 2.5.4).
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63: Results
63.1: Assayed Samples
Fifty-seven and 28 genotyped individuals were heterozygous for the expressed SNPs 
rs3751284 and rs348624 respectively, and therefore informative for allelic expression 
analysis. Twelve individuals were heterozygous at both SNPs. The mean age at death for 
the total of 73 informative individuals was 57 years (SD = 19.30), 45 were male, and 28 
were female. A large proportion (n = 37) had no known history of psychiatric or 
neurological disease, nine had schizophrenia, 1 0  had bipolar disorder, six had major 
depression, and 11 had Alzheimer’s disease. Samples were derived from frontal (n = 49), 
temporal (n = 16), and parietal {n = 8 ) brain tissue.
6 3 3 : Relative Allelic Expression
Analysis of cDNA ratios showed good reproducibility, with average coefficients of 
variation (SD / mean) of 0.06 and 0.10 for assays at rs3751284 and rs348624 respectively. 
In neither assay was significant correlation observed with sex, age, diagnostic status or 
brain region assayed.
6 3 3 : Full Length mRNA Transcripts
Analysis of full length mRNA transcripts at SNP rs3751284 showed that transcripts tagged 
by the G allele were on average 11% more abundant than those tagged by the A allele 
(Figure 6.2), although there was considerable variability with cDNA ratios ranging from 
0.74-1.31:1. In total, 15 samples showed an allelic difference of >20%. The difference 
between allelic ratios obtained with cDNA and genomic DNA was significant (P = 2.1 * 
10" ) .
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Figure 6.2: Scatter plot showing allelic ratios 
for genomic DNA and cDNA derived from 57 
individuals heterozygous for SNP rs3751284.
Data are presented as the G allele relative to the 
A allele (G:A). Each data point represents the 
average of four measurements. Ratios have been 
corrected by the average ratio obtained with 
genomic DNA.
There was one clear outlier, a 54-year-old anonymous female with no known history of 
neurological or psychiatric disorder. For this individual, the average G:A ratio over four 
replicate cDNA measurements was 0.74:1. When this individual’s sample was assayed a 
further four times, the average G:A ratio over eight replicate cDNA measurements was 
0.79:1 (95% C.I. = 0.76-0.82:1; Figure 6.3). Thus, in this individual, expression of the G 
allele was reduced by 21% (using the A allele as an arbitrary reference point), or 
expression of the A allele increased by 27% (using the G allele as an arbitrary reference 
point). Observed cDNA ratios from this individual were significantly different from ratios 
obtained with genomic DNA (P = 3.41 x 10'8).
6.3.4: Short mRNA Transcripts
In the analysis of short mRNA transcripts at SNP rs348624, allelic cDNA ratios obtained 
from one individual were extremely unreliable (SD / mean = 0.44), and thus excluded. The
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Figure 63: Bar chart comparing average allelic 
ratios obtained in the initial assay (red) with 
ratios obtained in the repeat assay (yellow) for 
the individual that initially showed relative 
under-expression of the G allele. The initial 
assay average is based on four measurements; 
the repeat assay average is based on eight 
measurements.
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remaining data showed that transcripts tagged by G and A alleles were, on average, 
approximately equally abundant (1.01:1) (Figure 6.4), hence, cDNA ratios were not 
significantly different from genomic ratios (P = 0.25).
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Figure 6.4: Scatter plot showing allelic ratios 
for genomic DNA and cDNA derived from 27 
individuals heterozygous for SNP rs348624. 
Data are presented as the G allele relative to the 
A allele (G:A). Each data point represents the 
average of four measurements. Ratios have been 
corrected by the average ratio obtained with 
genomic DNA.
Initial Repeat 
Figure 6.5: Bar chart comparing average allelic 
ratios obtained in the initial assay (red) with 
ratios obtained in the repeat assay (yellow) f°r 
the individual that initially showed relative over- 
expression of the G allele. The initial assay 
average is based on four measurements; the 
repeat assay average is based on eight 
measurements.
The individual that displayed a clear allelic difference in expression of the full length 
transcript was the only one that displayed an allelic expression difference of >20% for the 
short mRNA transcript. For this individual, the average G:A ratio over four replicate 
cDNA measurements was 1.32:1. When this individual’s sample was assayed a further four 
times, the average G:A ratio over eight replicate cDNA measurements was 1.42:1 (95% 
C.I. = 1.35-1.49:1; Figure 6.5). Thus, in this individual, expression of the G allele was 
increased by 42% (using the A allele as an arbitrary reference point), or expression of the 
A allele reduced by 30% (using the G allele as an arbitrary reference point). Observed
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cDNA ratios from this individual were significantly different from ratios obtained with 
genomic DNA {P = 6.33 x 10'7).
6 3 3 : Inter-Tmnscrint Allelic Expression Correlation
LD analyses showed that LD between assayed SNPs rs3751284 and rs348624 was low (£>’
= 0.26, r2 = 0.02). For double heterozygotes, the most probable (P = 0.69) phased 
diplotype was GG,AA. cDNA ratios denoted as the more highly expressed allele relative to 
the lower expressed allele (i.e. H:L) in brain samples informative at both SNPs (n = 11) 
were not significantly correlated (r = +0.30; P = 0.38).
63.6: Effect of SNPs rs!415263. rs4145621 and rs2661818
In the 148 brain samples genotyped in this study, neither of the assayed SNPs was in high 
LD with any of the three NOS1AP SNPs that showed association with schizophrenia in the 
previous study of Canadian families (Brzustowicz et al., 2004) (Table 6.2). Moreover, 
cDNA ratios denoted as the more highly expressed allele relative to the
rsl415263 rs4145621 rs2661818
rs3751284 0.01; 0.00 0.08; 0.01 0.14; 0.01
rs348624 0.10; 0.00 0.04; 0.00 0.35; 0.03
Table 63: LD between each assayed SNP (rows) and 
three putative schizophrenia risk SNPs (columns). D' 
and r2 values are shown (i.e. D ’; r2).
lower expressed allele i.e. H:L) did not significantly differ between homozygotes and 
heterozygotes for any of the three SNPs. This was true for both full length (Figure 6 .6 ; 
P > 0.50) and short mRNA transcripts (Figure 6.7; P > 0.73). These analyses had 80%
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power to detect a ratio difference of 0.06 and 0.07 for the full length and short mRNA 
transcript assays respectively (P = 0.05).
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Figure 6.6: Scatter plot showing allelic ratios for cDNA derived from 57 individuals 
heterozygous for SNP rs3751284 stratified by genotype for three putative 
schizophrenia risk SNPs. cDNA ratios from individuals that are homozygous for each 
SNP are shown in red, and ratios from heterozygotes are shown in yellow. Data are 
presented as the higher expressed allele relative to the lower expressed allele (H:L). 
Each data point represents the average of four measurements. Ratios have been 
corrected by the average ratio obtained with genomic DNA.
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Figure 6.7: Scatter plot showing allelic ratios for cDNA derived from 27 individuals 
heterozygous for SNP rs348624 stratified by genotype for three putative schizophrenia 
risk SNPs. cDNA ratios from individuals that are homozygous for each SNP are 
shown in red, and ratios from heterozygotes are shown in yellow. Data are presented 
as the higher expressed allele relative to the lower expressed allele (H:L). Each data 
point represents the average of four measurements. Ratios have been corrected by the 
average ratio obtained with genomic DNA.
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6.4: Discussion
The present study sought to test the hypothesis that NOS1AP contains common regulatory 
polymorphism, which might underlie reported genetic associations between the gene and 
schizophrenia in general populations. Assays of relative allelic expression targeted at the 
two known NOS1AP mRNA transcripts were applied to a total of 73 post-mortem brain 
samples. The data showed common weak cis effects on expression of full length but not 
short mRNA transcripts, and, in one sample derived from a 54-year-old female with no 
known psychiatric or neurological diagnosis, both transcripts showed moderately large 
allelic expression differences.
The results of the present study are not consistent with a previous study in which SNPs 
showing association with schizophrenia were associated with increased NOS1AP 
expression (Xu et al., 2005). In that study, heterozygosity or homozygosity for 
schizophrenia-associated alleles at SNPs rsl415263, rs4145621 and rs2661818 correlated 
with -33% higher brain levels of total short isoform mRNA as measured by real time PCR. 
In the present study, the largest short isoform allelic expression difference observed was 
42% in one individual, with all other individuals showing differences of <20%. Hence the 
present study strongly suggests that NOS1AP variants with large cis effects on short 
isoform expression are relatively infrequent. Also in disagreement with that earlier study is 
that when H:L cDNA ratios in homozygotes and heterozygotes for each of SNPs 
rsl415263, rs4145621 and rs2661818 were compared in the present study, no significant 
differences were found for the short (or full length) mRNA isoforms. Given the statistical 
power of these analyses (80% to detect a ratio difference of 0.06), this suggests that none 
of these SNPs have even a relatively modest influence on mRNA abundance, at least not in
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the brain tissues analysed. The association of these variants with schizophrenia, if genuine, 
is therefore unlikely to be mediated by this mechanism.
That common c/5-regulatory variants affecting expression of the short mRNA isoform 
were not detected in the present study is also contrary to the findings of a more recent 
study. In that study, a further common SNP in NOS JAP, SNP rs12742393, was found to be 
associated with schizophrenia in the Canadian families, and was subsequently found to 
have a functional effect on NOS1AP expression in neuronal cell lines, and to be associated 
with short mRNA isoform abundance in post-mortem brain (Wratten et al., 2009). 
Although the SNP in question was not genotyped in the present study, given its minor 
allele frequency of 0.38 in HapMap CEU samples, it is expected that many of the assayed 
brain samples were heterozygous for it. Therefore, if the SNP indeed has an effect on 
mRNA abundance, its effect is likely to be very small.
In the assay of full length isoforms, mRNAs tagged by the G allele at SNP rs3751284 were 
generally slightly (~11% on average) more abundant than mRNAs tagged by the A allele, 
with 15 samples showing a G allelic increase of >20%. These findings are consistent with 
the presence of a cis-acting regulatory variant of small effect that is in high LD with the 
assayed SNP. Although an effect of the putative variant on schizophrenia susceptibility is 
conceivable, no association was found between SNP rs3751284 and schizophrenia in the 
Canadian linkage families (Brzustowicz et al., 2004). Furthermore, in a previous report, 
full length NOSJAP mRNA abundance in brain did not significantly differ between 
individuals with schizophrenia or bipolar disorder and normal controls (Xu et al., 2005), 
suggesting that frill length isoform expression is of little relevance to psychiatric disease. 
However, the authors noted the possibility that the lack of difference in expression may
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have been due to normalisation by antipsychotic drug use. For instance, in the small 
number of drug-naive patients, full length mRNA was indeed 24% increased relative to 
normal controls, although this difference did not quite reach significance (P = 0.11).
According to a recent comparative genome hybridisation study, chromosome lq23 
harbours a common -512 kb deletion polymorphism that encompasses several genes along 
with the promoter and first exon of NOS1AP (de Smith et al., 2007). In the heterozygous 
state, deletion of the promoter is likely to ablate expression from one gene copy. However, 
if the deletion is as common in Caucasians as the report suggested (16 observations in 50 
individuals), it would be expected to have manifested in the present study as frequent 
monoallelic expression of the full length isoform. Since this was not found, the present 
study suggests the reported variant is either far less frequent than reported or does not 
extend to the NOS1AP gene. However, the possibility that the exon 6 SNP assayed in the 
present study tags an unidentified mRNA transcribed from a novel alternative promoter 
cannot be excluded.
In brain samples that were informative at both assayed SNPS there was no significant 
correlation in allelic expression differences between the two transcripts. However, given 
that allelic expression differences observed in one individual were of comparable size for 
both transcripts, and, for the full length transcript, in opposite direction to all other 
individuals, this suggests that the individual may carry a regulatory variant in a sequence 
element that coregulates both isoforms. Assuming the individual carries the most probable 
diplotype (GG,AA), the putative variant would be expected to have opposite effects (i.e. 
up- and down-regulation) on expression of the two isoforms. If the individual carries the 
lesser probable diplotype (GA,AG), the variant would be expected to have the same effect
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(i.e. up- or down-regulation) on both isoforms. Either way, the variant, if identified, could 
be a reasonable functional candidate for large case-control association studies of 
psychiatric disease.
6.4.1: Conclusions
The present study suggests that reports of genetic association between NOS1AP and 
schizophrenia cannot be accounted for by common variants that results in large or even 
relatively modest changes in short mRNA isoform abundance. The results are, however, 
consistent with the existence of a common regulatory variant affecting full length isoform 
expression, and a less common variant affecting both isoforms. If identified, the 
contribution of these variants to psychiatric disease susceptibility may deserve further 
investigation.
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Ch a pter  7: M ic r o tu bu le-A sso c ia ted  Pr o tein  Tau  (MAPT)
7.1: Introduction 
7.1.1: The MAPT Gene and Tau
The human MAPT gene (OMIM: 157140) spans -134 kb of chromosome 17q21, includes 
16 exons, and encodes the microtubule-associated protein tau (Neve et al., 1986; 
Andreadis, Brown & Kosik et al., 1992). Tau is an abundant protein in the central and 
peripheral nervous systems (Binder et al., 1985; Georgieff et al., 1991) where it is 
predominantly expressed in axons of developing and mature neurons (Brion et al.9 1988). It 
was originally recognised for its ability to promote assembly and stabilisation of 
microtubules (Weingarten et al., 1975; Cleveland et al., 1977a, 1977b; Drubin & 
Kirschner, 1986), and is now known to play roles in neurite outgrowth and in transduction 
of signals to the actin cytoskeleton (Shahani & Brandt, 2002).
In human brain, tau exists as six protein isoforms ranging from 352 to 441 amino acids in 
length generated by alternative splicing of exons 2, 3 and 10 (Himmler et al., 1989). Exons 
9-12 each encode an imperfect repeat of a microtubule-binding domain (Lee, Cowan & 
Kirschner, 1988; Goedert et al., 1989b). When exon 10 is spliced out the resultant protein 
contains three microtubule-binding domains (3R tau); when spliced in, a protein with an 
extra such domain is produced (4R tau) (Goedert et al., 1989b). In vitro experiments have 
shown that 4R tau isoforms bind microtubules with higher affinity, and assemble them 
more efficiently than 3R tau isoforms (Goedert & Jakes, 1990; Butner & Kirschner, 1991). 
Alternative splicing of exons 2 and 3 generates 3R and 4R isoforms with no (ON), one 
(IN), or two (2N) additional inserted domains of unknown function (Goedert et al., 
1989b). All six tau isoforms can be phosphorylated at several sites (Billingsley & Kincaid,
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1997; Buee et ah, 2000), and phosphorylation correlates with reduced affinity for 
microtubules (Biemat et al., 1993; Bramblett et al., 1993) and a slower rate of assembly 
(Lindwall & Cole, 1984).
The alternative splicing and phosphorylation status of tau are both developmentally 
regulated. The tau content in human embryonic brain is comprised entirely of the shortest 
tau isoform (Goedert et al., 1989b) and is highly phosphorylated (Kanemaru et al., 1992; 
Bramblett et al., 1993; Goedert et al., 1993; Watanabe et ah, 1993). In contrast, in adult 
brain, all six tau isoforms are expressed (Goedert et ah, 1989b) with a ratio of 3R and 4R 
isoforms of -1:1, and a ON, IN and 2N isoform composition of -37%, -54% and -9%  
respectively (Goedert & Jakes, 1990; Hong et ah, 1998). Furthermore, adult brain tau 
generally shows much lower levels of phosphorylation than embryonic brain tau 
(Kanemaru et ah, 1992; Bramblett et ah, 1993; Goedert et ah, 1993; Watanabe et ah,
1993), and the degree of phosphorylation gradually decreases with age (Mawal-Dewan et 
ah, 1994).
7.1.2: The Role of Tau in the Pathology of Neurodegenerative Disease
The involvement of tau in neurodegenerative disease was first realised when it was found 
to be the major constituent of the neurofibrillary tangle (Iqbal et ah, 1986; Kosik et ah,
1986; Goedert et ah, 1988), one of the two neuropathologic hallmarks of Alzheimer’s 
disease (AD). Neurofibrillary tangles are intracellular insoluble accumulations of abnormal 
filaments of hyperphosphorylated tau. In contrast to the distribution of p-amyloid- 
containing senile plaques, the other hallmark brain lesion in AD, the number of 
neurofibrillary tangles closely correlates with the degree of neuronal loss and severity of
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dementia (Arriagada et al., 1992; Gomez-Isla et al., 1997; Riley, Snowdon & Markesbery,
2002; Giaimakopoulos et al., 2003; Guillozet et al., 2003; Ingelsson et al., 2004).
In addition to AD, abnormal tau filaments are also a prominent pathologic feature of many 
other neurodegenerative diseases including sporadic forms, such as argyrophilic grain 
disease (AGD), corticobasal degeneration (CBD), Pick’s disease (PiD), and progressive 
supranuclear palsy (PSP), and familial forms collectively known as frontotemporal 
dementia with Parkinsonism linked to chromosome 17 (FTDP-17) (Lee, Goedert & 
Trojanowski, 2001). These and other diseases that feature tau pathology have collectively 
become known as ‘tauopathies’. Although the phosphorylation status of tau in these 
tauopathies is similar to that in AD (i.e. hyperphosphorylated), the composition of the 
filaments are different (Lee, Goedert & Trojanowski, 2001). In AD, neurofibrillary tangles 
are made up of all six tau isoforms. In contrast, tau filaments in AGD, CBD, PSP and some 
cases of FTDP-17 are composed primarily of 4R isoforms, whereas in PiD and other cases 
of FTDP-17, 3R isoforms predominate (Arai et al., 2001; Tolnay et al., 2002; Mott et al.,
2005; Yoshida, 2006). Hence, the role of tau in neurodegenerative disease is thought to 
relate to a dysregulation not just of tau phosphorylation, but also of alternative splicing.
7.13: Aberrant Tau Splicing as a Potential Pathogenic Mechanism in
Neurodegenerative Disease
The hypothesis that aberrant splicing of exon 10 of MAPT can play a primary pathogenic 
role in neurodegenerative disease is supported by the identification of several rare splice 
site mutations within or flanking exon 10 that cause FTDP-17 (Goedert, 2005; Goedert &
Jakes, 2005). The mutations are believed to destabilise a putative RNA stem-loop structure 
which is thought to regulate exon 10 splicing (Hutton et al., 1998; Spillantini et al., 1998).
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The majority of these mutations increase exon 10 inclusion and raise the 4R:3R mRNA 
ratio in vivo by two- to six-fold (Connel et al., 2005; Hutton et al., 1998; Spillantini et al.,
1998). Mutations that markedly reduce or abolish exon 10 inclusion in vitro have also been 
identified in a small number of FTD families (D’Souza et al., 1999; Stanford et al., 2003).
The relative abundance of 4R and 3R transcripts has also been examined in sporadic 
tauopathies. Consistent with the composition of neurofibrillary tangles, a number of studies 
have found no differences in abundance of 4R and 3R transcripts between patients with 
AD and normal individuals (Goedert et al. 1989a; Chambers et al., 1999; Boutajangout et 
al., 2004; Connel et al., 2005; Ingelsson et al., 2006), although others have found a shift 
towards increased levels of 4R isoforms (Yasojima et al., 1999; Umeda et al., 2004; 
Ginsberg et al., 2006, Glatz et al., 2006). With regards to the 4R tauopathies, CBD and 
PSP, the data are consistent, showing increased abundance of 4R mRNAs relative to 3R 
mRNAs, particularly in brain regions affected by these diseases (Chambers et al., 1999; 
Takanashi et al., 2002; Umeda et al., 2004). However, in PiD, a 3R tauopathy, the data 
have been mixed with some cases showing 4R:3R ratios of >1:1 and others with ratios of 
<1:1 (Umeda et al., 2004; Connell et al., 2005).
That several FTDP-17 mutations that affect splicing do not change the coded amino acid 
sequence (except through their splicing effect) provides strong evidence that an imbalance 
of 3R and 4R tau isoforms is sufficient to cause disease. However, despite extensive 
resequencing, coding or splicing mutations in MAPT have not been identified in the 
overwhelming majority of sporadic tauopathy cases (Bonifati et al., 1999; Roks et al.,
1999; Morris et al., 2002; Pastor et al., 2002; Zekanowski et al., 2003; Stanford et al.,
2004; Williams et al., 2007). Moreover, the failure of some studies to detect an imbalance
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of splice forms in AD, and the inconsistent results regarding PiD, suggests that tau- 
associated mechanisms not related to alternative splicing may also play an important role 
in triggering the neurodegenerative process.
7.1.4: MAPT as a Risk Factor for Sporadic Neurodegenerative Disease
An association of MAPT with sporadic neurodegenerative disease was first reported when 
one allele (AO) and the homozygous genotype (AO/AO) of a dinucleotide repeat 
polymorphism in intron 9 were found to be significantly over-represented in patients with 
PSP when compared with normal controls (Conrad et al., 1997). The association with PSP 
was then replicated (Bennett et al., 1998; Higgins et al., 1998; Oliva et al., 1998; Hoenicka 
et al., 1999; Morris et al., 1999), and extended to a haplotype that covered the entire MAPT 
locus (Baker et al., 1999). The haplotype, designated HI, and it allelic counterpart, H2, 
were found to be definable by eight common SNPs and a 238 bp insertion / deletion 
polymorphism, all in complete linkage disequilibrium (LD) with each other and the 
dinucleotide repeat (Baker et al., 1999).
The full extent of LD at the MAPT locus has now been defined and found to cover a 
maximal region of ~ 1.8 Mb (Pittman et al., 2004). In addition to MAPT', this region covers 
several other genes including STH (Saitohin, situated within intron 9 of MAPT), CRHR1 
(corticotrophin releasing hormone receptor 1), NSF (Af-ethylmaleimide sensitive factor),
IMP5 (a presenilin homologue), and LOC284058 (a gene of unknown function). It is 
believed that the HI and H2 haplotypes arose approximately 3 million years ago and 
correspond to a 900 kb inversion on 17q21, which had the effect of suppressing 
recombination between the two inverted regions (Stefansson et al., 2005). Interestingly, the 
inverted H2 haplotype is only found in Europeans and populations with a history of
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European admixture. In Caucasians, H2 has a frequency of -20% (Evans et al., 2004; 
Stefansson et al., 2005), whereas in African, Asian and Native American populations it is 
either very rare or completely absent (Evans et al., 2004; Stefansson et al., 2005).
The association of HI with PSP has now been replicated in several independent Caucasian 
populations with typical allele frequencies of >90% in patients and 70-80% in controls 
(Pittman, Fung & de Silva et al., 2006). In addition to PSP, the HI and H2 haplotypes have 
been analysed in relation to several other neurodegenerative diseases. Similar to PSP, the 
HI haplotype is over-represented in patients with CBD (Di Maria et al., 2000; Houlden et 
al., 2001; Pastor et al., 2004). With regards AD, the data have been largely negative (Roks 
et al., 1999; Baker et al., 2000; Kwon et al., 2000; Pastor et al., 2000; Russ et al., 2001;
Cook et al., 2002; Green et al., 2002; Verpillat et al., 2002b; Clark et al., 2003; Oliveira et 
al., 2003; Peplonska et al., 2003; Streffer et al., 2003; Forero et al., 2006; Zuo et al.,
2006), although two reports describe an increased risk associated with an interaction 
between HI and the APOE e4 allele (Lilius et a l, 1999; Bullido et al., 2000), and some 
studies have found an association with H2 (Conrad et al 2002, 2004, Combarros et al.,
2003; Seripa et al., 2004). Associations with HI dependent on (Ingelson et al., 2001; 
Verpillat et al., 2002a) and independent of (Hughes, Mann & Pickering-Brown, 2003) 
APOE genotype have also been reported for sporadic frontotemporal dementia (FTD), 
although other studies have found no association (Morris et al., 1999; Sobrido et al., 2003; 
Bemardi et al., 2006). Some support for a risk effect of HI in AGD has also been found 
(Ishizawa et al., 2002, Togo et al., 2002, Conrad et al., 2004). Interestingly, there is 
growing evidence that HI may also increase risk for Parkinson’s disease (PD) (Pastor et 
al., 2000; Golbe et al., 2001; Maraganore et al., 2001; Martin et al., 2001; Farrer et al.,
2002; Healy et al., 2004; Kwok et al., 2004; Levecque et al., 2004; Skipper et al., 2004;
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Fidani et al., 2006). Despite reports of conflicting results (Morris et al., 1999; de Silva et 
al., 2002; Clark et al., 2003; Peplonska et al., 2003; Zappia et al., 2003; Johansson et al.,
2005; Rademakers et al., 2006), meta-analysis supports the association, particularly for the 
HI/HI genotype (Healy et al., 2004; Zhang et al., 2005a). These findings are surprising as 
PD is not generally considered a tauopathy, although tau itself is a minor constituent of the 
Lewy body, the main neuropathologic hallmark of the disease (Arima et al., 1999; 
Ishizawa et al., 2003).
Although the association of HI with the mentioned neurodegenerative diseases is not 
specific to any one gene within the extended region of LD, the prominent tau pathology 
that characterises the majority of these disorders points directly to MAPT. To aid 
refinement of susceptibility loci, a number of studies have further explored the haplotypic 
diversity of MAPT in representative Caucasian populations. These studies identified a 
single H2 haplotype and multiple HI haplotypes, and determined that only one of the 
common HI haplotypes, designated H1C (or H1B), is highly significantly associated with 
PSP (Pittman et al., 2005; Rademakers et al., 2005). In one study, the region of MAPT with 
the strongest association stretches ~54 kb from intron 0 to intron 9 (Pittman et al., 2005).
In the other, the strongest association signal came from an overlapping 22 kb region from 
intron 0 to exon 1 (Rademakers et al., 2005). In both studies, SNP rs242557, a HI-specific 
variant in intron 0 and part of the HI C haplotype, showed particularly strong evidence for 
association, with the A allele being over-represented in PSP cases (Pittman et al., 2005; 
Rademakers et al., 2005).
Recently, the HIC haplotype was suggested also as a risk factor for late-onset AD (Myers 
et al., 2005). Moreover, efforts to refine the HI haplotype association in PD in Norwegian
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and Greek populations have narrowed the susceptibility locus to a 90 kb region from intron 
0 to intron 4 (Skipper et al., 2004; Fidani et al., 2006). However, in French and Belgian 
populations, early-onset PD was significantly associated with a 3.5 kb region around exon 
10, whilst late-onset PD was associated with a 1 kb region upstream of exon 1 
(Rademakers et al., 2006). In the Finnish population, an association between PD and the 
PSP-associated SNP rs242557 was detected (Fung et al., 2006). A significant association 
between this SNP and CBD has also been reported (Pittman et al., 2005).
Taken as a whole, the association data suggest that the same variants in MAPT may confer 
risk across diagnoses to several tau-related neurodegenerative diseases. In the absence of 
coding mutations that alter protein structure, it is assumed that the putative susceptibility 
variants are regulatory, affecting transcription and / or alternative splicing of MAPT.
7.1.5: Genetic Regulation of MAPT Expression
Resequencing of the MAPT promoter region has identified a series of potentially functional 
biallelic SNPs and deletion / insertion polymorphisms that segregate with the HI and H2 
haplotypes (Ezquerra et al., 1999; de Silva et al., 2001; Rademakers et al., 2002; Kwok et 
al., 2004). In luciferase reporter assays, the transcriptional activity of each promoter 
haplotype was found to be significantly different, with the HI variant driving -1.2 fold 
higher expression than the H2 variant in two human cell lines (Kwok et al., 2004). Given 
these findings, it is a reasonable hypothesis that variants in H1C, the only HI haplotype 
associated with disease, might increase transcriptional activity to an even higher degree.
The HIC-defining SNP rs242557 is located within a 182 bp region that is highly conserved 
from rats to humans, and is predicted to alter the binding site for two /ram-regulatory
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proteins (Rademakers et al., 2005). In reporter gene assays in which this SNP was cloned 
upstream of the MAPT HI promoter, it was the non-risk G allele that showed the highest 
transcriptional activity (Rademakers et al., 2005). However, in a more biologically relevant 
study in which the SNP was cloned downstream of the HI promoter, in accordance with 
expectations, the risk A allele was associated with 2.7 fold higher transcriptional activity 
than the G allele (Pittman et al., 2006). Moreover, the HI promoter with the A allele had 
4.2 fold higher activity than the H2 promoter with the G allele (Pittman et al., 2006). 
Together, these results suggest that the pathogenic basis of the HI and H1C associations 
with neurodegenerative disease, may, at least in part, be related to an overall increase in 
MAPT expression.
7.1.6: The Present Study
The HI and H2 alleles of MAPT encode identical tau proteins; hence associations between 
HI, H1C and SNP rs242557 and neurodegenerative diseases may be mediated by changes 
in MAPT expression, including alternative splicing of exon 10. The present study 
investigated this hypothesis using assays of relative allelic expression. Three assays 
targeted all MAPT mRNAs and a further assay specifically targeted at those containing 
exon 10 were applied to a total of 39 HI / H2 heterozygotes. Samples were additionally 
genotyped for SNP rs242557 and other SNPs that define the HIC haplotype to assess any 
effect these variants might have. Furthermore, given its importance as a risk factor for 
many neurodegenerative diseases, an effect of age was specifically checked for as well.
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7.2: Materials and Methods
Brain samples and the general methods used for DNA and RNA processing, 
genotyping, and the relative allelic expression assay are described in more detail in 
Chapter 2. 
7.2.1: Samples
Post-mortem brain tissue derived from frontal, temporal or parietal cortex of 126 unrelated 
anonymised individuals with no known history of neurodegenerative disease obtained from 
three sources (the MRC London Brain Bank for Neurodegenerative Diseases, the Stanley 
Medical Research Institute, and the Karolinska Institute) were used in this study. For each 
tissue sample, genomic DNA and total RNA were extracted by standard procedures. RNA 
was then treated with DNAse and reverse transcribed to cDNA.
7.2.2: Genotyping
PCR primers for SNPs used for relative allelic expression analysis (rsl052551, rs l052553, 
rs 17652121 and rs9468), and SNPs rs242557, rs2471738 and rs7521, were designed by use 
of the Primer3 program (Rozen & Skaletsky, 2000). PCR was carried out in a total reaction 
volume of 12 pi containing 48 ng of genomic DNA, and consisted of 35 cycles. 
Genotyping was carried out by primer extension using the SNaPshot™ Multiplex Kit 
(Applied Biosystems) and primers designed by use of the FP Primer program (Ivanov et 
al., 2004). All primer sequences are shown in Table 7.1, which, where relevant, also shows 
the annealing temperature used during PCR cycling.
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Polymorphism Primer Sequence (5’-3’) Ta (°C)
rsl 052551*
F:
R:
GGGCTGATGGTAAAACGAAG
CAGAGCTGGGTGGTGTCTTT
60
EXT: GGTGTCTTTGGAGCGGG -
rsl052553*
F:
R:
GATCGCAGCGGCTACAG
TTCTTCAGGTCTGGCATGG
60
EXT: GAGCCCAAGAAGGTGGC -
rsl7652121*
F:
R:
CCATGCCAGACCTGAAGAA
CCCGGGACGTGTTTGATATT
60
EXT: CCATGCCAGACCTGAAGAA -
rs9468*
F:
R:
AAGCAGGGTTTGTGATCAGG 
AATT AACCGAACTGCGAGG A
58
EXT: TCTCATTCTCTCCTCTCCAC -
rs242557
F:
R:
TGATGATGCATGGACCTCTC
CTGTGAGATCATCCCCTGGT
58
EXT: AAAACCGTGTCCTGGTG -
rs2471738
F:
R:
GGTTAGAGACCTTGGGG AAA 
GAATGAAAGTCACGGTGGTC
58
EXT: GGAAATAACTCACAGGTGACC -
rs7521
F:
R:
CGTGTCCCATCTACAGACCT
GCCAGAAATAGTCCTGCTCA
58
EXT: GTCCCATCTACAGACCTGC -
Table 7.1: Details of primers used in the study of the MAPT gene. Asterisks
indicate SNPs used for relative allelic expression analysis. F = forward primer, 
R = reverse primer, EXT = extension primer, Ta = annealing temperature used 
during PCR cycling.
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7.23: Relative Allelic Expression Assay
The SNPs chosen for relative allelic expression analysis were rsl052551, rsl052553 and 
rs9468. These SNPs are in complete LD with each other, and each defines the HI and H2 
haplotypes perfectly. All three SNPs are located in constitutive exons, and are thus present 
on all six MAPT mRNAs known to be transcribed in human brain (see Figure 7.1).
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Figure 7.1: The organisation of the MAPT gene and its six mRNA transcripts 
expressed in brain. 4R2N, 4R1N and 4R0N = isoforms containing four repeats and 
two (NM 005910), one (NM 001123067) or no (NM_016834) N-terminal domains 
respectively. 3R2N, 3R1N and 3R0N = isoforms containing three repeats and two, one 
or no (NM_016841) N-terminal domains respectively. Yellow rectangles represent 5’ 
and 3’ untranslated regions (UTRs), blue rectangles represent protein-coding exons, 
red rectangles represent alternatively spliced exons, and green rectangles represent 
exons not expressed in the brain. The black vertical line indicates a shorter 3’ UTR 
present in some transcripts. Asterisks indicate the positions of assayed SNPs 
rsl052551 in exon 7, rsl052553 and rsl7652121 in exon 9 and rs9468 in exon 13/14.
Genomic DNA ffom all brain samples was initially genotyped, as described, to identify 
heterozygotes for the HI and H2 haplotypes. For each heterozygous sample, cDNA 
produced ffom two separate reverse transcription reactions, alongside corresponding 
genomic DNA, was assayed on two separate occasions (i.e. 2 * (2 cDNA + 1 genomic 
DNA}) at each of the three SNPS. Genomic DNA and cDNA were assayed under identical 
conditions. This allowed the average allelic ratio obtained ffom genomic DNA
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(representing a 1:1 ratio) to be used to correct allelic ratios obtained from cDNA for any 
inequalities in allelic representation specific to the assay.
PCR consisted of 35 cycles and was carried out in a total reaction volume of 12 pi 
containing 48 ng of genomic DNA or 6 pi of cDNA at the standard cDNA concentration 
(see Chapter 2, section 2.1.8). Primers, shown in Table 7.1, were based on a single exon 
and therefore amplified an identical sequence from both templates. Allelic representation 
was measured by primer extension using the SNaPshot™ Multiplex Kit (Applied 
Biosystems) and the primers shown in Table 7.1. Peak heights of allele-specific extended 
primers were determined using Genotyper 2.5 (Applied Biosystems). The ratio of cDNA 
peak heights, corrected using the average ratio of genomic DNA peak heights, was then 
used to calculate the relative expression of mRNAs transcribed from each parental 
chromosome in each individual sample.
An assay of relative allelic expression that was specifically targeted at 4R mRNAs was 
also carried out. The procedure for this assay was similar to that described above, but 
instead utilised the exon 9 SNP, rsl7652121, which also perfectly defines the HI and H2 
haplotypes. For this assay it was necessary to use a reverse primer that was specific for 
exon 10. Since the forward and reverse primers targeted different exons, genomic DNA 
was not assayed, which meant that cDNA ratios could not be corrected. However, this did 
not prevent comparisons of cDNA ratios being made between brain samples with different 
genotypes.
To investigate potential influences of the HI C haplotype and the A allele of SNP rs242557 
on mRNA abundance, cDNA ratios obtained from samples carrying these variants were
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compared with ratios obtained from samples that did not. This comparison was made for 
ratios obtained in the initial three assays, and the assay that was specific for 4R transcripts.
7.2.4: Transcript Characterisation
To verify that exons 7, 9 and 13/14 (the exons tagged by the three SNPs used for allelic 
expression analysis) are present on the same mRNA transcripts and not alternatively 
spliced, RT-PCR and 3’ RACE PCR were carried out. High quality human brain RNA 
(Ambion) was reverse transcribed into cDNA using an oligo(dT)n adapter primer. Using 
the cDNA as template, MAPT transcripts were amplified using the three sets of primers 
shown in Table 7.2.
Target Primer Sequence (5’- 3 ’) Ta (°C)
Exon 7 -  Exon 13/14
F:
R:
GGGCTGATGGTAAAACGAAG
AATTAACCGAACTGCGAGGA
60
Exon 7 -  Poly(A)
GSP 1: 
GSP 2: 
AP:
GGGCTGATGGTAAAACGAAG
ACCAGGATTCCAGCAAAAAC
GAGTCCAGTCGACACAGAGC
60
Exon 9 -  Poly(A)
GSP 1: 
GSP 2: 
AP:
GATCGCAGCGGCTACAG
TGGTCCGTACTCCACCCA
GAGTCCAGTCGACACAGAGC
60
Table 7.2: Details of primers used to characterise MAPT mRNA transcripts. F = 
forward primer, R = reverse primer, GSP = gene-specific primer, AP = adapter 
primer, Ta = annealing temperature used during PCR cycling.
To increase specificity, 3’RACE PCR products were diluted 1 in 1,000 and reamplified 
using a second nested gene-specific primer. Products were then separated and sized by 
agarose gel electrophoresis, excised from the gel, purified, and sequenced. Sequencing was
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(fijperformed in the 5’ to 3’ direction by the fluorescent dideoxy method using the BigDye 
Terminator Kit (Applied Biosystems).
181
Chapter 7: MAPT
73: Results
73.1: Assayed Samples
A total of 39 genotyped individuals were heterozygous for the expressed HI / H2-defining 
SNPs rs l052551, rs l052553, and rs9468 and therefore informative for allelic expression 
analysis. Of these, 17 were heterozygous for the putative functional variant rs242557, and 
of these, eight carried the H1C haplotype as further defined by SNPs rs2471738 and 
rs7521. The mean age at death was 54 years (SD = 20.44, range = 19-102), 28 were male, 
and 11 were female. None of the individuals had a known history of neurodegenerative 
disease. Samples were derived from frontal (n = 29), temporal (n = 5), and parietal (n = 5) 
brain tissue.
73.2: Relative Allelic Expression: All MAPT mRNA Transcripts
Analysis of cDNA ratios showed good reproducibility, with average coefficients of 
variation (SD / mean) of 0.05, 0.07, and 0.06 for assays at SNPs rs l052551, rs l052553 and 
rs9468 respectively. The relative expression of HI and H2 mRNAs as measured in each 
SNP assay showed some variation, however, in each the mean ratio was close to 1:1 
(Figures 7.2 and 7.3). Individual differences in allelic expression were evident, with some 
showing an overall higher expression of HI versus H2 mRNAs, and others showing an 
opposite allelic pattern. Across the three independent SNP assays, cDNA ratios were 
significantly positively correlated (Table 7.3).
There was no significant difference in H1:H2 cDNA ratios between individuals carrying 
the HI C haplotype and individuals carrying other HI haplotypes in any of the three assays
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SNP rs l052553 rs9468
Assay r P r P
rsl052551 +0.61 5.18 x 10‘5 +0.62 3.73 x 10‘5
rsl052553 - - +0.50 0.002
Table 7.3: Correlation between cDNA ratios as 
measured at three MAPT SNPS.
(P > 0.76; Figure 7.2). Similarly, ratios did not significantly differ according to 
homozygosity and heterozygosity at SNP rs242557 in any assay (P > 0.20; Figure 7.3). 
These analyses had 80% power to detect a ratio difference between H1C non-carriers and 
carriers of 0.09, 0.20 and 0.10 respectively in each of the SNP rsl052551, rsl052553 and 
rs9468 assays (P = 0.05). Between homozygotes and heterozygotes for SNP rs242557, the 
corresponding power was 0.08, 0.12 and 0.09 respectively for each assay (P = 0.05). 
Furthermore, cDNA ratios did not significantly differ between the same genotypic
1.60 t--------------------------------------------------------------------------------------------
0 .60---------------------------------------------------------------------------------------------
0.40  -------------------------------------------------------------------------------------------
0.20  --------------------------------------------------------------------------------------
0 . 0 0  1 1 1 1 1 1 1
rsl052551 rsl052553 rs9468
Figure 7.2: Scatter plot showing allelic ratios for genomic DNA (blue) and cDNA 
derived ffom 39 individuals heterozygous for the H1/H2 haplotype. cDNA ratios ffom 
individuals that do not carry the H1C haplotype are shown in red, and ratios ffom 
those that do are shown in yellow. Data are presented as the HI allele relative to the 
H2 allele (H1:H2). Each data point represents the average of four measurements. 
Ratios have been corrected by the average ratio obtained with genomic DNA.
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categories when the analysis was confined to older individuals with age at death >50 years 
(P > 0.68 for HIC carriers vs. non-carriers; P > 0.14 for SNP rs242557 homozygotes vs. 
heterozygotes).
No significant correlation was observed between cDNA ratios and sex or brain region 
assayed (P > 0.05). However, there was a highly significant negative correlation between
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Figure 73: Scatter plot showing allelic ratios for genomic DNA (blue) and cDNA 
derived from 39 individuals heterozygous for the H1/H2 haplotype. cDNA ratios from 
individuals that are homozygous for SNP rs242557 are shown in red, and ratios from 
heterozygotes are shown in yellow. Data are presented as the HI allele relative to the 
H2 allele (H1:H2). Each data point represents the average of four measurements. 
Ratios have been corrected by the average ratio obtained with genomic DNA.
H1.H2 cDNA ratios obtained in two of the three assays, and age at death (Table 7.4). The 
extent of correlation was stronger when only samples with the highest quality data 
(coefficient of variation of <0.1) were included in the analysis. Furthermore, when only 
data obtained from samples derived from frontal cortex were included, a significant 
correlation was observed in all three assays (Table 7.4, Figure 7.4). Significant correlations 
were not specific to heterozygotes at SNP rs242557.
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rsl052551 rs1052553 rs9468
Samples n
r P r P r P
All 39 0.26 0.113 "0.44 0.006 "0.38 0.018
CofV <0.1 35 0.24 0.168 "0.53 0.002 "0.51 0.003
Frontal CofV <0.1 25 0.45 0.025 "0.57 0.005 "0.76 3.01 x 10'5
Table 7.4: Correlation between cDNA ratios as measured at three MAPT SNPs with age 
at death including all samples (top), samples that produced replicate cDNA ratios with 
coefficient of variation (CofV) <0.1 (middle), and frontal samples with CofV <0.1 
(bottom).
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Figure 7.4: Scatter plot showing the correlation of cDNA ratios as measured at rs9468 
with age at death (years) in samples derived from frontal cortex that produced 
replicate ratios with coefficient of variation of <0.1 (r = 0.76, P = 3.01 x 10‘5).
73.3: Transcript Characterisation
PCR using primers to amplify from exon 7 to exon 13/14 of MAPT using brain cDNA as 
template generated two products with sizes that corresponded with the expected sizes for 
known MAPT mRNA isoforms (i.e. 924 and 1,017 bp for 3R and 4R isoforms respectively) 
(Figure 7.5). Sequencing confirmed their identity and showed that exon 9 was included in 
both products. 3’ RACE PCR using MAPT-specific forward primers in exons 7 and 9 also 
generated two products each that corresponded with known MAPT mRNA isoforms 
(Figure 7.5). Sequencing showed that the two products generated using the exon 7-specific
185
Chapter 7: MAPT
primer included exons 9 and 13/14, and that the two products generated using the exon 9- 
specific primer included exon 13/14. All products also included exons 11 and 12.
Figure 7.5: Gel photograph showing a 100 bp DNA ladder (lane 
1), MAPT exon 7-13/14 PCR products (lane 2), and 3’ RACE PCR 
products using nested MAPT exon 7- (lane 4) and exon 9- (lane 5) 
specific forward primers.
7.3.4: Relative Allelic Expression: 4R MAPT mRNA Transcripts
In an assay that was specific for transcripts that contained exon 10, HI :H2 cDNA ratios did 
not significantly differ between individuals carrying the H1C haplotype and individuals 
carrying other HI haplotypes (P = 0.58; Figure 7.6). Similarly, ratios did not significantly 
differ according to homozygosity and heterozygosity at SNP rs242557 {P = 0.11; Figure 
7.7). These analyses had 80% power to detect a ratio difference of 0.10 between H1C non­
carriers and carriers, and 0.08 between rs242557 homozygotes and heterozygotes (P = 
0.05).
No significant correlation was observed between cDNA ratios and sex or brain region 
assayed (P > 0.05). However, in samples with the highest quality data (coefficient of 
variation of <0.1), there was a significant positive correlation between H1:H2 ratios and 
age at death (n = 17, r == *0.52, P = 0.031; Figure 7.8).
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Figure 7.6 (left) & 7.7 (right): Scatter plots showing 4R-specific allelic ratios for cDNA derived 
from 33 individuals heterozygous for the H1/H2 haplotype. In Figure 7.6, ratios from individuals 
that do not carry the H1C haplotype are shown in red, and ratios from those that do are shown in 
yellow. In Figure 7.7, ratios from individuals that are homozygous for SNP rs242557 are shown in 
red, and ratios from heterozygotes are shown in yellow. Data are presented as the HI allele relative 
to the H2 allele (HI :H2). Each data point represents the average of four measurements. Ratios have 
not been corrected for uneven allelic representation and should thus be considered arbitrary.
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Figure 7.8: Scatter plot showing the correlation of 4R-specific cDNA ratios as 
measured at rs 17652121 with age at death (years) in samples that produced replicate 
ratios with coefficient of variation of <0.1 (n = 17, r = +0.52, P = 0.031). Ratios have 
not been corrected for uneven allelic representation and should thus be considered 
arbitrary.
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7.4: Discussion
The present study sought to test the hypothesis that the haplotypes and variants in MAPT 
identified as risk factors for neurodegenerative disease are associated with altered 
expression and splicing of the gene in human brain. Assays of relative allelic expression 
were applied to a total of 39 brain samples heterozygous for the HI and H2 haplotypes. 
Data from three assays did not show marked allelic expression differences, and mean 
HI :H2 ratios for each assay were close to 1:1. There was no significant difference in ratios 
obtained from samples carrying the risk H1C haplotype and samples carrying other HI 
haplotypes, and no effect of the putatively functional SNP rs242557 was detected. This 
was apparent not just in assays targeted at all brain-expressed MAPT mRNAs, but also in 
an assay specifically targeted at transcripts containing exon 10 (4R mRNA isoforms).
Taken as a whole, the data from the present study do not support the hypothesis that the 
HI, H1C and SNP rs242557 associations with neurodegenerative disease are mediated by a 
pathogenic increase in MAPT mRNA abundance. These studies had 80% power to detect a 
cDNA ratio difference of 0.08, and so do not exclude effects smaller than that size. 
Individual samples did show allelic expression differences, however, and this may indicate 
either the presence of c/s-acting loci that are not well captured by the HI / H2 division or 
may reflect inter-individual variance in measurement. The observation that cDNA ratios 
were significantly positively correlated across the three independent SNP assays suggests 
the observed differences between individuals are unlikely to be entirely attributable to 
measurement error.
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The assay targeted at 4R mRNAs was carried out to investigate possible genetic influences 
on alternative splicing of exon 10. The assay did not include genomic DNA, meaning 
cDNA ratios could not be not corrected, which thus precluded any conclusion about which 
of the HI and H2 alleles produced more abundant 4R mRNAs. However, the data from this 
assay was amenable to between-samples comparisons to assess possible effects of the HI C 
haplotype and SNP rs242557. That cDNA ratios did not significantly differ between 
carriers and non-carriers of the H1C haplotype, or between heterozygotes and 
homozygotes for SNP rs242557, suggests that the putative pathogenic effect of these 
variants is not related to alternative splicing of exon 10.
The results of the present study are consistent with some of the findings of a recent study 
that also used measures of relative allelic expression to assess cz's-acting effects on MAPT 
expression in human brain (Caffrey et al., 2006). In that study, which used primer 
extension and matrix-assisted laser desorption / ionisation time of flight mass 
spectrometry, HI and H2 haplotypes showed no difference in total MAPT expression in 
healthy post-mortem brain. However, the authors additionally found that the HI haplotype 
expressed, on average, 29% and 43% more 4R mRNA than H2 in frontal cortex and globus 
pallidus respectively, although the assay did not fully control for possible allelic biases in 
PCR efficiency.
A limitation of the methodologies used in that earlier study and in the present work is that 
neither provides a direct measure the 4R:3R ratio of mRNAs transcribed from each 
haplotype, which may also be an important factor. Nonetheless, if the reported finding of a 
4R-specific effect is genuine, it would suggest that the pathogenic basis of the HI 
association with neurodegenerative disease might be, as postulated, related to alternative
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splicing of exon 10. More recently, the same research group also reported that HI 
expresses ~50% less 2N mRNA (containing exons 2 and 3) than H2 (Caffrey et al., 2008), 
which may indicate a further effect on splicing of exon 3. Consistent with the present 
findings, and challenging the pathological relevance of the expression changes, however, 
in neither of their studies did they detect any significant effect on MAPT expression of the 
H1C haplotype or SNP rs242557.
An effect of the H1C haplotype on brain MAPT expression has, however, been detected in 
one other study, which employed a relative allelic expression assay based on real-time 
PCR (Myers et al., 2007b). In that study, HI expression of total MAPT mRNA and 
specifically of 4R mRNA isoforms was found to be, respectively, 11-13% and 25% higher 
in H1C / H2 heterozygotes than in heterozygotes carrying other HI haplotypes, suggesting 
effects on both transcription and alternative splicing. The different results between the 
studies may possibly be explained by differences in the specific brain regions studied.
Although, taken together, the data generated in the initial three SNP assays of the present 
study clearly suggest that HI and H2 produce approximately equal levels of mRNA, the 
cDNA ratios were spread about a slightly different mean value for each one. A plausible 
explanation for this was that one or more of the SNPs did not tag all the same transcripts as 
the others. However, investigation of this possibility by RT-PCR and 3’ RACE did not 
support this hypothesis, but was instead consistent with early studies that showed exons 7,
9 and 13/14 to be constitutively expressed in all brain-expressed MAPT mRNAs (Goedert 
et al., 1989a, 1989b; Andreadis, Brown & Kosik, 1992). An alternative hypothesis is that 
there are minor differences in RT efficiency that are dependent on the base composition at 
each SNP site, but this is speculative. Nevertheless, a similar phenomenon was also
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observed in the study described above (Caffrey et al., 2006). For instance, whereas the 
average H1:H2 cDNA ratios for 4R mRNAs was 1.43:1 as measured at SNP rsl052553, 
the average at SNP rsl7652121 in the same tissue was -1.30:1 (Figure 4 in Caffrey et al.,
2006).
A notable difference between the present study and those described above is that the 
present study included brain samples from both younger and older individuals (range = 1 9 - 
102 years). By definition, age is a risk factor for neurodegenerative diseases, and it is 
conceivable that part of its contribution to susceptibility is related to temporal changes in 
gene expression rather than simply the lifetime accumulation of abnormal processes. For 
this reason, the present finding that age is correlated with allelic expression of MAPT is 
intriguing. It is well-documented that alternative splicing of exon 10 is modified from 
foetal stages of life to adulthood (Goedert et al., 1989a, 1989b; Kosik et al., 1989; Goedert 
& Jakes, 1990). In the present study, the three assays targeted at all MAPT mRNA isoforms 
(i.e. both 3R and 4R isoforms) showed a negative correlation between HI :H2 cDNA ratios 
and age at death. Thus, with increasing age, HI produced relatively less mRNA encoding 
total tau as compared with H2. Conversely, in the assay that specifically targeted 4R 
mRNAs, H1:H2 cDNA ratios showed a positive correlation with age. Thus, with 
increasing age, HI produced relatively more mRNA specifically encoding 4R tau isoforms 
as compared with H2. Although no equivalent assay targeted specifically at 3R mRNA 
isoforms was performed, the present data suggest that the HI haplotype produces a relative 
increase in 4R tau compared with all other tau isoforms with age. A progressive increase in 
the 4R:3R ratio of mRNAs generated from HI may be of relevance to the risk effect of this 
haplotype on susceptibility to tauopathies such as CBD and PSP, which are associated with 
neurofibrillary tangles comprised mainly of 4R tau isoforms. Importantly, carriers of H1C
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and heterozygotes for SNP rs242557 had similar age ranges as non-carriers and 
homozygotes, suggesting that the age correlation did not affect the failure to detect effects 
of these variants.
It is important to emphasise that the results of the present study do not rule out alteration of 
MAPT mRNA abundance as the pathogenic basis of the reported associations. For 
example, the present study does not exclude effects that are specific to brain regions not 
tested, particular cell types, or particular mRNA isoforms. However, it is possible that the 
associated variants may actually influence the regulation of other genes within the vicinity 
of MAPT. Of note is the STH  gene of unknown function nested within intron 9 of the 
MAPT gene (Conrad et al., 2002). The expression of this gene has been reported to be 
increased in post-mortem brain from individuals with PSP (Ezquerra et al., 2007) and PD 
(Tobin et al., 2008) and positively correlated with the ratio of 4R:3R MAPT mRNA 
(Ezquerra et al., 2007). Hence, it is not difficult to imagine that the identified risk variants 
could have a cis effect on STH  expression, which in turn may act in trans to alter splicing 
of MAPT exon 10. A similar cis x trans effect on MAPT transcription is also plausible 
given the recent identification of natural antisense transcripts that map to the promoter 
region of the gene (D’ Souza et al., 2006; Guo et al., 2006).
An alternative hypothesis is that the identified risk variants might only increase 
susceptibility in the context of additional disease-specific trans-acting factors that interact 
with MAPT. For example, risk variants for AD on the HI background were recently found 
to be associated with increased MAPT expression, but only in individuals with evidence of 
(3-amyloid deposition (Kauwe et al., 2008). A further hypothesis, with particular reference 
to the rare tauopathies, CBD and PSP, is that these disorders are caused by pathogenic
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regulatory mutations that may have arisen in the context of the identified risk variants but 
are too rare to have been detected in the present study. Consistent with this, resequencing 
of MAPT has identified intronic mutations on the HI background in sporadic CBD and 
PSP cases that were not found in healthy controls (Cruts et al., 2005; Rademakers et al.,
2005). Relative allelic expression assays of MAPT in brain samples from relevant patient 
groups could be useful in testing these possibilities.
7.4.1: Conclusions
The present study suggests that haplotypes HI and H1C and SNP rs242557 do not have a 
major cis effect on total MAPT mRNA abundance in normal human brain. The association 
between these variants and AD, CBD, PSP, PD and other tau-related neurodegenerative 
diseases may relate to altered regulation of nearby genes, disease-specific trans factors, 
rare mutations, or possibly an effect on specific MAPT mRNA isoforms. An effect of age 
on the relative amount of MAPT mRNA produced by HI compared with H2 was observed, 
and warrants further investigation.
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____________________ C h a p t e r  8 : G e n e r a l  D isc u ssio n ____________________
8.1: Introduction
The series of studies described in this thesis investigated the possibility that genes 
implicated in psychiatric and neurodegenerative diseases contain regulatory variants that 
could contribute to disease pathogenesis. In total, 10 genes were investigated. These genes 
had previously been found to be genetically associated with one or more psychiatric or 
neurodegenerative diseases, and, in several instances, to show altered expression in post­
mortem analyses of brain tissue from individuals affected by such disorders. None of the 
genes were known to contain protein-coding variants that could fully account for reported 
disease associations.
Each gene was investigated by one or more assays of relative allelic expression, which are 
well-suited for the detection of c/5-regulatory variants with effects on mRNA abundance 
and for testing individual variants or haplotypes for czs-regulatory effects. These assays 
were applied to a large number of post-mortem brain samples. Although c/s-regulatory 
variation was detected in most of the genes assayed, only in two genes (i.e. RELN and 
MAPT) was there evidence that this is related to variants associated with disease. In the 
following sections, the principal findings of each study will be briefly reiterated followed 
by a more general discussion of the methods and avenues for future work.
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8.2: Principal Findings 
8.2.1: Disrupted in Schizophrenia 1 (DISCI)
The DISCI gene was selected for study based on several findings of association with 
schizophrenia, schizoaffective disorder, and bipolar disorder (Hennah et al., 2006; Chubb 
et al., 2008). Although DISCI is known to contain variants that alter the amino acid 
sequence of the encoded protein, the majority of reported associations are not fully 
explicable in terms of these changes. For example, where DISCI protein-coding changes 
have been associated with a psychiatric phenotype, it has usually been as part of a 
haplotype including non-coding SNPs (as described in Chapter 3, section 3.1.2), 
suggesting that effects on gene expression or splicing may be involved. A pathogenic role 
for altered DISCI expression was suggested by the finding that DISCI expression in 
lymphoblastoid cells of DISCI t ( l ; l l )  translocation carriers is approximately halved, 
which is consistent with haploinsufficiency (Millar et al., 2005).
Out of 65 brain samples assayed in the study described in Chapter 3, only one showed a 
robust allelic expression difference. In that sample, one gene copy was expressed -50% 
higher than the other. Sequencing of the DISCI promoter in that sample’s genomic DNA 
revealed the heterozygous presence of an insertion / duplication variant and a TG repeat 
polymorphism. However, both variants were detected in samples that did not show allelic 
expression differences, indicating that these variants were not in themselves sufficient to 
alter expression. That this study did not detect common variants that markedly alter 
expression of DISCI suggests that common DISCI haplotypes associated with 
schizophrenia and bipolar disorder, the HEP3 haplotype in particular (Hennah et al., 2003, 
2005; Palo et al., 2007), do not exert their pathogenic effect by altering mRNA abundance.
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8.2.2: Reelin (RELN)
The RELN gene was principally selected for study on the basis of the fairly robust findings 
of a -50% reduction in expression of this gene’s mRNA and protein in brains of 
schizophrenic and bipolar patients (Torrey et al., 2005). A similar sized reduction had also 
been observed in the brains of autistic individuals (Fatemi et al., 2005a). Moreover, RELN 
is located within a consistent linkage region (7q22) for autism (Badner & Gershon, 2002; 
Trikalinos et al., 2006), and non-coding polymorphisms in the gene had been associated 
with autism as well as schizophrenia (as described in Chapter 4, section 4.1.4). Together, 
these findings highlighted the possibility that genetic effects on RELN expression may 
influence susceptibility to these disorders.
Out of 66 brain samples assayed in the study described in Chapter 4, three showed allelic 
expression differences of >20%, of which two were clear outliers. Interestingly, the repeat 
number of a 5’ UTR CGG polymorphism that had previously been associated with autism 
in some studies (Persico et al., 2001; Zhang et al., 2002; Skaar et al., 2005) was found to 
be correlated with RELN allelic expression differences, suggesting a pathogenic 
mechanism in the disorder. However, variants in linkage disequilibrium (LD) with this 
polymorphism were not found to be associated with schizophrenia or bipolar disorder 
using imputed genotype data, suggesting that any alterations in RELN expression that 
result from the CGG repeat are not relevant to susceptibility to those disorders (with 
caveats, noted in Chapter 4, about power to detect association). In addition, a SNP reported 
to be associated with schizophrenia in females (Shifman et al., 2008) was not found to 
have any influence on allelic expression.
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8.23: GABAa Receptor Subunit Genes
A selection of six GABAa receptor subunit genes (GABRB1, GABRA4, GABRA5, 
GABRB3, GABRG2 and GABRG3) were selected for study based on findings of association 
with bipolar disorder, and more specifically, RDC-defined schizoaffective disorder, bipolar 
type (Craddock et al., 2008). This family of receptors plays a major role, directly or 
indirectly, in probably all brain functions, and alterations in their expression had previously 
been implicated in schizophrenia and bipolar disorder (as described in Chapter 5, section
5.1.4).
Although, in the study described in Chapter 5, c/s-regulatory variation in most of these 
genes was detected, no evidence that the putative susceptibility variants had any influence 
on mRNA abundance was obtained. The c/s-regulatory variants that were detected may, 
however, be relevant to several other disorders in which this family of genes is thought to 
be important. For example, if identified, the variants in some of the genes may represent 
good candidates for case-control association studies for autism and epilepsy.
8.2.4: Nitric Oxide Synthase 1 Adapter Protein (NOS1AP)
The NOS1AP gene was selected for study based on linkage and association findings that 
implicated it in schizophrenia in a Canadian family sample (Brzustowicz et al., 2000,
2002, 2004). Resequencing had failed to identify any protein-coding variants in the gene 
(Brzustowicz et al., 2004), and post-mortem analyses had found the gene’s short mRNA 
isoform to show increased expression in schizophrenic and bipolar disorder brain (Xu et 
al., 2005). Moreover, increased expression of the short, but not the full length, mRNA 
isoform in brain had been found to be associated with risk alleles of three putative 
susceptibility SNPs identified in the Canadian families (Xu et al., 2005).
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In the study described in Chapter 6, analysis of this gene in 57 brain samples for the full 
length mRNA isoform and 28 for the short mRNA isoform identified one that showed 
unequal allelic expression of both isoforms. Evidence was also obtained for a common 
variant in high LD with the assayed SNP that has a small effect on expression of the full 
length isoform, but no evidence for common c/s-regulatory variation that influences 
expression of the short isoform was found. Genotyping of the three SNPs that showed 
association with schizophrenia in the Canadian families did not support the hypothesis that 
those variants influenced expression of either isoform. Based on these findings, it was 
concluded that the association of those SNPs in NOS1AP is probably not mediated by 
direct effects on mRNA abundance.
8.2.5: Microtubule-Associated Protein Tau (MAPT)
The MAPT gene was selected for study on the basis of reported association of an extended 
haplotype (denoted HI) and sub-haplotype (denoted H1C) in this gene with progressive 
supranuclear palsy (PSP) and other neurodegenerative diseases in which aggregation of the 
tau protein is a characteristic neuropathologic feature (described in Chapter 7, section
7.1.4). The association data could not be explained by protein-coding changes, as both HI 
and its allelic counterpart, H2, encode identical tau proteins and do not include such 
polymorphisms. Furthermore, resequencing of the gene failed to identify protein coding 
mutations in the vast majority of cases (as described in section 7.1.3).
In the study described in Chapter 7, a direct relationship between disease-associated 
haplotypes and variants and MAPT expression was not found. However, total MAPT 
expression from the HI haplotype was found to reduce with age relative to that from H2, 
while the proportion of transcripts containing exon 10 (encoding 4R tau, the isoform that is
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prone to aggregation in PSP and other tauopathies) was found to increase with age from 
HI relative to H2. This finding may be of relevance to the aetiology of 4R tauopathies, but 
requires further investigation.
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83: Potential Confounds and Limitations
Assays of relative allelic expression were the principle method used in the studies reported 
in this thesis. Although they are a particularly powerful means of studying c/s-regulatory 
phenomena, a number of potential confounds and limitations should be noted.
83.1: Relative Allelic Expression Assays Only Measure Effects on mRNA Abundance
It is important to emphasise that the studies presented in this thesis only examined effects 
on mRNA abundance. It is possible that putative disease susceptibility variants in these 
genes operate via other effects on gene expression, such as RNA splicing, mRNA transport 
or translational efficiency, which were not examined in detail in the present series of 
studies.
Another limitation of relative allelic expression assays is that they measure only the 
relative expression of each gene copy in heterozygotes. Findings of differential allelic 
expression may not necessarily indicate changes in total expression levels. For instance, it 
is quite possible that if transcription is more or less efficient from one allele of a gene, 
trans-acting homeostatic mechanisms might restore total expression levels to those 
required for proper cell function. However, where c/s-regulatory variants are associated 
with a disorder, this implies that levels are not adequately restored, at least not in some 
cells. Indeed, in a polygenic disorder, it is possible that the trans-regulators are themselves 
affected by susceptibility variation, which will impact on their capacity to restore optimal 
expression.
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8.3.2: Genetic or Epigenetic?
Where allelic expression differences are seen, it is not immediately obvious whether this is 
the result of genetic sequence variation or allele-specific epigenetic modification. 
However, where differences in allelic expression are found to associate with a specific 
genetic polymorphism, these changes can be reasonably attributed to a primary genetic 
change, although the effects may additionally be mediated by epigenetic modification. 
Additional methods such as bisulphite sequencing may indicate epigenetic mechanisms.
8 3 3 : Potential Allelic Bias in Reverse Transcription
In the investigations reported in this thesis, potential allelic biases in PCR or primer 
extension efficiency when assaying cDNA were controlled for by assaying genomic DNA 
under identical conditions. However, it was not possible to apply an equivalent measure to 
control for potential allelic biases in RT efficiency. Since this would manifest as a general 
shift in allelic expression in all samples heterozygous for the assayed SNP, it would be 
difficult to distinguish from regulatory effects arising from the SNP itself or from cis- 
regulatory variation in high LD with it. Gene assays showing this pattern of allelic 
expression should therefore be interpreted with this caveat.
83.4: The Choice of SNP
The specific mRNA isoforms targeted in relative allelic expression assays is entirely 
dependent on the choice of SNP used to distinguish between mRNAs transcribed from 
each gene copy and the primers that are used to amplify it in PCR. Therefore if cis- 
regulatory variants affect an mRNA isoform that does not contain the SNP, then the effects 
of those variants will not be detected. In contrast, if czs-regulatory variants have an effect 
on specific mRNA isoforms, then the simultaneous assay of additional mRNA isoforms
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that are not influenced by those variants may cause the size of their effect to be under­
estimated or indeed to go undetected.
A further limitation with the use of SNPs in exons is that if an allelic expression difference 
is detected, it is usually unclear whether the difference is a result of an effect on 
transcription, mRNA stability or alternative splicing. In theory, this limitation can be partly 
addressed by using a SNP within an intron. Since this will assay only unspliced RNA, any 
differences in relative allelic expression will most likely arise from effects on transcription. 
However, assays that target pre-mRNA are reportedly more variable and more likely to fail 
probably due to the fact that pre-mRNA represents only a small fraction of total RNA 
preparations (Pastinen & Hudson, 2004). This approach may also be more susceptible to 
bias towards a 1:1 ratio arising from any residual genomic DNA contamination if present.
83.5: Context Specificity of Allelic Expression Differences
The detection of a c/s-regulatory variant that affects expression of a gene in a tissue or cell 
is dependent not only on expression of that gene, but also its regulation by trans factors 
that act at the variant regulatory sequence. Since regulation of a gene can be tissue- or cell 
type-specific and may be highly dynamic, it is expected that many c/s-regulatory 
polymorphisms will only give rise to an allelic expression difference in certain tissues or 
cell types or under certain conditions. This is illustrated in a study of the BMPS gene, in 
which relative allelic expression was analysed across a variety of mesenchymal synovial 
joint tissues within a number of individuals (Wilkins et al., 2007). Out of 16 individuals 
assayed, 11 showed relative allelic expression differences that were seen in some but not 
all of the tissues analysed. Where relative allelic expression was seen in more than one 
tissue, the allelic ratios were often significantly different between them, and in one
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individual, the allele that was most abundant in ligament and synovial tissue was the least 
abundant in cartilage tissue.
In light of these findings, since, in the studies reported in this thesis, tissue from only one 
brain region was assayed in each individual and that tissue from only three different brain 
regions was assayed in total, it is quite possible that there were c/s-regulatory variants in 
the samples assayed that were not detected. Furthermore, brain tissue is made up of several 
cell types, including glia as well as neurons, and it is not known from which of these types 
allelic expression differences arose. It is also possible that allelic expression differences in 
one type of cell might be ‘diluted out’ by the simultaneous assay of mRNAs from the other 
cell types. Moreover, brain samples from different individuals, as well as differing in brain 
region, may also differ in the cellular makeup of the tissue. Whilst this will not give rise to 
false positive results, it may mean that true effects of haplotypes on expression when 
compared between groups of individuals with and without that haplotype may go 
undetected due to confounding.
As well as being tissue- or cell type-specific, c/s-regulatory effects can also be specific to 
certain developmental time points (e.g. Parker-Katiraee et al., 2008). This may be 
particularly relevant to neurodevelopmental disorders such as autism and schizophrenia. 
Similarly, c/'s-regulatory variants might only have an effect in the presence of certain trans 
factors, which may be elevated in disease in the form of additional susceptibility genes or 
environmental risk factors. The use of control individuals, which constitute the majority of 
subjects in the current studies, may have reduced power to detect presence of regulatory 
variation in such circumstances.
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8.4: Further Work and Future Prospects
Given the context-specific nature of relative allelic expression, for some genes, it may be 
necessary to perform relative allelic expression analyses across multiple discrete regions of 
the human brain, perhaps also at different developmental stages, in order to capture the 
effects of c/s-regulatory variation. That allelic expression can differ between brain regions 
has recently been demonstrated in an assay of the RGS4 gene (N. Bray, personal 
communication, 2009). Assay of this gene across 10 discrete brain regions within 12 
individuals showed clear regional differences, with the most pronounced effects seen in 
sub-cortical regions of the brain. It may be possible to localise the effects of c/s-regulatory 
variation even further using techniques for isolating particular cell populations, such as 
laser capture microdissection.
It may also be instructive to compare relative allelic expression between normal 
individuals and those affected with disease. According to the common disease common 
variant hypothesis, it is unlikely that affected individuals will carry c/s-regulatory variants 
that are absent in reasonable sized samples of unaffected individuals, but examining cases 
may bring to light c/s-regulatory variants that are only active in the disease state, perhaps 
as a result of gene * environment or gene x gene interactions.
An interesting observation from the work presented in this thesis is that nearly all the genes 
tested had at least one brain sample that showed allelic expression differences, although in 
several genes (e.g. DISCI, NOS1AP, RELN, GABRA4) such variants were uncommon. 
Where just one observation of allelic expression difference is seen, it is difficult to discern 
its relevance to disease susceptibility, since it is unlikely to strongly correlate with the
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variants showing disease association in current studies, which typically have minor allele 
frequencies of >0.05. In such circumstances, extensive sequencing may reveal the 
causative regulatory variants, although, unless they have a fairly profound effect on 
sequence (e.g. a copy number variant), they may be difficult to recognise as such. If 
identified, such variants could be tested for disease association in large samples of cases 
and controls to test their pathogenic role. Alternatively, under a multiple rare variant 
hypothesis, the relative allelic expression method could be used to screen candidate genes 
for c/s-regulatory variants of strong effect in large case-control samples, with the 
frequency of these variants compared between groups.
In addition to testing association between specific haplotypes and gene expression, relative 
allelic expression assays are of demonstrated utility for defining common regulatory 
haplotypes (Pastinen et al., 2005). Thus, allelic expression can be assessed in a series of 
samples and this then compared with genotype at SNPs across the gene. The identification 
of functional regulatory variation will enable direct tests of association with disease and 
related phenotypes (Hudson, 2003; Bray, 2008).
An important step for relative allelic expression assays would be to scale-up the process for 
simultaneous assay of multiple genes. Although microarrays have been used to assay large 
numbers of genes in parallel (e.g. Lo et al., 2003), these generally have a large level of 
noise, and can therefore only detect larger allelic expression differences. With recent 
developments in next generation sequencing technologies, large scale allelic expression 
analyses are now possible. The so called RNA-Seq approach (reviewed in Wang, Gerstein 
& Snyder, 2009) enables transcriptome-wide analysis of gene expression. Each RNA 
molecule is digitally quantified, meaning highly accurate absolute quantification of
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individual RNA isoforms is possible with little noise. Furthermore, because it is based on 
sequencing, mRNAs from each chromosome can be distinguished in SNP heterozygotes, 
allowing for highly accurate measures of relative allelic expression.
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8.5: Concluding Remarks
The series of studies presented in this thesis explored c/s-regulatory variation in 10 
candidate susceptibility genes for psychiatric and neurodegenerative disease in human 
brain tissue. Differences in allelic expression were observed in nearly all of these genes, 
consistent with previous observations that c/s-regulatory variation affects expression of a 
large proportion of human genes. However, in only a small proportion of the genes 
analysed was allelic expression found to be related to variants or haplotypes associated 
with disease, making the pathological significance of most of the detected regulatory 
variation unknown. Future studies, using higher throughput technologies, may allow the 
allelic expression method to be applied on a genome-wide scale in multiple tissues. The 
data that this approach would produce could then be integrated with genome-wide 
association data based upon some of the principles applied in this thesis.
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